Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"
ABCB1	"ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1"	ENSG00000085563	"ATP binding cassette subfamily B member 1"	P08183	7	87503633-87713323	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 57.8;intestine: 49.6"	"Cell line enhanced"	"Detected in some"		"CACO-2: 29.4;HEK 293: 9.0;HEL: 16.3;Hep G2: 8.1;RPTEC TERT1: 11.3;SH-SY5Y: 36.0"	"Cancer enhanced"	"Detected in many"		"renal cancer: 14.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 19.2"	"Group enriched"	"Detected in many"	8	"NK-cells: 11.4;T-cells: 19.2"									"CAB001716, HPA002199"	Enhanced		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"				"Nucleoplasm, Focal adhesion sites, Cytosol"		"CAB001716: , HPA002199: AB_1844428"	"unprognostic (5.38e-3)"	"unprognostic (2.45e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.25e-2)"	"unprognostic (9.99e-5)"	"unprognostic (2.23e-3)"	"unprognostic (5.65e-3)"	"unprognostic (1.14e-1)"	"unprognostic (5.17e-2)"	"prognostic favourable (3.33e-4)"	"unprognostic (5.19e-1)"	"prognostic favourable (2.95e-4)"	"unprognostic (2.06e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.83e-1)"	"unprognostic (6.12e-2)"	2.6	57.8	9.4	3.2	11.5	1.2	3.4	5.1	10.5	5.5	22.7	3.8	2.0	14.4	9.4	3.5	2.0	3.2	9.0	1.8	9.2	6.6	19.1	15.6	3.8	2.2	9.4	5.7	2.2	1.5	1.7	1.3	3.1	11.1	2.7	10.7	7.6	1.5	2.1	1.1	1.3	49.6	5.7	9.0	2.4	1.7	1.3	8.6	0.1	2.4	1.4	2.2	2.6	5.9	1.9	0.0	0.1	0.0	11.4	19.2	1.5	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	29.4	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	9.0	16.3	1.9	8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.4	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	11.3	0.0	0.4	36.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.8	0.0	0.4	3.2	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	7.8	0.0	19.2	0.4	2.0	4.7	0.0	1.9	1.2	4.8	0.1	11.4	0.0	0.0	0.0	1.5	9.4	11.5	5.1	10.5	9.2	6.6	9.4	5.7	11.1	8.6
ABCB4	"GBD1, MDR2, MDR3, PFIC-3, PGY3"	ENSG00000005471	"ATP binding cassette subfamily B member 4"	P21439	7	87401697-87480435	"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Lipid transport, Transport"		"Disease mutation, Intrahepatic cholestasis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	8	"liver: 93.2"	"Group enriched"	"Detected in some"	5	"SH-SY5Y: 11.7;WM-115: 22.3"	"Cancer enriched"	"Detected in some"	11	"liver cancer: 16.3"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	6	"memory B-cell: 4.9;naive B-cell: 11.4"	"Lineage enriched"	"Detected in many"	8	"B-cells: 11.4"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA049395, HPA053288"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Actin filaments,Focal adhesion sites"				"Nucleoplasm, Plasma membrane, Actin filaments"	"Focal adhesion sites"	"HPA049395: , HPA053288: "	"unprognostic (7.92e-2)"	"unprognostic (8.87e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.90e-1)"	"unprognostic (8.95e-2)"	"unprognostic (1.06e-2)"	"unprognostic (2.35e-3)"	"unprognostic (9.91e-2)"	"unprognostic (3.53e-1)"	"unprognostic (1.19e-1)"	"unprognostic (2.44e-3)"	"unprognostic (8.43e-2)"	"unprognostic (2.83e-2)"	"unprognostic (8.01e-3)"	"unprognostic (7.12e-2)"	"unprognostic (2.11e-2)"	"unprognostic (2.47e-1)"	0.5	4.1	0.2	4.3	0.2	0.2	0.3	0.1	1.1	0.2	0.6	0.4	0.0	0.0	0.1	0.2	0.6	0.1	0.3	4.0	0.3	0.2	0.4	93.2	0.1	4.1	0.3	0.2	0.3	0.1	0.0	0.5	0.0	0.3	0.3	0.4	0.8	0.4	0.1	2.9	0.6	1.2	1.6	0.5	5.2	0.2	0.5	0.4	0.1	0.4	4.2	3.2	0.6	0.5	11.4	1.4	0.0	0.0	0.0	0.1	0.2	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.1	2.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.3	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.1	11.7	0.0	0.5	2.2	0.2	0.5	0.0	0.2	1.6	0.1	0.0	0.0	0.0	2.7	0.2	0.0	22.3	0.0	0.0	0.0	0.0	0.0	0.1	4.9	0.0	0.1	1.4	11.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.2	0.2	0.1	1.1	0.3	0.2	0.3	0.2	0.3	0.4
AC093827.5		ENSG00000285458	"Uncharacterized protein C4orf36 "	Q96KX1	4	86886472-86936178	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at transcript level"		"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 12.0"									"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											HPA057434	Uncertain		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA057434: "																		2.0	2.0	4.4	0.9	8.1	1.5	3.4	1.0	4.5	2.0	1.3	9.7	2.2	1.6	1.8	3.7	2.2	1.6	1.1	6.8	4.6		3.0	0.8	1.5	0.3	8.9	3.7	1.8	1.2	3.3	1.6	1.6	5.8	2.5	1.8	2.6	2.0	2.4	4.8	5.1	1.6	3.0	8.9	1.2	2.1	3.2	8.2	0.0	3.9	2.4	0.3	1.6	0.0	2.0	2.8	3.3	1.8	2.0	3.1	0.6	2.9	1.7	0.9	1.3	2.7	2.4	1.4	2.7	2.7	0.9	1.3	1.3	4.8	0.5	2.5	1.8	2.0	1.3	1.5	1.0	2.3	1.0	2.2	2.2	1.3	1.5	3.5	1.5	1.6	4.2	0.9	3.2	0.8	1.6	12.0	0.5	0.9	1.5	1.4	2.1	1.2	2.8	1.2	2.5	2.8	2.1	1.0	1.7	2.0	2.0	2.3	3.7	2.6	1.0	2.3	3.1	1.0	1.6	4.3	1.9	3.9	1.8	1.7	1.1	1.6	1.7	1.5	2.0	1.8	2.5	1.6	1.4	2.0	1.5	2.0	1.9	3.1	3.3	2.0	1.3	2.8	0.7	0.6										
ACTN1		ENSG00000072110	"Actinin alpha 1"	P12814	14	68874143-68979440	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 71.8"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004303, HPA006035"	Approved		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"			780000000	"Plasma membrane, Actin filaments, Focal adhesion sites"		"CAB004303: AB_626633, HPA006035: AB_1078095"	"unprognostic (4.40e-2)"	"unprognostic (1.03e-3)"	"unprognostic (2.49e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.19e-1)"	"prognostic unfavourable (2.49e-4)"	"unprognostic (6.19e-3)"	"prognostic unfavourable (7.63e-5)"	"unprognostic (3.62e-1)"	"unprognostic (3.23e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.71e-1)"	"prognostic unfavourable (9.08e-10)"	"unprognostic (2.87e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.05e-3)"	"prognostic unfavourable (8.00e-4)"	27.6	10.8	18.7	33.1	28.4	31.0	38.8	4.1	20.0	30.5	101.8	3.1	43.7	11.6	80.3	24.6	48.3	38.7	53.3	31.2	9.9	6.2	11.2	20.3	23.9	23.1	4.7	15.0	27.8	12.4	2.3	7.9	22.0	8.7	43.2	26.4	11.1	30.1	72.7	7.1	14.6	25.9	135.4	10.3	19.4	52.3	9.5	9.6	7.0	9.3	9.9	11.3	81.1	53.1	0.0	8.8	71.8	12.5	0.7	22.0	14.9	83.8	25.9	16.0	12.1	28.4	18.8	60.0	74.2	71.1	78.1	58.4	20.7	19.6	0.0	26.1	73.2	36.6	12.6	78.3	98.8	0.4	3.8	11.4	13.6	17.3	51.2	8.2	1.4	23.9	15.4	48.5	55.2	42.8	5.4	0.1	61.2	23.9	0.9	17.4	12.5	19.8	5.7	29.7	3.1	29.7	22.2	5.7	6.9	64.4	9.7	17.9	14.6	16.6	53.9	111.0	44.2	12.8	64.5	11.5	4.4	0.3	32.1	11.3	58.3	11.2	12.5	25.6	1.1	5.7	1.4	0.0	4.6	2.5	8.8	0.0	22.0	18.7	71.8	0.7	1.6	0.4	1.8	14.9	18.7	28.4	4.1	20.0	9.9	6.2	4.7	15.0	8.7	9.6
AFAP1	"AFAP, AFAP-110"	ENSG00000196526	"Actin filament associated protein 1"	Q8N556	4	7758714-7939926	"Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"TIME: 42.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 6.0"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.0;T-cells: 2.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015642, CAB024712"	Enhanced		Supported	"Actin filaments,Focal adhesion sites,Cytosol"				"Actin filaments, Cytosol"	"Focal adhesion sites"	"CAB024712: , HPA015642: AB_1844632"	"unprognostic (1.12e-1)"	"unprognostic (2.78e-2)"	"unprognostic (3.97e-1)"	"unprognostic (7.29e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.93e-1)"	"unprognostic (3.30e-1)"	"prognostic unfavourable (2.84e-4)"	"unprognostic (2.00e-1)"	"unprognostic (3.39e-2)"	"unprognostic (3.40e-2)"	"unprognostic (1.38e-1)"	"prognostic unfavourable (8.18e-4)"	"unprognostic (1.40e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.85e-1)"	"unprognostic (2.44e-2)"	14.0	3.9	9.5	11.6	10.2	1.0	15.8	10.3	12.2	11.0	17.8	4.4	6.5	6.7	18.7	6.6	13.1	9.0	14.7	11.0	7.1	5.8	5.2	1.8	8.7	5.3	4.7	6.9	12.1	6.6	31.9	13.0	14.4	5.6	10.3	11.7	12.4	9.6	12.7	5.7	5.8	8.8	32.1	8.3	4.6	8.4	21.7	3.2	3.3	8.6	5.6	6.1	16.2	13.1	0.0	0.0	6.0	0.9	0.0	2.9	1.5	10.3	7.7	5.5	4.3	5.3	9.7	7.2	15.4	22.9	14.9	13.7	2.4	2.4	0.0	5.2	24.9	5.0	2.9	6.2	9.8	0.2	1.9	0.0	11.1	1.4	15.0	0.0	0.1	6.0	4.7	18.5	12.2	17.8	0.2	2.3	7.7	3.3	0.1	0.0	2.3	14.9	0.0	4.1	0.5	1.6	1.3	10.8	18.1	5.3	3.7	4.1	1.3	0.1	42.0	18.2	4.1	23.6	7.5	0.0	0.0	0.0	6.5	0.0	20.7	0.0	0.9	6.0	1.1	0.2	1.4	0.0	1.6	1.5	0.0	0.0	2.9	1.3	2.3	0.0	0.1	0.0	1.3	1.5	9.5	10.2	10.3	10.8	7.1	5.8	4.7	6.9	5.6	3.2
AJM1	"ajm-1, C9orf172"	ENSG00000232434	"Apical junction component 1 homolog"	C9J069	9	136844415-136848801	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 22.7;testis: 15.0"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 22.7"	"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 3.9"	"Group enriched"	"Detected in many"	11	"dendritic cells: 3.9;monocytes: 1.6;T-cells: 1.9"	"Low region specificity"	"Detected in all"							HPA021200	Uncertain		Approved	"Focal adhesion sites,Cytosol"				"Focal adhesion sites, Cytosol"		"HPA021200: AB_10601695"	"unprognostic (3.30e-3)"	"unprognostic (1.67e-1)"	"unprognostic (7.68e-3)"	"unprognostic (9.54e-2)"	"unprognostic (2.34e-1)"	"unprognostic (1.08e-2)"	"unprognostic (1.27e-2)"	"unprognostic (8.00e-2)"	"unprognostic (6.29e-2)"	"unprognostic (4.33e-1)"	"unprognostic (2.72e-3)"	"unprognostic (4.34e-2)"	"unprognostic (1.05e-1)"	"unprognostic (2.71e-3)"	"unprognostic (2.94e-1)"	"unprognostic (6.07e-3)"	"unprognostic (7.27e-2)"	1.1	1.9	4.6	1.3	6.3	1.4	1.1	22.7	7.9	1.1	4.0	1.1	1.1	3.3	1.2	1.1	1.1	0.3	1.1	1.2	4.4	3.1	1.1	1.1	1.1	1.1	2.1	1.1	1.1	7.6	1.1	5.2	1.1	1.1	2.6	1.1	1.1	2.0	2.2	3.9	1.5	4.3	1.1	1.3	3.6	2.3	15.0	1.1	1.1	1.1	1.1	1.1	2.6	1.1	0.2	3.9	0.1	1.6	0.2	1.9	0.8	3.6	2.9	0.4	1.1	0.5	0.4	4.8	2.9	0.5	0.4	0.2	1.0	2.0	2.2	2.5	0.8	4.1	0.4	1.1	0.0	5.7	2.2	0.6	5.5	0.8	1.6	1.3	4.1	0.9	1.4	0.5	0.3	0.2	3.4	1.5	0.7	4.1	0.4	4.5	1.1	3.8	2.7	0.9	7.2	0.8	0.7	7.3	2.6	1.9	7.5	3.9	5.9	2.8	3.1	5.0	3.4	1.7	1.7	6.5	4.4	0.8	8.7	4.5	1.2	0.0	1.6	0.1	1.9	1.0	0.4	0.2	0.5	0.9	1.5	0.0	0.2	0.9	0.1	0.2	1.5	3.9	0.1	0.8	4.6	6.3	22.7	6.8	4.4	3.1	2.1	1.1	1.1	1.1
AL132780.3		ENSG00000259132			14	22946270-22982258	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"				"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Hep G2: 27.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											HPA029803	Approved		Approved	"Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"		"HPA029803: AB_10601428"																		4.8	6.2	4.5	4.7	5.5	6.6	5.3	3.5	2.4	16.1	7.1	2.3	7.1	5.5	12.4	9.2	16.2	6.6	11.2	6.0	4.6	3.8	20.4	24.5	10.5	7.9	5.3	1.9	11.8	13.8	0.0	3.5	18.1	3.8	13.1	6.1	10.4	5.7	16.0	6.2	8.8	4.5	3.5	4.5	11.3	4.5	6.0	1.9	10.3	22.1	7.7	9.6	5.0	7.9	3.3	5.7	10.2	5.9	1.1	4.1	2.8	4.0	8.7	6.1	2.0	6.0	7.1	3.9	0.7	5.7	3.6	3.8	2.9	3.1	0.0	2.4	6.7	1.5	2.8	3.1	2.6	0.0	0.7	1.3	6.7	27.6	3.9	3.2	2.6	3.1	8.1	2.8	6.8	5.0	0.0	6.0	3.9	16.5	6.9	11.8	3.0	1.9	3.3	4.3	3.8	10.1	8.2	3.4	2.0	2.7	3.6	1.7	5.4	6.9	1.0	4.6	3.4	1.9	3.4	5.9	7.2	6.2	1.5	3.2	2.8	0.5	5.9	2.1	2.5	4.2	1.2	2.7	1.8	2.1	5.7	3.3	3.4	1.7	10.2	1.1	2.9	2.6	4.1	2.8	4.5	5.5	3.5	2.4	4.6	3.8	5.3	1.9	3.8	1.9
ALKBH6	MGC15677	ENSG00000239382	"AlkB homolog 6"	Q3KRA9	19	36009120-36014239	"Cancer-related genes, Predicted intracellular proteins"		"Dioxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA073835, HPA074340"	Approved		Supported	"Nucleoplasm,Focal adhesion sites"				Nucleoplasm	"Focal adhesion sites"	"HPA073835: , HPA074340: "	"unprognostic (1.90e-3)"	"unprognostic (1.82e-1)"	"unprognostic (5.16e-3)"	"unprognostic (1.12e-2)"	"unprognostic (1.24e-1)"	"unprognostic (5.86e-5)"	"unprognostic (6.21e-2)"	"unprognostic (4.53e-2)"	"unprognostic (3.95e-1)"	"unprognostic (3.56e-2)"	"unprognostic (8.78e-4)"	"unprognostic (1.77e-2)"	"unprognostic (2.31e-5)"	"unprognostic (9.34e-2)"	"unprognostic (2.15e-1)"	"unprognostic (3.82e-1)"	"unprognostic (1.05e-3)"	8.4	7.0	14.1	6.4	15.2	6.8	6.3	7.8	18.9	5.8	8.2	7.8	2.5	6.6	6.5	6.6	6.5	8.2	7.7	9.2	13.0	14.9	5.7	12.6	6.8	8.7	14.8	12.5	5.4	3.4	8.2	8.5	6.2	19.5	9.7	4.6	6.5	8.7	9.9	6.3	5.8	6.4	8.5	10.5	8.9	9.6	4.2	4.9	5.7	6.2	3.7	8.4	7.2	4.7	18.1	13.5	29.5	15.0	15.7	19.5	9.4	10.3	11.1	4.2	6.2	6.6	4.0	7.1	10.3	6.9	12.1	12.3	4.6	5.5	9.1	16.5	5.7	4.1	4.4	11.9	6.4	14.3	8.0	5.2	4.2	4.9	7.5	4.5	16.0	6.0	8.6	10.0	3.4	8.2	8.1	6.9	6.5	10.8	10.8	5.9	3.3	7.2	6.9	5.8	6.5	8.7	4.6	5.1	5.3	7.0	8.4	8.6	6.7	10.2	3.5	6.3	9.3	14.3	10.0	13.0	7.7	6.4	13.7	5.1	6.7	29.5	11.4	27.3	17.1	15.0	13.0	18.1	15.5	16.1	9.6	14.6	13.2	12.8	9.6	15.7	11.7	13.5	19.5	9.4	14.1	15.2	7.8	18.9	13.0	14.9	14.8	12.5	19.5	4.9
ARAP2	"CENTD1, PARX"	ENSG00000047365	"ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2"	Q8WZ64	4	35948221-36244509	"Predicted intracellular proteins"		"GTPase activation"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 32.5"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 12.1;hTCEpi: 11.4;MOLT-4: 10.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA035925	Approved		Approved	"Actin filaments,Focal adhesion sites"				"Focal adhesion sites"	"Actin filaments"	"HPA035925: AB_10672075"	"unprognostic (2.97e-2)"	"unprognostic (8.62e-2)"	"unprognostic (3.43e-3)"	"unprognostic (1.04e-1)"	"unprognostic (8.86e-2)"	"unprognostic (2.72e-3)"	"unprognostic (1.09e-1)"	"unprognostic (3.78e-3)"	"unprognostic (2.04e-1)"	"unprognostic (2.45e-2)"	"unprognostic (2.72e-3)"	"unprognostic (2.96e-1)"	"unprognostic (4.48e-2)"	"unprognostic (4.54e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.57e-1)"	"unprognostic (6.72e-2)"	5.2	2.5	16.3	9.1	27.5	32.5	5.2	4.8	20.8	4.2	5.1	18.3	0.3	8.5	3.5	4.1	12.7	3.5	9.2	2.5	16.0	9.5	3.9	8.8	12.7	13.7	24.4	12.1	1.9	6.8	8.2	5.1	3.5	18.4	2.9	5.8	0.7	5.8	3.3	1.4	16.1	8.2	4.4	15.3	10.4	5.8	5.9	32.0	26.4	22.4	4.0	10.2	6.2	7.2	2.4	1.7	0.6	5.8	8.6	5.7	0.7	7.3	0.6	0.7	0.3	0.0	0.0	3.7	0.0	0.0	0.0	0.0	3.6	12.1	3.5	2.9	0.3	2.8	1.1	5.8	0.0	0.0	6.7	0.1	2.5	0.2	1.5	4.7	0.0	0.4	11.4	0.0	2.5	0.0	0.2	0.6	0.0	3.1	10.8	3.8	0.8	2.3	5.6	0.0	4.0	8.3	7.5	6.5	0.0	0.4	1.9	2.4	5.0	1.4	0.0	2.0	6.8	0.0	1.0	0.0	0.0	6.8	0.8	5.3	1.7	0.0	0.8	0.0	5.7	2.7	5.3	2.4	3.2	3.9	0.4	1.4	1.1	2.9	0.6	8.6	5.8	1.7	1.5	0.7	16.3	27.5	4.8	20.8	16.0	9.5	24.4	12.1	18.4	32.0
ARHGAP4	"C1, KIAA0131, p115, RhoGAP4, SrGAP4"	ENSG00000089820	"Rho GTPase activating protein 4"	P98171	X	153907367-153934999	"Predicted intracellular proteins"		"GTPase activation"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 44.8;lymphoid tissue: 48.4"	"Cell line enhanced"	"Detected in many"		"Daudi: 25.7;Karpas-707: 26.4;MOLT-4: 24.8;RPMI-8226: 48.8;THP-1: 23.8;U-698: 22.7;U-937: 21.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001012, HPA001083"	Enhanced		Approved	"Nucleoplasm,Focal adhesion sites"				"Focal adhesion sites"	Nucleoplasm	"HPA001012: AB_1078201, HPA001083: AB_1078199"	"unprognostic (3.54e-2)"	"prognostic favourable (3.94e-5)"	"prognostic unfavourable (1.97e-5)"	"unprognostic (5.79e-2)"	"unprognostic (9.42e-2)"	"prognostic favourable (3.31e-4)"	"unprognostic (5.72e-3)"	"unprognostic (1.39e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.37e-1)"	"unprognostic (7.81e-3)"	"unprognostic (1.45e-1)"	"prognostic unfavourable (2.49e-4)"	"unprognostic (8.47e-3)"	"unprognostic (2.01e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.99e-1)"	7.0	4.8	5.3	24.3	5.8	44.8	5.0	4.5	3.2	3.1	6.5	5.2	2.1	6.0	3.9	7.0	4.4	5.2	6.5	4.2	4.5	3.2	7.4	4.9	13.4	29.1	5.2	0.9	2.6	2.3	0.9	3.5	9.0	4.8	4.2	3.0	5.7	7.5	1.8	1.6	1.8	18.0	3.9	5.9	48.4	4.9	3.6	4.2	43.2	4.2	1.6	29.0	7.1	3.6	10.8	17.7	18.7	30.5	8.5	15.7	12.6	0.4	0.1	0.2	1.7	0.0	0.0	0.7	0.2	0.1	0.0	0.0	0.1	12.3	25.7	1.5	0.0	0.2	1.3	0.0	0.0	6.9	1.0	9.9	0.1	0.4	1.0	18.2	16.9	0.0	0.1	0.0	0.1	2.6	0.0	26.4	0.1	1.3	24.8	0.3	0.8	0.0	11.8	3.5	48.8	0.1	0.2	2.4	3.5	0.2	0.6	0.2	5.7	23.8	0.5	0.1	0.3	0.2	0.1	16.0	13.6	22.7	0.2	21.3	0.0	5.1	14.1	18.7	15.7	23.1	10.9	10.8	11.2	12.4	14.1	10.4	10.1	10.1	12.0	8.5	30.5	17.7	12.6	12.6	5.3	5.8	4.5	3.2	4.5	3.2	5.2	0.9	4.8	4.2
ARL14EP	"ARF7EP, C11orf46, FLJ38968"	ENSG00000152219	"ADP ribosylation factor like GTPase 14 effector protein"	Q8N8R7	11	30323051-30338227	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039634, HPA048127"	Approved		Supported	"Nucleoplasm,Vesicles,Focal adhesion sites,Cytosol"				"Vesicles, Focal adhesion sites, Cytosol"	Nucleoplasm	"HPA039634: , HPA048127: AB_2680277"	"prognostic favourable (2.50e-5)"	"unprognostic (8.93e-2)"	"unprognostic (6.19e-3)"	"unprognostic (1.34e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.09e-1)"	"prognostic unfavourable (5.26e-4)"	"unprognostic (2.50e-2)"	"unprognostic (6.50e-3)"	"unprognostic (5.76e-2)"	"unprognostic (8.86e-2)"	"unprognostic (1.04e-1)"	"unprognostic (8.57e-3)"	"unprognostic (1.60e-1)"	"unprognostic (3.47e-1)"	"unprognostic (4.50e-2)"	"prognostic favourable (7.49e-4)"	13.9	21.5	24.5	12.9	29.1	6.3	18.7	22.7	23.4	17.0	14.5	8.0	22.4	8.7	18.1	22.7	11.1	15.8	12.4	20.5	17.7	15.5	16.5	17.6	10.3	23.5	15.5	20.5	20.1	15.0	33.4	28.6	10.6	15.1	19.0	10.3	9.0	17.0	19.9	28.0	11.6	12.5	18.3	16.0	18.2	14.4	14.5	15.0	11.6	23.3	13.9	19.1	16.1	15.1	17.6	12.7	5.5	9.6	24.4	28.7	11.2	5.7	8.3	9.3	8.2	15.3	16.6	4.7	11.2	14.2	10.2	11.3	4.6	2.2	23.4	7.7	8.1	9.7	13.5	9.5	14.5	18.5	16.8	7.0	6.6	8.0	24.1	12.6	8.1	17.2	19.2	4.8	18.3	11.2	11.1	12.8	17.8	5.4	11.3	10.4	10.8	11.6	10.0	22.8	9.5	13.7	8.0	10.6	11.3	8.8	11.7	13.8	12.5	7.1	9.8	11.7	6.2	23.0	10.6	20.0	11.3	15.2	11.2	7.9	11.1	5.5	9.6	3.0	12.1	9.4	28.7	17.6	14.8	13.4	12.7	14.0	13.7	13.1	1.7	24.4	7.0	9.1	9.5	11.2	24.5	29.1	22.7	23.4	17.7	15.5	15.5	20.5	15.1	15.0
ARL2	ARFL2	ENSG00000213465	"ADP ribosylation factor like GTPase 2"	P36404	11	65014113-65022184	"Predicted intracellular proteins"	"Cell cycle"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA044610	Supported		Approved	"Nucleoplasm,Nucleoli,Golgi apparatus,Focal adhesion sites,Cytosol"				Nucleoplasm	"Nucleoli, Golgi apparatus, Focal adhesion sites, Cytosol"	"HPA044610: AB_10964207"	"unprognostic (9.23e-2)"	"unprognostic (3.66e-1)"	"unprognostic (1.43e-1)"	"prognostic unfavourable (4.58e-4)"	"unprognostic (1.61e-1)"	"unprognostic (5.08e-2)"	"unprognostic (1.07e-3)"	"unprognostic (2.34e-1)"	"unprognostic (9.85e-3)"	"unprognostic (6.43e-2)"	"unprognostic (6.87e-3)"	"prognostic favourable (7.70e-4)"	"unprognostic (2.15e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.60e-1)"	"unprognostic (4.39e-1)"	"unprognostic (1.24e-2)"	39.6	32.0	37.3	17.7	78.7	19.8	26.8	16.1	46.5	21.2	23.5	34.7	13.4	23.9	26.8	20.2	23.7	35.2	22.4	52.6	34.8	32.7	33.8	6.6	23.1	14.8	36.1	38.2	27.2	29.9	22.5	15.4	25.5	32.7	25.3	15.5	30.3	26.9	33.1	78.3	19.6	23.4	28.2	44.9	16.7	18.9	31.4	28.7	7.9	26.3	23.6	12.9	24.7	22.8	43.7	37.8	18.7	21.8	21.0	40.7	34.7	35.8	57.1	17.7	26.2	48.1	36.6	16.1	17.7	40.9	25.4	25.1	16.1	24.8	13.8	33.8	24.9	23.0	18.6	31.1	12.1	14.5	29.2	13.9	25.8	24.3	36.9	16.9	12.7	28.8	26.1	21.1	47.4	33.7	32.9	25.9	17.0	42.4	14.0	38.1	27.7	46.7	7.4	19.4	33.3	27.3	15.6	33.0	18.6	15.1	15.7	49.7	16.5	20.8	25.3	47.8	16.1	38.0	18.2	8.9	12.5	8.5	22.6	24.5	38.8	10.2	21.8	18.7	34.8	21.2	37.6	43.7	32.2	33.6	27.6	37.3	36.8	40.7	2.8	21.0	12.4	37.8	20.6	34.7	37.3	78.7	16.1	46.5	34.8	32.7	36.1	38.2	32.7	28.7
ARMC5	FLJ13063	ENSG00000140691	"Armadillo repeat containing 5"	Q96C12	16	31458080-31467166	"Disease related genes, Predicted intracellular proteins"			"Cushing syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NB-4: 34.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA041524, HPA063706"	Approved		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"	"Intracellular and membrane"			"Nucleoplasm, Cytosol"	"Focal adhesion sites"	"HPA041524: AB_10796676, HPA063706: "	"unprognostic (1.37e-1)"	"unprognostic (1.68e-3)"	"unprognostic (8.22e-3)"	"unprognostic (9.96e-2)"	"unprognostic (2.59e-1)"	"unprognostic (2.94e-3)"	"unprognostic (4.09e-2)"	"unprognostic (6.14e-3)"	"unprognostic (2.37e-1)"	"unprognostic (1.11e-1)"	"prognostic favourable (1.97e-6)"	"unprognostic (4.70e-2)"	"unprognostic (3.60e-2)"	"unprognostic (1.99e-2)"	"unprognostic (2.34e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.45e-1)"	8.3	8.1	6.6	8.1	11.6	35.3	8.4	13.1	13.6	5.3	5.7	7.8	5.5	9.7	9.1	6.0	8.4	7.1	4.9	6.6	8.4	7.5	6.7	16.1	8.4	7.3	8.9	5.4	8.6	9.3	9.2	9.4	7.3	9.1	7.2	2.9	6.5	10.4	5.8	14.2	13.2	8.3	4.5	5.9	8.6	8.0	6.0	8.9	6.8	9.9	6.8	5.3	5.1	16.8	4.0	10.0	2.8	3.1	9.8	4.9	3.2	2.9	4.6	2.0	2.9	1.3	1.0	5.2	3.8	1.7	2.3	1.9	4.3	3.0	2.8	8.1	2.1	4.4	2.3	3.5	0.4	4.0	5.9	1.2	7.0	9.9	2.5	8.6	8.8	2.3	4.0	2.2	0.6	3.4	6.3	7.0	1.5	7.3	3.3	34.7	3.3	2.9	5.8	2.9	10.6	1.7	3.4	6.6	5.8	3.5	4.8	2.6	3.1	10.3	6.4	4.9	3.6	2.0	3.1	6.4	5.5	1.8	3.2	7.3	3.4	2.8	3.1	0.9	4.9	1.6	4.1	4.0	3.8	3.8	4.1	3.5	3.4	3.8	1.8	9.8	1.7	10.0	4.6	3.2	6.6	11.6	13.1	13.6	8.4	7.5	8.9	5.4	9.1	8.9
ASAH2		ENSG00000188611	"N-acylsphingosine amidohydrolase 2"	Q9NR71	10	50182778-50248610	"Enzymes, Predicted intracellular proteins"	"Apoptosis, Lipid metabolism, Sphingolipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	17	"intestine: 43.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in single"							"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"											HPA061171	Supported		Approved	"Focal adhesion sites"	"Intracellular and membrane"		1200000	"Focal adhesion sites"		"HPA061171: "	"unprognostic (3.59e-2)"	"unprognostic (3.63e-2)"	"unprognostic (1.66e-1)"	"unprognostic (3.84e-2)"	"unprognostic (3.66e-1)"	"unprognostic (4.48e-2)"	"unprognostic (2.25e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.65e-2)"	"unprognostic (4.33e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.14e-1)"	"unprognostic (8.29e-2)"	"unprognostic (1.86e-2)"	"unprognostic (5.64e-2)"	"unprognostic (3.22e-1)"	"unprognostic (1.02e-3)"	0.3	1.1	0.6	0.2	0.9	0.0	0.5	0.5	1.3	1.7	0.5			43.9	0.7	0.3	0.7	0.5	0.2	0.9	0.5	1.4	0.6	1.6	0.4	0.2	1.2		1.4	1.5	0.3	1.0	0.4		0.5	0.3		0.9	0.2	0.8	0.7	33.4	0.7	0.6	0.2	2.5	1.1			0.6		0.1	1.0	0.5	0.9	0.9	0.0	0.0	0.0	2.2	0.1	1.8	1.4	1.6	2.2	2.9	1.1	2.0	2.0	1.3	3.8	3.5	1.0	4.6	0.0	2.2	2.7	1.7	2.1	0.7	4.7	2.3	3.8	1.3	3.8	2.9	1.8	0.4	0.2	0.4	2.6	6.5	7.4	0.8	2.5	1.2	2.5	1.5	1.4	0.1	4.8	4.1	0.0	6.4	1.6	2.1	0.3	2.7	7.3	2.5	1.8	3.3	1.5	1.0	2.0	1.9	4.3	4.7	6.0	1.9	0.2	0.0	5.5	0.0	1.7	0.0	0.0	0.0	0.7	0.0	2.2	0.9	0.4	1.7	0.0	0.1	1.4	2.1	0.0	0.0	0.0	0.9	0.6	0.1										
ASAH2B	"ASAH2C, ASAH2L, bA449O16.3, bA98I6.3"	ENSG00000204147	"N-acylsphingosine amidohydrolase 2B"	P0C7U1	10	50739318-50816495	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in all"		"intestine: 27.5"	"Cell line enhanced"	"Detected in many"		"PC-3: 19.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"											HPA061171	Supported		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA061171: "	"unprognostic (6.86e-3)"	"unprognostic (1.91e-2)"	"unprognostic (7.22e-2)"	"unprognostic (1.13e-1)"	"unprognostic (8.55e-2)"	"unprognostic (1.18e-2)"	"unprognostic (5.42e-3)"	"unprognostic (5.03e-3)"	"unprognostic (2.21e-2)"	"unprognostic (1.11e-1)"	"unprognostic (3.79e-2)"	"unprognostic (1.78e-2)"	"unprognostic (2.21e-3)"	"unprognostic (2.80e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.46e-1)"	2.8	8.3	6.5	3.3	10.7	2.3	4.6	4.4	14.5	4.0	4.5	1.5	3.8	27.5	5.1	6.2	4.4	4.8	4.3	7.8	7.2	9.0	7.3	12.2	3.7	2.9	5.7	8.3	5.6	7.6	8.8	12.8	2.1	7.4	6.3	5.3	7.0	6.6	4.4	5.7	3.0	16.0	4.4	3.9	3.0	6.4	5.2	2.0	2.7	5.6	6.8	4.8	3.8	3.4	1.4	3.2	0.5	0.1	0.7	6.0	1.5	1.9	2.0	3.1	5.1	1.0	2.6	2.5	9.5	5.2	5.8	4.8	6.7	4.9	0.1	3.6	2.0	2.0	3.5	4.1	4.8	3.6	4.0	1.3	5.8	4.4	3.8	1.7	1.9	3.2	4.8	5.6	8.5	1.2	6.1	2.5	4.7	4.2	2.7	0.2	4.0	19.0	0.1	7.2	2.4	3.4	7.1	5.9	11.9	3.2	4.0	3.3	6.8	1.2	6.3	2.5	11.4	5.2	11.2	2.9	0.4	0.0	12.6	0.0	4.2	0.5	0.1	0.0	2.2	0.0	6.0	0.7	3.5	2.5	0.0	1.4	4.9	4.5	0.4	0.7	0.1	3.2	3.9	1.5	6.5	10.7	4.4	14.5	7.2	9.0	5.7	8.3	7.4	2.0
ASB16	FLJ30165	ENSG00000161664	"Ankyrin repeat and SOCS box containing 16"	Q96NS5	17	44170447-44179083	"Predicted intracellular proteins"	"Ubl conjugation pathway"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"skeletal muscle: 38.4;tongue: 17.6"	"Cell line enhanced"	"Detected in many"		"U-266/70: 12.5"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in single"	13	"cerebellum: 11.4"	"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA066834	Approved		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA066834: "	"unprognostic (2.72e-2)"	"unprognostic (8.47e-3)"	"unprognostic (4.24e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.12e-1)"	"unprognostic (5.95e-2)"	"unprognostic (2.45e-2)"	"unprognostic (2.31e-3)"	"unprognostic (1.03e-2)"	"unprognostic (6.13e-2)"	"unprognostic (7.23e-4)"	"unprognostic (5.84e-2)"	"unprognostic (3.97e-2)"	"unprognostic (8.53e-3)"	"unprognostic (7.33e-2)"	"unprognostic (2.20e-1)"	"unprognostic (1.07e-3)"	0.9	0.6	0.2	1.3	0.3	1.2	0.5	11.4	0.7	0.6	1.2	0.3	0.9	1.3	1.3	1.9	1.1	1.0	0.6	12.6	0.7	0.4	0.8	0.4	0.7	1.9	0.6	0.2	1.1	7.0	1.6	1.8	0.3	0.8	1.7	0.0	2.7	1.2	0.1	38.4	1.9	1.3	4.1	0.2	1.8	1.3	0.6	0.3	0.0	0.9	17.6	1.1	1.6	1.5	4.4	2.9	9.6	2.4	4.0	4.5	2.7	2.1	4.0	4.9	4.5	0.0	0.0	4.0	4.4	0.0	0.0	0.0	3.0	2.4	3.2	2.7	0.0	5.1	0.0	0.0	0.0	5.0	7.2	2.0	7.0	3.4	0.0	2.2	6.5	0.0	0.0	0.0	0.0	0.0	3.7	8.1	0.0	3.5	2.6	4.0	1.4	4.8	8.2	4.7	4.9	0.0	3.3	5.0	2.8	2.0	0.6	0.7	6.4	2.0	2.2	6.1	5.6	3.7	2.8	12.5	6.1	3.1	1.4	3.1	4.0	4.0	2.4	9.6	3.1	2.2	3.7	4.4	3.3	3.0	1.2	3.8	4.5	2.8	7.3	4.0	1.9	2.9	3.2	2.7	0.2	0.3	11.4	0.6	0.7	0.4	0.6	0.2	0.8	0.3
ASCC2	"ASC1p100, DKFZp586O0223, FLJ21588"	ENSG00000100325	"Activating signal cointegrator 1 complex subunit 2"	Q9H1I8	22	29788608-29838304	"Predicted intracellular proteins"	"DNA damage, DNA repair, Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001439, HPA052879"	Approved		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"				"Focal adhesion sites, Cytosol"	Nucleoplasm	"HPA001439: AB_1078229, HPA052879: "	"unprognostic (1.70e-1)"	"unprognostic (1.02e-2)"	"unprognostic (8.58e-2)"	"unprognostic (3.83e-3)"	"unprognostic (1.84e-1)"	"unprognostic (2.45e-3)"	"unprognostic (3.01e-3)"	"unprognostic (1.16e-1)"	"unprognostic (1.35e-1)"	"unprognostic (5.39e-2)"	"unprognostic (1.56e-2)"	"unprognostic (1.24e-1)"	"unprognostic (3.97e-3)"	"unprognostic (5.19e-2)"	"unprognostic (7.53e-2)"	"unprognostic (3.81e-1)"	"unprognostic (2.05e-3)"	19.5	24.2	13.1	22.1	15.1	32.3	23.1	13.4	14.0	16.8	16.9	17.9	22.5	16.5	17.1	17.7	31.1	14.6	19.0	17.7	10.8	8.2	15.8	35.3	19.2	20.2	15.4	9.1	16.2	18.4	17.5	20.6	23.2	12.5	20.1	17.8	17.6	22.2	30.9	50.0	21.7	22.3	14.2	12.9	22.7	25.8	41.0	13.0	28.9	21.9	25.0	26.6	19.1	21.2	11.3	21.1	28.5	27.6	17.3	18.8	10.9	19.6	11.5	12.5	16.9	18.7	16.7	17.9	20.5	15.8	21.4	21.4	13.3	10.7	19.7	14.8	19.8	24.0	16.0	23.3	18.1	25.1	27.9	16.9	14.6	15.9	23.6	30.2	51.3	17.9	21.2	24.3	22.3	18.7	17.3	19.1	19.3	24.3	18.5	15.9	9.1	15.7	22.3	15.3	20.6	13.1	32.6	19.4	17.0	19.1	21.1	15.3	14.9	15.9	18.4	29.9	5.0	18.1	20.3	22.9	17.5	23.3	17.4	17.0	21.5	18.2	16.7	28.5	18.8	27.6	16.8	11.3	14.2	15.8	21.1	8.9	14.7	14.8	5.1	17.3	22.5	12.0	16.4	10.9	13.1	15.1	13.4	14.0	10.8	8.2	15.4	9.1	12.5	13.0
ATP2C2	"KIAA0703, SPCA2"	ENSG00000064270	"ATPase secretory pathway Ca2+ transporting 2"	O75185	16	84368527-84464187	"Enzymes, Predicted membrane proteins, Transporters"	"Calcium transport, Ion transport, Transport"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 23.0;salivary gland: 35.8"	"Cell line enhanced"	"Detected in some"		"HaCaT: 6.3;MCF7: 16.3;RT4: 12.9;SK-BR-3: 22.7;T-47d: 7.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	24	"neutrophil: 2.7"	"Lineage enriched"	"Detected in single"	24	"granulocytes: 2.7"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in single"			"HPA052262, HPA075812"	Approved		Approved	"Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"		"HPA052262: , HPA075812: "	"unprognostic (2.28e-2)"	"unprognostic (6.13e-2)"	"unprognostic (3.34e-2)"	"prognostic favourable (6.20e-6)"	"unprognostic (2.04e-1)"	"unprognostic (2.41e-2)"	"unprognostic (8.36e-2)"	"unprognostic (1.72e-1)"	"unprognostic (9.92e-2)"	"unprognostic (1.89e-2)"	"unprognostic (5.08e-2)"	"unprognostic (2.16e-1)"	"unprognostic (8.37e-3)"	"unprognostic (1.17e-1)"	"unprognostic (1.02e-1)"	"unprognostic (4.32e-4)"	"unprognostic (1.39e-1)"	0.3	0.0	2.1	8.0	1.5	6.1	2.5	0.2	2.0	3.5	23.0	0.5	1.9	16.3	1.8	1.9	2.7	4.0	18.8	0.4	1.8	1.9	2.6	0.2	21.9	0.2	1.3	0.7	1.3	0.5	0.0	2.9	4.8	0.7	7.9	21.9	1.0	35.8	0.2	0.9	15.2	14.5	0.5	0.6	0.2	3.4	0.4	0.4	0.3	8.2	2.2	8.1	4.8	7.8	0.0	0.0	2.7	0.0	0.0	0.1	0.0	4.1	0.3	0.5	0.0	0.0	0.0	4.4	0.1	0.0	0.0	0.0	3.9	3.6	0.0	0.0	0.0	6.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	16.3	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	12.9	3.3	0.0	0.0	22.7	0.2	7.6	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	2.1	1.5	0.2	2.0	1.8	1.9	1.3	0.7	0.7	0.4
BTBD7	"FLJ10648, FUP1"	ENSG00000011114	"BTB domain containing 7"	Q9P203	14	93237550-93333092	"Predicted intracellular proteins"		"Developmental protein"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA049926, HPA053406"	Uncertain		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA049926: , HPA053406: "	"unprognostic (3.36e-1)"	"unprognostic (4.36e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.01e-1)"	"unprognostic (7.74e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.67e-2)"	"unprognostic (2.69e-1)"	"unprognostic (6.55e-2)"	"unprognostic (1.31e-1)"	"unprognostic (8.97e-3)"	"unprognostic (4.34e-2)"	"prognostic favourable (1.69e-6)"	"unprognostic (7.27e-2)"	"unprognostic (1.97e-1)"	"unprognostic (4.72e-2)"	"unprognostic (9.52e-2)"	11.1	8.4	10.2	11.0	11.6	11.8	9.9	14.1	11.6	11.9	10.4	14.3	10.9	8.2	11.4	8.0	13.2	10.9	10.8	9.6	8.9	5.4	13.3	8.7	10.6	7.5	10.1	7.8	11.6	10.1	26.1	10.2	18.0	10.3	9.2	10.5	8.0	10.8	10.3	13.0	11.3	12.0	11.0	7.4	9.5	8.9	20.0	10.7	9.1	15.4	6.7	9.1	13.5	15.5	1.6	1.7	4.4	1.3	0.5	1.5	0.2	7.4	5.7	7.2	3.9	5.7	7.6	10.3	6.6	6.5	5.9	4.6	5.1	6.4	3.9	5.1	9.8	7.1	7.0	14.6	9.9	4.5	3.0	4.0	4.3	3.7	2.8	6.9	4.6	6.3	4.5	7.2	8.6	9.2	3.8	5.0	8.5	6.6	2.8	2.0	4.6	7.4	7.8	10.7	1.9	9.0	24.6	9.0	5.5	7.3	3.3	3.1	6.7	4.7	12.4	5.7	5.5	5.2	4.9	3.9	3.3	4.6	5.1	3.5	6.7	3.1	0.7	4.4	1.4	0.7	0.4	1.5	1.0	1.3	0.6	1.6	0.9	1.0	1.8	0.5	1.3	1.7	1.5	0.2	10.2	11.6	14.1	11.6	8.9	5.4	10.1	7.8	10.3	10.7
C11orf96	AG2	ENSG00000187479	"Chromosome 11 open reading frame 96"		11	43942505-43944338	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"				"Tissue enhanced"	"Detected in many"		"ovary: 152.0"	"Cell line enriched"	"Detected in some"	9	"SH-SY5Y: 63.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038843	Uncertain		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"				"Nucleoplasm, Focal adhesion sites, Cytosol"		"HPA038843: AB_10673296"	"unprognostic (1.55e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.28e-2)"	"unprognostic (8.15e-3)"	"unprognostic (5.49e-2)"	"unprognostic (3.42e-3)"	"unprognostic (8.11e-3)"	"unprognostic (1.15e-2)"	"unprognostic (2.46e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.01e-1)"	"unprognostic (5.98e-2)"	"prognostic unfavourable (2.34e-5)"	"unprognostic (2.65e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.18e-2)"	"unprognostic (3.19e-2)"	68.2	81.2	4.9	23.4	17.4	3.4	42.6	2.6	10.5	39.7	32.2	3.3	6.6	12.4	35.1	41.5	16.3	69.3	70.0	34.3	8.8	7.9	17.9	67.7	61.9	4.9	7.6	4.7	152.0	18.1	3.8	14.2	14.6	32.8	28.6	6.2	7.6	2.3	12.8	38.2	10.1	17.2	22.9	15.3	12.7	31.3	41.7	4.2	0.0	16.7	14.0	2.3	62.9	32.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.6	0.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.9	1.9	0.0	0.0	0.2	0.1	0.1	0.1	0.0	0.4	0.0	0.4	0.7	0.0	0.0	0.0	0.7	0.8	0.5	0.3	3.2	0.2	1.4	0.0	0.0	0.7	63.8	0.0	0.0	5.9	0.0	0.6	0.8	3.1	1.2	0.7	0.0	7.4	0.0	0.9	2.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	17.4	2.6	7.1	8.8	7.9	7.6	4.7	32.8	4.2
C4orf36	MGC26744	ENSG00000163633	"Chromosome 4 open reading frame 36"	Q96KX1	4	86876205-86892422	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in some"		"testis: 14.0"	"Cell line enhanced"	"Detected in some"		"A-431: 5.7;CAPAN-2: 4.5;hTCEpi: 3.8;hTERT-HME1: 5.3"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"basal ganglia: 1.8;cerebral cortex: 1.6;hippocampal formation: 3.3;pons and medulla: 1.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA057434	Uncertain		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA057434: "	"unprognostic (2.01e-1)"	"unprognostic (2.68e-1)"	"unprognostic (7.78e-2)"	"unprognostic (4.76e-2)"	"unprognostic (7.31e-2)"	"unprognostic (5.68e-2)"	"unprognostic (5.93e-3)"	"unprognostic (2.39e-2)"	"unprognostic (5.20e-2)"	"unprognostic (2.77e-1)"	"unprognostic (2.76e-2)"	"unprognostic (2.55e-1)"	"prognostic favourable (7.69e-5)"	"unprognostic (2.85e-1)"	"unprognostic (2.44e-1)"	"unprognostic (4.28e-2)"	"unprognostic (7.75e-2)"	0.6	0.2	0.1	0.7	1.8	0.0	2.1	0.4	1.6	1.7	0.3	0.7	0.0	0.3	1.0	0.4	1.0	0.4	0.0	1.4	3.3	0.2	0.6	0.5	0.9	0.0	0.2	0.4	1.7	0.5	0.0	2.6	0.2	1.4	1.3	0.3	0.1	0.6	0.3	0.1	4.2	0.1	0.6	0.3	0.8	0.2	14.0	0.0	0.0	0.8	0.0	0.4	0.5	0.8	0.1	0.9	0.3	0.0	0.0	0.1	0.0	5.7	0.5	0.3	0.2	0.0	0.3	1.1	2.9	0.8	0.7	0.0	0.3	4.5	0.0	0.5	0.0	2.6	0.4	2.5	0.7	0.1	0.4	0.0	0.9	0.0	0.0	0.0	0.0	0.0	3.8	0.0	5.3	0.0	0.4	0.1	0.0	2.6	1.7	0.2	0.8	0.0	1.4	0.0	0.0	0.9	2.4	0.7	1.8	0.8	0.4	0.0	1.1	0.0	0.0	0.6	0.9	0.3	0.4	0.2	0.9	0.3	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.9	0.0	0.0	0.1	1.8	0.4	1.6	3.3	0.2	0.2	0.4	1.4	0.0
CAPN12		ENSG00000182472	"Calpain 12"	Q6ZSI9	19	38730187-38769904	"Enzymes, Predicted intracellular proteins"		"Hydrolase, Protease, Thiol protease"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"blood: 24.5;gallbladder: 21.0;liver: 21.8;salivary gland: 34.3"	"Cell line enriched"	"Detected in some"	5	"HMC-1: 17.2"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in some"		"pons and medulla: 2.4"	"Group enriched"	"Detected in many"	7	"basophil: 24.5;NK-cell: 12.7"	"Group enriched"	"Detected in many"	7	"granulocytes: 24.5;NK-cells: 12.7"	"Low region specificity"	"Detected in single"			"Region enhanced"	"Detected in some"		"hippocampal formation: 3.6"	HPA053322			Approved	"Nucleoplasm,Focal adhesion sites"				"Focal adhesion sites"	Nucleoplasm	"HPA053322: "	"unprognostic (1.81e-1)"	"unprognostic (4.48e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.95e-2)"	"unprognostic (2.81e-2)"	"unprognostic (1.02e-1)"	"unprognostic (6.01e-3)"	"unprognostic (7.20e-2)"	"unprognostic (2.45e-2)"	"unprognostic (1.29e-1)"	"unprognostic (4.01e-2)"	"prognostic unfavourable (5.90e-6)"	"unprognostic (7.04e-2)"	"unprognostic (4.01e-2)"	"unprognostic (3.00e-1)"	"unprognostic (4.59e-2)"	0.6	0.4	0.2	4.7	0.2	0.2	0.7	0.2	0.3	4.2	4.1	0.1	5.6	1.2	1.1	1.0	1.2	3.6	21.0	0.7	1.0	0.4	7.1	21.8	2.0	1.8	0.2	0.1	0.4	5.0	0.2	0.7	0.5	2.4	2.2	0.7	0.4	34.3	3.0	0.3	4.5	1.9	0.5	0.4	4.9	1.6	0.6	0.1	0.4	0.4	1.6	5.2	1.5	1.0	1.7	0.0	24.5	0.0	12.7	2.6	0.7	0.2	1.8	0.1	0.0	0.3	0.1	2.2	0.1	0.0	0.0	0.1	3.2	0.1	0.7	0.1	0.0	1.3	0.0	0.7	0.0	0.1	0.0	0.3	0.7	0.9	0.0	0.0	17.2	0.8	2.5	0.3	0.0	0.0	0.4	0.5	0.3	0.3	0.0	0.0	0.4	0.0	0.0	0.0	0.2	1.8	0.0	0.1	0.0	0.1	0.4	0.1	0.1	1.4	0.0	0.0	0.1	0.0	0.4	0.9	0.7	0.0	0.1	0.0	0.6	24.5	0.0	1.8	2.6	0.0	2.5	1.5	0.7	1.3	0.0	1.7	0.0	0.6	0.4	12.7	0.0	0.0	0.5	0.7	0.2	0.2	0.2	0.3	1.0	0.4	0.2	0.1	2.4	0.1
CEP135	"CEP4, FLJ13621, KIAA0635"	ENSG00000174799	"Centrosomal protein 135"	Q66GS9	4	55948871-56033363	"Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Mental retardation, Primary microcephaly"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 27.1"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA073950			Uncertain	"Focal adhesion sites"				"Focal adhesion sites"		"HPA073950: "	"unprognostic (2.75e-1)"	"unprognostic (2.71e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.06e-2)"	"unprognostic (3.63e-1)"	"unprognostic (3.42e-2)"	"unprognostic (4.65e-3)"	"unprognostic (4.78e-3)"	"unprognostic (1.83e-3)"	"unprognostic (9.89e-3)"	"unprognostic (9.50e-2)"	"unprognostic (2.27e-1)"	"unprognostic (6.02e-9)"	"unprognostic (7.55e-2)"	"unprognostic (5.54e-2)"	"unprognostic (1.95e-1)"	"prognostic favourable (6.11e-5)"	5.5	3.0	2.9	13.8	6.0	12.8	5.2	5.1	5.3	8.5	4.6	3.1	7.5	4.3	12.8	4.5	4.7	7.4	4.5	3.4	5.3	3.4	5.7	2.9	7.0	13.0	5.8	3.9	9.6	4.5	4.1	6.9	8.1	4.5	4.4	4.6	2.5	3.7	5.9	2.3	5.4	6.2	7.1	5.5	11.1	3.6	9.3	4.6	27.1	5.0	4.5	10.1	4.8	5.6	9.2	8.7	11.9	4.4	7.1	7.5	2.0	6.9	3.8	10.6	9.9	2.2	4.2	4.5	6.9	4.8	6.3	7.4	4.2	7.2	18.6	5.2	3.1	3.3	11.0	4.3	12.0	5.1	7.0	6.5	5.6	3.7	2.4	11.7	10.3	3.2	3.3	8.0	5.7	5.2	11.9	9.0	6.4	4.1	16.4	7.3	6.7	4.1	12.0	5.0	3.8	4.5	5.1	7.7	8.0	6.1	4.2	5.0	5.6	7.6	5.1	8.6	14.1	10.2	12.0	4.9	3.4	12.7	4.3	9.3	10.5	11.9	3.4	4.2	4.7	4.1	4.3	4.6	6.0	4.5	2.1	9.2	7.5	4.8	7.0	7.1	4.4	8.7	3.7	2.0	2.9	6.0	5.1	5.3	5.3	3.4	5.8	3.9	4.5	4.6
CHRNA5		ENSG00000169684	"Cholinergic receptor nicotinic alpha 5 subunit"	P30532	15	78565520-78595269	"Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"vagina: 33.9"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA054381	Approved		Approved	"Plasma membrane,Focal adhesion sites"				"Focal adhesion sites"	"Plasma membrane"	"HPA054381: "	"unprognostic (2.66e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.32e-2)"	"unprognostic (3.20e-3)"	"unprognostic (6.66e-2)"	"unprognostic (1.29e-3)"	"unprognostic (7.03e-5)"	"prognostic unfavourable (3.64e-5)"	"unprognostic (1.34e-2)"	"unprognostic (1.31e-2)"	"unprognostic (4.52e-2)"	"unprognostic (8.97e-2)"	"unprognostic (6.50e-11)"	"unprognostic (4.37e-1)"	"unprognostic (5.39e-1)"	"unprognostic (5.44e-2)"	"unprognostic (2.22e-1)"	2.9	3.3	1.7	4.4	1.7	0.6	4.9	1.8	1.7	2.7	6.4	0.4	1.6	7.8	4.7	1.9	4.0	1.1	16.3	2.4	1.7	1.8	0.9	1.8	1.4	2.0	1.9	0.3	1.7	11.8	0.0	0.7	2.1	1.2	3.6	7.1	3.5	1.7	0.7	5.8	1.0	6.8	6.1	1.3	1.9	5.3	9.8	0.6	4.5	1.6	2.9	4.4	5.7	33.9	0.9	1.1	3.4	1.6	1.6	1.4	0.7	6.6	17.1	9.3	5.2	1.1	0.8	3.8	4.9	2.4	5.4	9.9	6.5	31.6	3.9	12.1	1.0	5.9	17.9	7.2	5.6	8.0	21.4	7.3	13.4	6.5	0.6	4.9	10.4	0.3	1.3	1.4	2.0	10.1	7.1	5.2	3.4	14.5	6.2	1.7	7.5	4.7	8.0	10.8	4.0	6.5	15.9	15.8	23.2	11.7	11.4	5.4	25.4	1.2	2.2	7.4	8.9	5.4	15.3	6.0	24.7	4.4	4.5	8.0	6.8	3.0	1.6	2.5	0.8	1.6	0.4	0.3	0.8	0.5	0.9	0.9	1.4	1.4	3.4	1.6	1.3	1.1	0.3	0.7	1.7	1.7	1.8	1.7	1.7	1.8	1.9	0.3	1.2	0.6
CNTD1	"CNTD, FLJ40137"	ENSG00000176563	"Cyclin N-terminal domain containing 1"	Q8N815	17	42798792-42811587	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	11	"testis: 31.0"	"Cell line enhanced"	"Detected in some"		"A-431: 6.1;ASC diff: 4.2;SiHa: 3.3;T-47d: 2.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.7"	"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA023324			Uncertain	"Nucleoplasm,Plasma membrane,Focal adhesion sites"				Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"HPA023324: AB_1848931"	"unprognostic (5.92e-2)"	"unprognostic (1.99e-3)"	"unprognostic (3.66e-2)"	"unprognostic (2.13e-2)"	"unprognostic (1.25e-1)"	"unprognostic (6.29e-3)"	"unprognostic (6.61e-2)"	"unprognostic (1.09e-2)"	"unprognostic (7.82e-2)"	"unprognostic (6.18e-2)"	"unprognostic (1.36e-2)"	"unprognostic (2.07e-1)"	"unprognostic (5.89e-7)"	"unprognostic (1.52e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.81e-4)"	0.2	0.1	0.7	0.0	1.4	0.0	1.6	0.2	1.7	0.2	0.6	0.4	0.0	0.0	0.1	0.9	0.1	0.5	0.0	0.1	1.5	0.3	1.2	0.1	0.3	0.0	0.5	0.8	0.3	0.8	0.0	0.1	0.0	0.9	1.1	1.5	0.1	0.5	0.0	0.2	0.1	0.2	0.7	0.8	0.1	2.3	31.0	1.6	0.0	0.1	0.0	0.0	0.2	0.1	0.9	0.1	2.7	0.3	0.1	0.3	0.3	6.1	0.7	0.4	1.3	4.2	1.5	0.0	0.0	0.3	0.4	1.4	0.0	0.0	0.0	0.1	1.2	0.0	0.0	0.0	1.0	0.2	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.6	0.0	0.0	1.1	0.0	0.6	1.3	0.0	0.0	0.2	0.5	0.0	0.0	0.2	0.0	0.3	0.7	0.0	0.0	0.0	3.3	0.3	0.8	2.4	0.0	0.0	1.4	0.2	0.0	0.0	0.0	0.3	0.1	0.1	0.5	0.4	0.0	0.3	0.0	0.3	0.2	0.3	0.4	0.1	0.0	0.1	0.9	0.0	0.0	2.7	0.1	0.1	0.0	0.0	0.3	0.7	1.4	0.2	1.7	1.5	0.3	0.5	0.8	0.9	1.6
CORO2B	"ClipinC, KIAA0925"	ENSG00000103647	"Coronin 2B"	Q9UQ03	15	68578969-68727806	"Plasma proteins, Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 53.5;fallopian tube: 27.4"	"Cell line enhanced"	"Detected in many"		"ASC diff: 12.7;ASC TERT1: 27.4;HSkMC: 19.7;hTEC/SVTERT24-B: 16.0;U-87 MG: 27.3"	"Group enriched"	"Detected in many"	8	"glioma: 34.7;melanoma: 21.5"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	13	"memory B-cell: 1.2;naive B-cell: 4.5"	"Lineage enriched"	"Detected in single"	21	"B-cells: 4.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA017960	Enhanced		Approved	"Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"		"HPA017960: AB_1847167"	"unprognostic (1.35e-1)"	"unprognostic (2.63e-2)"	"unprognostic (2.81e-3)"	"unprognostic (4.71e-3)"	"unprognostic (3.28e-1)"	"unprognostic (8.11e-5)"	"unprognostic (4.77e-2)"	"unprognostic (1.24e-1)"	"unprognostic (3.68e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.33e-3)"	"unprognostic (4.12e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.10e-2)"	"unprognostic (5.83e-2)"	"unprognostic (3.59e-2)"	"unprognostic (1.87e-2)"	10.9	4.4	15.7	3.2	30.1	1.9	4.8	33.7	53.5	6.5	3.4	27.3	0.8	2.4	7.5	3.9	2.7	27.4	6.3	7.2	23.0	15.1	5.5	2.0	5.8	3.5	20.9	18.8	18.4	2.9	1.6	1.5	4.7	23.6	3.2	2.9	11.8	3.4	6.9	3.8	5.6	3.3	8.4	35.0	3.6	2.0	2.2	17.5	0.0	4.6	0.6	1.9	3.0	1.6	4.5	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.3	12.1	1.0	12.7	27.4	0.0	6.1	6.8	1.0	1.5	0.1	1.3	1.4	0.7	1.0	0.0	0.4	0.1	4.4	0.0	0.5	0.0	0.0	0.6	4.6	0.0	0.1	19.7	0.1	16.0	0.9	0.4	0.0	0.0	11.2	0.0	0.0	0.0	2.9	0.0	0.9	0.0	0.5	1.7	0.0	7.0	0.1	0.1	0.0	3.6	0.0	1.4	0.1	3.6	4.1	0.7	8.1	0.0	0.0	1.4	27.3	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.2	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.7	30.1	33.7	29.3	23.0	15.1	20.9	18.8	23.6	17.5
CPAMD8	"K-CAP, KIAA1283, VIP"	ENSG00000160111	"C3 and PZP like, alpha-2-macroglobulin domain containing 8"	Q8IZJ3	19	16892947-17026815	"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 19.3;retina: 23.7;seminal vesicle: 30.5"	"Group enriched"	"Detected in some"	7	"BEWO: 14.4;EFO-21: 9.3;T-47d: 25.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"classical monocyte: 1.5"	"Low lineage specificity"	"Detected in single"							"Low region specificity"	"Detected in single"			"HPA031327, HPA031328, HPA031329, HPA031330"	Uncertain		Uncertain	"Focal adhesion sites"	"Secreted to blood"		180000	"Focal adhesion sites"		"HPA031327: , HPA031328: , HPA031329: , HPA031330: AB_10603788"	"unprognostic (4.71e-3)"	"unprognostic (1.07e-2)"	"unprognostic (4.20e-2)"	"unprognostic (2.76e-2)"	"unprognostic (4.32e-2)"	"unprognostic (4.06e-3)"	"unprognostic (7.85e-2)"	"unprognostic (9.30e-2)"	"unprognostic (1.58e-1)"	"unprognostic (2.71e-2)"	"unprognostic (1.62e-1)"	"unprognostic (4.24e-2)"	"unprognostic (8.69e-2)"	"unprognostic (1.01e-3)"	"unprognostic (2.08e-1)"	"unprognostic (8.45e-2)"	"unprognostic (1.80e-2)"	3.1	1.3	1.0	0.4	2.3	0.2	3.6	0.6	2.3	5.3	0.4	2.9	6.5	0.2	1.5	8.2	0.6	0.6	0.4	7.0	1.2	1.3	8.9	0.5	11.5	1.5	4.9	0.4	0.6	0.4	3.5	2.0	3.1	5.1	19.3	0.0	23.7	1.1	30.5	1.7	0.4	0.4	0.4	5.6	1.1	0.1	0.9	2.8	0.9	11.6	1.4	0.4	1.2	1.4	0.2	0.0	0.6	1.5	0.1	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	14.4	0.0	0.1	0.0	0.0	0.0	0.0	0.3	9.3	0.2	0.0	0.1	0.3	0.0	0.0	0.0	0.2	0.0	0.0	0.8	0.0	0.2	0.2	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	2.2	0.5	0.0	1.4	0.0	0.1	0.3	1.9	0.0	0.0	0.0	0.4	0.0	25.2	0.1	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.5	0.6	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	1.0	2.3	0.6	2.3	1.2	1.3	4.9	0.4	5.1	2.8
CUTA	"ACHAP, C6orf82"	ENSG00000112514	"CutA divalent cation tolerance homolog"	O60888	6	33416442-33418317	"Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016787, HPA064369"	Uncertain		Approved	"Plasma membrane,Focal adhesion sites"	"Secreted to blood"		35000000	"Plasma membrane, Focal adhesion sites"		"CAB016787: , HPA064369: "	"unprognostic (7.03e-2)"	"unprognostic (5.44e-2)"	"unprognostic (4.56e-2)"	"unprognostic (8.91e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.98e-2)"	"prognostic favourable (8.50e-4)"	"unprognostic (1.87e-1)"	"unprognostic (2.78e-2)"	"unprognostic (1.27e-3)"	"unprognostic (1.91e-1)"	"unprognostic (5.55e-2)"	"unprognostic (9.90e-2)"	"unprognostic (1.54e-1)"	"unprognostic (7.94e-2)"	"unprognostic (2.74e-1)"	26.6	65.6	47.9	28.3	60.1	33.5	47.6	37.7	73.7	47.7	37.9	36.8	53.9	42.1	40.1	78.5	30.5	46.0	48.8	49.6	45.2	44.9	46.3	61.6	39.0	77.4	46.5	37.8	57.7	66.6	43.8	86.1	45.7	39.8	38.8	28.9	34.2	74.3	69.7	34.6	32.7	37.2	32.4	47.0	36.0	38.7	27.3	31.6	52.2	69.7	30.3	31.3	42.6	28.9	56.5	31.4	27.1	32.0	49.9	69.8	60.8	43.2	25.9	41.5	52.6	31.3	30.8	20.1	39.6	74.0	76.5	81.6	25.8	27.0	30.6	30.7	45.3	26.5	27.0	40.3	43.2	25.9	59.7	31.9	43.0	67.6	40.7	24.8	24.3	40.8	34.0	36.7	31.1	20.5	39.1	62.2	55.9	33.6	37.5	52.8	37.2	34.3	41.2	24.8	80.8	52.6	18.8	81.3	41.4	23.7	41.2	71.8	30.3	52.1	22.6	41.4	35.2	29.4	41.2	61.2	60.8	33.4	35.8	54.9	33.6	27.1	32.0	16.5	45.7	22.9	63.2	56.5	67.6	52.7	31.4	44.2	68.5	53.2	4.6	49.9	16.8	27.1	69.8	60.8	47.9	60.1	37.7	73.7	45.2	44.9	46.5	37.8	39.8	31.6
DCAF6	"IQWD1, PC326"	ENSG00000143164	"DDB1 and CUL4 associated factor 6"	Q58WW2	1	167935783-168075843	"Predicted intracellular proteins"	"Ubl conjugation pathway"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 155.9"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054305			Supported	"Nucleoplasm,Focal adhesion sites"				"Nucleoplasm, Focal adhesion sites"		"HPA054305: "	"unprognostic (1.54e-1)"	"unprognostic (2.11e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.31e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.19e-1)"	"unprognostic (5.42e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.20e-2)"	"unprognostic (9.21e-2)"	"unprognostic (7.06e-2)"	"unprognostic (6.00e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.49e-1)"	10.6	17.0	10.9	7.8	12.2	6.2	8.8	10.5	17.8	10.2	11.5	3.9	8.4	6.2	9.5	11.4	9.3	7.7	8.2	43.8	7.6	5.5	9.5	26.2	7.3	4.8	5.2	11.5	8.3	6.1	10.8	11.3	7.8	6.5	10.5	8.7	5.7	10.3	11.9	155.9	6.4	7.8	10.2	4.8	5.9	9.8	21.5	4.8	7.8	8.2	27.3	7.3	9.1	7.3	6.2	7.7	12.5	13.9	4.4	7.2	5.0	22.9	11.0	6.1	9.9	20.2	28.8	21.5	23.5	35.3	16.7	24.9	18.2	19.4	19.0	13.7	30.3	17.3	9.5	17.6	23.7	10.7	10.2	20.2	16.7	13.1	16.3	9.0	9.7	20.4	17.8	15.8	13.2	18.2	22.8	15.7	24.5	5.3	10.0	8.3	3.9	12.2	7.8	12.6	14.7	41.7	11.2	9.0	7.1	18.8	17.3	12.9	29.6	11.1	25.6	16.7	10.4	16.1	9.7	16.9	13.7	14.8	22.3	7.8	6.8	6.0	7.0	12.5	6.7	9.6	7.2	6.2	5.4	5.8	7.7	4.5	5.0	6.4	7.2	4.4	13.9	4.6	6.1	5.0	10.9	12.2	10.5	17.8	7.6	5.5	5.2	11.5	6.5	4.8
DLGAP4	"DAP4, KIAA0964, SAPAP4"	ENSG00000080845	"DLG associated protein 4"	Q9Y2H0	20	36306336-36528637	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-138 MG: 62.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054105, HPA056378"	Approved		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"				"Nucleoplasm, Cytosol"	"Focal adhesion sites"	"HPA054105: , HPA056378: "	"unprognostic (1.11e-1)"	"unprognostic (1.42e-1)"	"unprognostic (9.00e-2)"	"prognostic unfavourable (2.24e-5)"	"unprognostic (1.35e-1)"	"unprognostic (1.37e-1)"	"prognostic unfavourable (3.73e-6)"	"unprognostic (1.23e-1)"	"prognostic favourable (9.88e-5)"	"unprognostic (1.28e-1)"	"unprognostic (2.18e-2)"	"unprognostic (8.45e-2)"	"prognostic unfavourable (2.48e-4)"	"unprognostic (1.07e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.53e-1)"	18.8	16.6	25.7	14.3	32.9	4.5	18.0	16.2	31.9	19.0	20.1	9.0	14.9	13.5	23.1	13.1	16.8	18.5	17.0	25.9	23.7	12.7	10.2	11.0	21.6	9.8	9.5	20.7	18.9	30.2	7.7	10.2	16.9	8.8	15.7	10.1	15.4	19.3	21.2	58.0	27.1	13.6	27.2	6.8	14.5	12.2	12.6	10.9	8.3	13.8	16.8	10.8	29.0	15.0	16.1	13.5	19.5	13.1	6.9	12.5	9.1	13.9	12.6	15.5	12.8	14.7	24.1	15.6	21.0	19.3	20.6	14.3	19.1	8.9	3.9	11.3	29.4	13.4	4.1	21.5	15.4	6.3	1.5	8.9	6.5	12.9	21.3	3.6	7.8	15.8	16.7	24.3	17.0	20.2	6.2	10.8	15.5	10.4	7.2	13.7	6.7	27.1	7.3	4.1	5.4	9.6	6.9	10.2	14.1	13.7	28.0	17.3	16.0	6.3	20.3	62.8	19.2	27.0	11.5	3.7	2.7	4.2	25.1	4.5	24.6	2.1	12.8	19.5	12.5	13.1	9.8	16.1	11.3	8.7	11.3	14.9	8.8	7.0	18.5	6.9	12.6	13.5	8.7	9.1	25.7	32.9	16.2	31.9	23.7	12.7	9.5	20.7	8.8	10.9
DOK5	"C20orf180, dJ805C22.1"	ENSG00000101134	"Docking protein 5"	Q9P104	20	54475597-54651171	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"skeletal muscle: 41.3"	"Cell line enhanced"	"Detected in some"		"AF22: 19.3;ASC diff: 7.9;hTEC/SVTERT24-B: 8.1;U-138 MG: 30.5"	"Group enriched"	"Detected in many"	6	"glioma: 18.0;ovarian cancer: 29.4"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054460, HPA065235"	Uncertain		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA054460: , HPA065235: "	"unprognostic (2.69e-1)"	"unprognostic (1.49e-1)"	"unprognostic (8.90e-2)"	"prognostic unfavourable (8.99e-7)"	"unprognostic (1.02e-1)"	"unprognostic (1.72e-2)"	"unprognostic (5.88e-4)"	"unprognostic (5.12e-2)"	"unprognostic (4.51e-3)"	"unprognostic (2.97e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.49e-1)"	"unprognostic (6.49e-2)"	"unprognostic (4.23e-3)"	"unprognostic (3.08e-1)"	"unprognostic (4.56e-2)"	"unprognostic (1.99e-2)"	3.5	2.7	15.5	2.3	11.0	0.6	2.0	1.4	14.8	1.8	1.3	6.6	0.4	1.0	2.1	1.0	2.4	13.6	10.6	18.1	11.0	12.5	3.6	3.2	1.0	1.2	8.4	6.2	2.4	1.9	0.9	1.2	2.4	7.3	1.6	1.4	7.6	1.7	1.5	41.3	0.6	1.1	3.5	5.4	0.9	0.9	2.2	6.4	0.0	5.9	6.4	1.0	3.6	3.5	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	19.3	0.0	7.9	6.7	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	2.6	0.0	8.1	0.0	1.0	0.0	2.3	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	2.0	4.1	0.0	5.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	30.5	1.9	0.8	0.0	0.0	0.0	0.1	1.3	0.0	2.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.5	11.0	1.4	12.6	11.0	12.5	8.4	6.2	7.3	6.4
DOK6	"DOK5L, HsT3226, MGC20785"	ENSG00000206052	"Docking protein 6"	Q6PKX4	18	69401055-69849087	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 22.1"	"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 10.4;Hep G2: 10.9;RPMI-8226: 10.6;SCLC-21H: 4.8;SH-SY5Y: 10.9"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA041099, HPA063534"	Approved		Approved	"Focal adhesion sites,Cytosol"				"Focal adhesion sites, Cytosol"		"HPA041099: , HPA063534: "	"unprognostic (5.83e-2)"	"unprognostic (1.39e-1)"	"unprognostic (2.06e-1)"	"unprognostic (1.21e-1)"	"unprognostic (2.77e-2)"	"unprognostic (2.59e-1)"	"unprognostic (1.55e-1)"	"unprognostic (1.90e-2)"	"unprognostic (8.62e-2)"	"unprognostic (5.99e-2)"	"unprognostic (1.04e-2)"	"unprognostic (4.60e-3)"	"unprognostic (2.13e-4)"	"unprognostic (2.30e-3)"	"unprognostic (2.88e-2)"	"unprognostic (4.49e-3)"	"unprognostic (1.09e-3)"	2.1	1.6	21.3	1.6	11.3	0.6	1.3	6.8	22.1	3.8	1.5	0.9	0.3	1.0	3.0	1.4	1.7	1.7	5.8	10.2	19.2	9.2	8.7	4.4	4.2	1.2	13.7	13.1	4.2	0.7	3.4	1.1	9.9	14.0	3.5	1.3	5.5	1.7	4.2	0.6	1.2	1.3	6.6	2.7	1.8	1.3	2.8	2.7	0.0	4.1	0.0	1.2	5.2	6.6	0.0	0.0	0.0	0.0	0.9	0.9	0.4	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.2	0.0	10.4	0.0	0.0	0.0	0.0	0.0	1.2	1.0	0.0	10.9	0.3	0.0	0.2	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	10.6	0.0	0.0	4.8	10.9	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.6	0.0	1.5	0.3	0.0	0.0	3.1	0.0	3.2	0.0	0.0	0.0	0.9	0.0	0.6	0.0	0.2	0.4	0.0	0.0	0.1	0.5	0.0	0.9	0.0	0.0	0.3	0.4	21.3	11.3	6.8	17.1	19.2	9.2	13.7	13.1	14.0	2.7
EIF2B2	"EIF-2Bbeta, EIF2B"	ENSG00000119718	"Eukaryotic translation initiation factor 2B subunit beta"	P49770	14	75002911-75012366	"Disease related genes, Predicted intracellular proteins"	"Protein biosynthesis"	"Initiation factor"	"Disease mutation, Leukodystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005841, CAB037105, HPA048028"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"	Nucleoplasm	"CAB037105: AB_1840834, HPA005841: AB_1078725, HPA048028: "	"unprognostic (1.10e-1)"	"unprognostic (4.41e-2)"	"unprognostic (5.70e-2)"	"unprognostic (6.71e-2)"	"unprognostic (7.64e-2)"	"unprognostic (3.45e-3)"	"prognostic unfavourable (2.26e-6)"	"unprognostic (1.48e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.65e-2)"	"unprognostic (4.95e-2)"	"unprognostic (1.01e-1)"	"prognostic favourable (2.95e-4)"	"unprognostic (4.15e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.28e-2)"	11.8	20.1	11.6	9.2	12.3	9.1	11.6	11.0	16.4	13.2	13.9	13.2	9.2	9.8	11.6	15.8	14.3	10.4	12.6	15.0	11.5	12.0	19.6	18.8	10.3	11.6	13.6	11.4	12.3	12.9	32.3	11.9	20.4	15.7	13.6	12.2	11.7	11.1	14.8	29.0	12.5	13.1	11.0	14.8	12.1	10.9	20.1	11.0	17.7	33.4	11.2	12.7	14.9	9.7	4.2	5.1	7.7	3.9	6.5	8.1	4.8	5.0	6.1	5.0	5.7	5.8	4.8	6.6	3.3	5.4	6.4	7.4	7.7	5.2	4.5	2.1	5.1	3.9	7.7	7.6	9.6	2.7	5.8	3.9	5.4	5.3	7.5	2.9	4.7	4.4	7.3	8.1	8.4	21.8	3.5	4.4	13.6	14.9	4.6	3.6	3.6	9.1	2.9	5.9	3.7	9.0	6.1	5.4	4.3	3.4	4.9	7.2	7.9	2.8	5.6	4.9	4.8	2.2	4.1	7.6	6.2	5.3	5.4	3.7	3.7	7.7	3.9	2.8	6.7	3.9	5.6	4.2	5.9	5.4	5.1	4.1	4.4	4.6	2.2	6.5	3.7	4.2	8.1	4.8	11.6	12.3	11.0	16.4	11.5	12.0	13.6	11.4	15.7	11.0
EMC4	"FLJ90746, MGC24415, PIG17, TMEM85"	ENSG00000128463	"ER membrane protein complex subunit 4"	Q5J8M3	15	34224999-34230156	"Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Apoptosis			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026868, HPA053440"	Approved		Supported	"Focal adhesion sites"				"Focal adhesion sites"		"HPA026868: , HPA053440: "	"unprognostic (8.99e-2)"	"unprognostic (1.59e-1)"	"unprognostic (7.68e-2)"	"unprognostic (3.29e-2)"	"unprognostic (9.23e-2)"	"unprognostic (1.29e-3)"	"unprognostic (3.25e-1)"	"unprognostic (3.61e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.78e-3)"	"unprognostic (1.33e-1)"	"unprognostic (2.20e-2)"	"unprognostic (2.52e-1)"	"unprognostic (5.42e-2)"	"unprognostic (4.20e-2)"	"unprognostic (2.96e-1)"	"unprognostic (1.97e-2)"	36.3	34.3	43.5	23.4	48.3	25.4	35.2	34.9	54.3	33.5	32.2	31.0	25.7	27.5	33.5	54.3	36.2	35.4	28.4	38.5	39.4	40.6	39.1	47.5	27.1	24.5	41.7	42.8	35.3	45.2	29.1	29.5	41.5	48.6	32.5	30.1	32.8	38.9	34.7	95.1	29.6	27.9	30.1	36.7	27.2	31.2	26.4	32.0	26.9	34.6	41.2	29.0	28.9	32.6	71.6	53.3	65.7	59.4	60.3	65.9	78.0	31.5	66.4	27.9	36.2	36.5	33.2	25.7	36.3	41.6	44.8	39.0	43.2	28.2	12.5	48.0	41.8	60.9	28.4	35.6	32.2	38.2	27.5	23.7	61.2	39.6	44.1	35.9	23.8	33.3	33.9	32.6	36.7	37.0	29.5	50.0	39.0	36.0	28.5	38.5	31.3	43.5	26.4	25.5	35.5	42.7	49.7	36.9	45.0	27.0	39.6	19.2	26.5	42.7	28.1	41.2	28.2	35.4	36.9	44.3	62.7	32.0	50.1	42.8	34.7	65.7	52.3	54.5	53.0	54.0	57.9	71.6	59.5	63.4	52.2	54.6	60.8	59.8	29.1	60.3	59.4	53.3	65.9	78.0	43.5	48.3	34.9	54.3	39.4	40.6	41.7	42.8	48.6	32.0
ENAH	"FLJ10773, MENA, NDPP1"	ENSG00000154380	"ENAH, actin regulator"	Q8N8S7	1	225486835-225653142	"Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"HPA028448, HPA028696"	Enhanced		Enhanced	"Plasma membrane,Focal adhesion sites,Cytosol"			18000	"Plasma membrane, Focal adhesion sites, Cytosol"		"HPA028448: AB_10600766, HPA028696: AB_10611249"	"unprognostic (2.56e-2)"	"unprognostic (8.03e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.35e-2)"	"unprognostic (5.61e-3)"	"unprognostic (2.85e-1)"	"unprognostic (1.21e-3)"	"unprognostic (2.30e-1)"	"unprognostic (2.23e-1)"	"unprognostic (9.22e-2)"	"unprognostic (4.71e-3)"	"unprognostic (2.14e-1)"	"unprognostic (2.24e-3)"	"unprognostic (8.84e-2)"	"unprognostic (5.83e-2)"	"unprognostic (7.92e-2)"	"unprognostic (2.93e-2)"	19.2	17.4	15.8	11.9	17.0	0.6	11.1	7.6	17.6	17.8	24.4	15.3	39.9	9.3	21.9	19.9	16.7	11.8	29.0	18.2	16.7	15.3	5.8	5.9	13.8	3.5	13.7	11.3	24.3	16.7	22.5	10.3	13.5	12.7	26.4	8.0	3.3	14.5	44.9	20.2	8.2	8.0	61.4	13.4	17.3	21.0	18.5	17.2	5.3	6.8	11.4	3.5	35.3	21.9	2.1	0.4	1.0	0.3	0.5	0.4	0.0	20.2	16.2	20.1	18.2	7.9	10.4	26.0	22.5	10.8	13.6	10.3	10.4	7.5	8.6	60.0	34.7	17.9	23.5	8.5	12.9	0.1	14.5	8.9	14.4	14.0	23.6	1.0	0.3	16.1	10.3	17.6	22.6	10.7	0.6	0.4	13.4	3.9	4.0	1.0	33.9	14.7	6.1	28.5	0.2	6.2	15.7	19.8	16.0	44.2	16.9	14.9	20.1	1.3	20.8	35.3	26.0	29.3	44.6	0.9	2.5	5.8	19.4	1.1	18.0	1.0	0.3	0.2	0.4	0.1	0.3	0.6	0.4	0.3	0.0	2.1	0.4	0.4	1.0	0.5	0.2	0.4	0.2	0.0	15.8	17.0	7.6	13.7	16.7	15.3	13.7	11.3	12.7	17.2
EXD3	"FLJ20433, LOC54932, mut-7"	ENSG00000187609	"Exonuclease 3'-5' domain containing 3"	Q8N9H8	9	137306896-137423262	"Predicted intracellular proteins"		"Exonuclease, Hydrolase, Nuclease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HMC-1: 21.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			HPA047395	Approved		Approved	"Actin filaments,Focal adhesion sites"				"Focal adhesion sites"	"Actin filaments"	"HPA047395: AB_10962864"	"unprognostic (2.91e-1)"	"unprognostic (5.67e-2)"	"unprognostic (1.75e-3)"	"prognostic favourable (4.30e-4)"	"unprognostic (1.88e-1)"	"unprognostic (1.70e-1)"	"unprognostic (6.65e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.50e-3)"	"unprognostic (1.72e-2)"	"unprognostic (5.21e-2)"	"unprognostic (7.99e-3)"	"unprognostic (2.05e-1)"	"unprognostic (8.67e-2)"	"unprognostic (5.05e-2)"	9.7	10.9	8.0	10.1	11.1	8.4	10.4	11.9	12.4	11.2	15.5	16.5	14.9	22.8	10.2	17.5	11.1	11.5	14.1	10.5	8.7	7.9	11.8	7.3	12.3	8.0	9.5	11.2	11.1	13.3	8.3	13.8	8.3	11.0	14.0	8.9	13.9	17.5	11.4	15.9	17.4	20.6	15.8	7.4	16.3	14.3	5.1	9.1	1.7	11.4	6.8	7.8	10.0	10.8	4.0	5.3	10.8	6.0	5.3	8.5	3.6	5.7	4.9	2.4	6.8	2.0	3.0	5.7	2.8	3.3	2.5	3.9	3.3	12.3	2.5	7.9	2.1	10.7	0.7	3.1	0.8	5.8	5.9	2.0	8.7	5.1	6.2	1.4	21.5	3.4	4.3	2.2	1.9	8.6	4.7	4.6	2.1	15.4	0.1	4.9	2.8	3.4	4.4	2.0	17.2	5.1	3.3	3.3	5.9	2.8	6.0	2.7	9.7	6.4	10.7	3.5	3.4	5.5	4.3	6.1	2.7	2.1	6.7	4.5	6.6	10.8	5.0	10.6	3.5	6.0	4.0	3.9	6.0	3.3	5.3	4.0	4.8	3.7	1.2	5.3	5.8	3.4	8.5	3.6	8.0	11.1	11.9	12.4	8.7	7.9	9.5	11.2	11.0	9.1
FABP3	"FABP11, H-FABP, MDGI, O-FABP"	ENSG00000121769	"Fatty acid binding protein 3"	P05413	1	31365625-31376850	"Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins"	Transport			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	9	"heart muscle: 420.9;skeletal muscle: 129.4"	"Cell line enriched"	"Detected in some"	5	"ASC TERT1: 117.9"	"Cancer enhanced"	"Detected in all"		"renal cancer: 92.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"							"CAB017830, HPA055754"	Enhanced		Uncertain	"Golgi apparatus,Plasma membrane,Focal adhesion sites"			4400000	"Focal adhesion sites"	"Golgi apparatus, Plasma membrane"	"CAB017830: , HPA055754: "	"unprognostic (2.07e-2)"	"unprognostic (2.50e-2)"	"unprognostic (1.32e-3)"	"unprognostic (1.73e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.62e-1)"	"unprognostic (6.07e-3)"	"unprognostic (1.04e-1)"	"unprognostic (6.86e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.67e-1)"	"prognostic favourable (1.54e-7)"	"unprognostic (5.80e-3)"	"unprognostic (3.45e-1)"	"unprognostic (7.38e-3)"	"unprognostic (9.76e-3)"	2.3	5.2	8.1	0.7	6.0	0.5	22.7	1.4	14.6	3.9	1.3	0.8	3.4	0.7	6.8	5.3	3.1	2.8	1.1	420.9	11.0	5.3	21.3	1.9	4.3	1.3	9.8	6.0	2.2	0.4	0.3	0.7	1.1	13.7	5.0	1.5	3.0	4.4	14.0	129.4	0.9	0.6	13.0	3.4	3.9	3.6	2.0	1.3	0.1	1.7	31.6	2.2	2.5	2.5	1.4	0.5	0.0	0.9	0.2	0.9	0.6	0.1	0.0	3.2	0.2	22.6	117.9	1.1	0.9	8.7	0.1	3.1	0.2	0.8	0.2	12.5	2.4	0.3	0.9	0.0	0.1	0.1	0.5	0.3	1.1	2.3	1.5	0.2	0.0	10.4	0.0	2.3	0.0	0.0	0.2	0.0	1.1	0.0	0.0	0.2	6.0	0.4	0.1	1.2	0.0	2.8	0.0	0.3	0.0	0.5	0.0	13.5	0.1	1.4	0.3	0.2	0.1	2.1	0.1	0.1	0.4	0.1	0.5	0.1	0.2	0.0	0.4	0.0	0.9	0.9	0.6	0.2	0.5	0.5	0.5	1.4	0.0	0.9	0.0	0.2	0.1	0.4	0.6	0.6	8.1	6.0	1.4	13.3	11.0	5.3	9.8	6.0	13.7	1.3
FAM222A	"C12orf34, FLJ14721"	ENSG00000139438	"Family with sequence similarity 222 member A"	Q5U5X8	12	109714228-109770507	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 37.9"	"Cell line enriched"	"Detected in many"	4	"SH-SY5Y: 50.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA040181, HPA058774"	Uncertain		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites,Mitochondria"				"Nucleoplasm, Plasma membrane"	"Focal adhesion sites, Mitochondria"	"HPA040181: AB_10796448, HPA058774: "	"unprognostic (8.59e-3)"	"prognostic favourable (1.82e-5)"	"unprognostic (1.43e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.92e-1)"	"unprognostic (2.05e-2)"	"unprognostic (1.46e-2)"	"unprognostic (1.03e-1)"	"unprognostic (6.66e-2)"	"unprognostic (8.17e-2)"	"prognostic favourable (4.81e-4)"	"unprognostic (1.15e-1)"	"unprognostic (4.16e-2)"	"prognostic favourable (8.59e-4)"	"unprognostic (3.93e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.24e-1)"	1.8	16.0	7.3	2.3	17.4	2.0	3.0	15.1	25.5	1.6	3.3	37.9	0.0	10.0	1.5	2.7	2.1	1.4	2.6	4.4	11.7	9.6	7.7	2.7	1.8	1.7	23.2	7.9	7.8	6.9	1.5	13.1	1.3	15.1	2.3	3.0	10.3	7.3	2.1	2.8	4.7	5.1	1.8	27.8	6.3	8.0	17.4	23.0	0.0	1.4	0.0	2.1	1.4	2.4	0.2	0.6	0.9	0.2	0.0	0.2	0.0	0.8	1.3	0.7	1.6	0.4	0.0	0.5	0.2	0.1	0.7	0.1	11.7	0.2	0.1	1.0	0.3	0.5	0.8	0.0	0.2	7.5	1.7	1.4	0.3	2.6	0.1	1.1	1.5	0.0	0.0	0.1	0.0	0.0	0.5	0.2	0.1	4.7	0.3	1.5	1.3	2.3	0.9	3.4	0.5	1.5	0.6	8.3	50.2	1.0	1.6	3.3	1.9	1.2	0.1	0.2	1.4	0.6	1.0	1.3	1.6	1.0	0.1	0.8	1.6	0.0	0.2	0.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.0	7.3	17.4	15.1	13.7	11.7	9.6	23.2	7.9	15.1	23.0
FBLIM1	"CAL, FBLP-1, migfilin"	ENSG00000162458	"Filamin binding LIM protein 1"	Q8WUP2	1	15756607-15786594	"Predicted intracellular proteins"	"Cell adhesion, Cell shape"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 53.1;TIME: 82.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA025287, HPA072750"	Approved		Enhanced	"Nucleoli fibrillar center,Cell Junctions,Focal adhesion sites"				"Cell Junctions, Focal adhesion sites"	"Nucleoli fibrillar center"	"HPA025287: AB_1848443, HPA072750: "	"unprognostic (4.10e-2)"	"prognostic unfavourable (4.07e-4)"	"unprognostic (2.26e-1)"	"unprognostic (5.33e-2)"	"unprognostic (2.46e-2)"	"unprognostic (1.52e-1)"	"unprognostic (9.33e-2)"	"unprognostic (8.77e-3)"	"prognostic unfavourable (6.15e-4)"	"unprognostic (2.02e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.09e-1)"	"prognostic unfavourable (8.64e-4)"	"unprognostic (8.33e-2)"	"unprognostic (3.01e-1)"	"unprognostic (1.08e-1)"	"unprognostic (8.21e-2)"	11.6	6.0	1.7	12.8	1.4	0.0	10.1	0.8	1.3	21.5	36.6	1.4	26.8	24.6	30.3	15.8	17.8	16.5	60.2	21.7	1.2	1.0	18.2	3.0	14.7	16.1	1.8	1.6	36.0	13.0	13.9	3.8	21.5	2.3	26.7	15.7	9.0	13.0	26.5	4.1	6.2	62.8	18.7	1.3	22.7	18.9	22.3	0.9	1.3	10.3	7.4	6.3	24.7	16.9	1.8	1.3	4.6	1.2	1.6	1.2	0.3	6.4	3.6	3.2	0.1	0.8	1.7	4.4	11.0	17.6	8.2	6.5	1.2	9.7	0.0	23.9	17.6	12.5	2.3	25.2	4.0	0.0	1.2	0.0	0.9	6.2	21.1	0.0	0.1	8.4	16.8	6.8	16.1	53.1	0.2	1.6	2.7	0.1	0.1	0.1	3.3	4.7	0.0	0.0	0.2	10.2	4.5	0.0	7.8	5.8	0.7	1.2	1.3	0.1	82.8	10.8	1.4	0.1	5.0	0.1	0.2	0.1	1.6	0.0	0.1	4.6	1.2	1.0	0.7	0.5	0.6	1.0	0.7	0.7	0.4	1.8	1.1	1.2	3.5	1.6	0.7	1.3	0.4	0.3	1.7	1.4	0.8	1.3	1.2	1.0	1.8	1.6	2.3	0.9
FBXO28	"CENP-30, Fbx28, FLJ10766, KIAA0483"	ENSG00000143756	"F-box protein 28"	Q9NVF7	1	224114087-224162047	"Plasma proteins, Predicted intracellular proteins"	"Ubl conjugation pathway"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA003289			Supported	"Nucleoplasm,Focal adhesion sites"				Nucleoplasm	"Focal adhesion sites"	"HPA003289: "	"unprognostic (4.91e-2)"	"unprognostic (5.57e-2)"	"unprognostic (1.78e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.43e-1)"	"unprognostic (2.12e-1)"	"unprognostic (8.25e-2)"	"unprognostic (2.03e-1)"	"unprognostic (7.09e-2)"	"unprognostic (5.09e-3)"	"unprognostic (2.60e-1)"	"unprognostic (1.98e-3)"	"unprognostic (9.46e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.61e-1)"	17.4	13.1	16.4	14.9	19.7	12.1	19.6	22.5	21.6	18.7	15.9	15.0	13.1	13.3	16.2	13.3	22.2	14.1	15.1	15.0	15.3	15.6	21.4	26.6	14.0	14.9	15.9	13.6	18.7	13.4	25.7	16.2	15.8	20.2	16.5	17.1	11.9	16.6	14.9	24.6	32.3	14.4	15.7	15.6	16.1	13.7	11.9	15.5	19.4	15.7	13.1	16.1	17.5	20.0	10.3	10.0	14.7	8.9	10.9	11.0	5.7	14.0	6.2	9.7	10.4	10.2	11.8	16.0	14.2	11.7	9.7	9.2	8.6	11.1	6.8	14.8	13.0	12.4	14.3	13.8	16.7	9.6	16.0	8.6	7.9	6.2	12.7	16.2	11.4	11.4	16.7	14.0	25.5	16.0	14.0	9.8	17.3	4.6	8.4	8.2	23.2	13.4	9.0	13.9	12.8	18.2	9.4	15.8	17.0	14.8	22.8	15.8	12.0	16.3	18.3	12.0	9.1	15.0	26.8	10.6	12.5	10.6	14.9	7.9	23.3	8.9	8.7	14.7	7.8	8.1	10.1	10.3	8.2	9.6	10.0	10.2	8.3	9.1	5.3	10.9	8.9	4.7	11.0	5.7	16.4	19.7	22.5	21.6	15.3	15.6	15.9	13.6	20.2	15.5
FCHSD2	"KIAA0769, SH3MD3"	ENSG00000137478	"FCH and double SH3 domains 2"	O94868	11	72836745-73142261	"Predicted intracellular proteins"	"Endocytosis, Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"RPMI-8226: 53.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038545, HPA038546"	Uncertain		Approved	"Nuclear speckles,Plasma membrane,Actin filaments,Focal adhesion sites"				"Nuclear speckles, Plasma membrane, Actin filaments"	"Focal adhesion sites"	"HPA038545: , HPA038546: AB_10673013"	"unprognostic (1.80e-2)"	"unprognostic (1.50e-2)"	"prognostic favourable (1.71e-4)"	"unprognostic (1.63e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.62e-3)"	"unprognostic (1.41e-2)"	"unprognostic (2.62e-1)"	"unprognostic (1.27e-2)"	"unprognostic (2.56e-1)"	"unprognostic (3.69e-2)"	"unprognostic (6.16e-2)"	"unprognostic (2.89e-3)"	"unprognostic (2.02e-1)"	"unprognostic (4.70e-1)"	"unprognostic (2.92e-1)"	"unprognostic (1.23e-1)"	18.5	15.1	28.4	41.5	27.8	19.0	26.5	16.9	25.2	13.2	11.4	17.0	6.8	7.0	12.7	10.2	9.7	11.5	18.1	19.2	24.8	21.4	10.6	13.3	26.2	31.7	19.7	12.1	26.3	9.2	10.2	7.6	24.1	17.6	11.2	11.2	12.5	11.1	11.7	7.4	7.0	14.4	16.4	15.6	30.8	10.1	17.4	26.3	19.2	11.9	4.8	33.0	17.9	11.3	16.8	19.0	11.6	4.8	1.1	2.4	2.0	5.1	4.4	9.1	11.9	3.7	9.3	8.5	9.1	19.5	5.6	4.7	3.4	7.5	27.9	11.2	11.7	7.4	5.3	5.3	7.5	9.6	2.7	22.5	5.0	11.2	9.6	11.0	2.9	5.6	5.8	5.5	6.7	13.4	4.9	18.2	7.2	5.5	13.3	18.9	2.0	5.4	20.3	14.2	53.2	8.8	6.9	4.6	6.5	3.3	6.2	11.9	4.5	8.1	17.2	18.0	6.9	12.5	2.8	17.5	9.7	24.8	3.1	18.3	5.2	11.0	4.8	10.5	1.7	3.1	1.2	13.0	1.8	2.0	4.8	16.8	2.1	2.4	11.6	1.1	1.6	19.0	1.8	2.0	28.4	27.8	16.9	20.2	24.8	21.4	19.7	12.1	17.6	26.3
FCMR	"FAIM3, TOSO"	ENSG00000162894	"Fc fragment of IgM receptor"	O60667	1	206904386-206923247	"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 99.6;intestine: 30.1;lymphoid tissue: 84.9"	"Group enriched"	"Detected in some"	5	"RPMI-8226: 51.7;U-266/70: 26.1"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"B-cells: 99.6;T-cells: 60.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA003910	Approved		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"	"Secreted to blood"		2400000	"Focal adhesion sites, Cytosol"	Nucleoplasm	"HPA003910: AB_1078798"	"prognostic favourable (4.23e-4)"	"unprognostic (1.16e-3)"	"unprognostic (7.48e-2)"	"unprognostic (3.06e-3)"	"unprognostic (2.04e-1)"	"unprognostic (2.69e-3)"	"unprognostic (1.15e-1)"	"unprognostic (4.85e-3)"	"unprognostic (1.03e-1)"	"unprognostic (3.97e-1)"	"unprognostic (3.23e-2)"	"unprognostic (2.01e-1)"	"unprognostic (8.15e-3)"	"unprognostic (8.06e-2)"	"unprognostic (2.12e-2)"	"unprognostic (3.74e-2)"	"unprognostic (5.05e-3)"	15.5	0.6	0.5	42.9	0.5	2.9	1.5	0.4	0.4	0.8	2.5	0.4	0.3	1.2	1.2	0.8	3.4	1.3	2.6	1.0	0.5	0.5	2.4	1.5	3.9	77.2	0.5	0.0	1.3	0.7	0.0	0.9	0.8	0.2	1.4	2.3	1.3	10.1	0.3	1.9	0.6	30.1	0.4	0.6	78.8	2.8	0.5	0.0	51.8	1.8	1.2	84.9	8.5	1.2	99.6	1.4	5.3	0.4	18.4	60.0	28.2	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	1.9	0.1	0.1	0.0	0.0	3.3	0.0	0.1	0.1	0.0	0.4	0.2	0.0	0.1	0.0	0.4	0.0	0.8	0.0	0.0	0.0	0.3	0.1	0.6	0.0	0.0	7.2	0.0	0.1	1.0	0.1	0.0	0.0	1.6	0.2	51.7	0.0	0.1	0.0	0.0	1.0	0.2	4.8	0.1	0.0	0.2	0.0	0.2	0.0	0.0	26.1	1.9	7.2	0.3	0.0	0.2	0.5	0.2	0.2	20.3	0.4	26.4	80.3	28.1	26.2	0.2	99.6	49.5	33.3	5.3	18.4	0.3	1.4	60.0	28.2	0.5	0.5	0.4	0.4	0.5	0.5	0.5	0.0	0.2	0.0
FERMT2	"KIND2, mig-2, PLEKHC1, UNC112B"	ENSG00000073712	"Fermitin family member 2"	Q96AC1	14	52857268-52952435	"Predicted intracellular proteins"	"Cell adhesion, Cell shape, Wnt signaling pathway"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	12	"MAIT T-cell: 3.8"	"Lineage enriched"	"Detected in single"	39	"T-cells: 3.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA040505	Uncertain		Supported	"Nucleoplasm,Focal adhesion sites"			58000	"Nucleoplasm, Focal adhesion sites"		"HPA040505: AB_10673300"	"unprognostic (4.38e-2)"	"unprognostic (4.25e-2)"	"unprognostic (8.00e-3)"	"unprognostic (2.42e-2)"	"unprognostic (2.51e-2)"	"unprognostic (4.89e-3)"	"unprognostic (2.50e-2)"	"unprognostic (1.92e-1)"	"unprognostic (4.21e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.58e-1)"	"unprognostic (1.99e-1)"	"unprognostic (3.87e-2)"	"unprognostic (3.96e-3)"	"unprognostic (7.69e-2)"	"unprognostic (3.14e-1)"	"unprognostic (1.73e-3)"	45.9	7.2	15.5	12.3	14.3	0.1	24.4	7.9	12.8	24.1	36.6	12.7	16.0	4.2	41.6	14.2	20.6	22.2	22.2	21.8	18.3	7.5	18.4	35.3	18.1	5.4	15.0	9.1	23.3	6.7	5.8	7.2	37.9	10.7	24.1	11.5	11.0	7.1	41.3	14.5	5.0	11.0	56.7	12.9	11.7	21.4	10.2	15.5	0.6	13.3	6.2	2.1	49.5	16.5	0.0	0.0	0.0	0.0	0.0	3.8	0.0	4.8	4.2	22.5	10.3	36.8	30.3	18.7	32.2	20.9	38.3	24.2	7.2	3.8	0.0	11.0	32.9	2.0	17.5	2.4	28.8	0.0	4.9	6.7	19.3	8.5	47.3	0.1	2.8	29.1	5.1	21.0	28.0	19.8	0.1	33.9	28.6	5.8	1.6	0.1	14.2	11.1	0.8	22.9	0.0	13.4	4.4	1.3	28.9	34.1	7.6	7.9	6.6	0.2	24.6	30.2	20.7	23.9	11.9	5.0	6.0	0.1	6.9	0.0	7.2	0.0	0.0	0.0	0.1	0.0	3.8	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.5	14.3	7.9	12.4	18.3	7.5	15.0	9.1	10.7	15.5
FHL2	"DRAL, SLIM3"	ENSG00000115641	"Four and a half LIM domains 2"	Q14192	2	105357712-105438513	"Predicted intracellular proteins"	"Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	11	"heart muscle: 312.0;ovary: 80.7"	"Cell line enhanced"	"Detected in many"		"LHCN-M2: 79.9;RPTEC TERT1: 73.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"granulocytes: 7.8;T-cells: 4.6"	"Group enriched"	"Detected in many"	4	"amygdala: 34.7;basal ganglia: 20.4;cerebral cortex: 51.8;hippocampal formation: 36.9;olfactory region: 18.3"	"Low region specificity"	"Detected in all"			"HPA005922, HPA006028, CAB008368"	Enhanced		Enhanced	"Actin filaments,Focal adhesion sites"				"Actin filaments, Focal adhesion sites"		"CAB008368: AB_591383, HPA005922: AB_1078860, HPA006028: AB_1078858"	"unprognostic (1.04e-1)"	"unprognostic (1.63e-3)"	"unprognostic (3.30e-1)"	"unprognostic (3.42e-2)"	"unprognostic (5.89e-2)"	"prognostic unfavourable (2.01e-4)"	"unprognostic (2.80e-2)"	"unprognostic (1.02e-3)"	"unprognostic (1.81e-1)"	"unprognostic (2.42e-2)"	"unprognostic (3.34e-2)"	"unprognostic (8.11e-2)"	"prognostic unfavourable (6.42e-5)"	"unprognostic (2.06e-1)"	"unprognostic (3.49e-1)"	"unprognostic (9.92e-3)"	"unprognostic (4.73e-2)"	8.3	9.8	1.5	5.7	3.6	1.5	8.9	0.8	5.6	16.3	10.5	1.4	5.1	6.0	14.8	12.1	9.2	6.8	16.5	312.0	2.5	0.4	5.5	7.8	2.1	2.7	0.9	3.0	80.7	1.6	0.2	4.1	16.7	1.1	12.8	7.4	18.5	6.2	8.7	9.4	5.6	16.9	11.9	0.8	3.9	12.7	13.4	0.7	3.1	6.6	16.9	5.1	18.1	7.6	1.4	1.3	7.8	0.8	1.5	4.6	2.6	22.5	5.3	3.1	0.1	10.1	12.8	29.6	42.8	11.3	27.5	33.1	9.5	35.3	0.0	3.6	52.1	7.0	4.6	38.9	31.4	0.9	3.5	15.8	6.5	7.1	40.0	0.0	3.5	26.6	21.4	43.3	28.8	56.0	4.1	1.3	79.9	0.8	3.6	0.1	6.5	16.7	0.0	4.8	0.6	73.7	16.0	0.1	1.0	16.0	7.2	11.1	9.0	0.5	26.9	20.0	20.3	22.1	34.4	0.4	0.0	0.1	31.9	0.0	20.6	7.8	0.8	1.0	2.2	0.4	1.5	1.1	1.8	3.6	0.7	1.4	1.4	2.9	4.5	1.5	0.3	1.3	4.6	2.6	1.5	3.6	0.8	5.6	2.5	0.4	0.9	3.0	1.1	0.7
GAS7	"KIAA0394, MGC1348"	ENSG00000007237	"Growth arrest specific 7"	O60861	17	9910609-10198551	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Differentiation, Neurogenesis"	"Developmental protein"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 86.2"	"Cell line enriched"	"Detected in some"	9	"WM-115: 107.7"	"Cancer enhanced"	"Detected in all"		"melanoma: 54.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 17.6"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004838, HPA064678"	Enhanced		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"				"Plasma membrane"	"Actin filaments, Focal adhesion sites"	"HPA004838: AB_2667263, HPA064678: "	"unprognostic (1.68e-2)"	"unprognostic (2.84e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.28e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.01e-2)"	"unprognostic (7.32e-2)"	"unprognostic (7.16e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.48e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.94e-3)"	"unprognostic (6.48e-2)"	"unprognostic (8.78e-2)"	"unprognostic (3.08e-2)"	"prognostic unfavourable (6.89e-4)"	19.1	6.5	22.1	15.4	40.3	18.7	10.8	86.2	64.7	22.6	9.3	33.4	1.7	5.2	9.7	4.4	17.0	12.6	11.5	23.1	25.8	15.0	1.5	2.1	9.9	5.9	28.1	25.0	5.9	2.8	1.4	1.7	11.0	14.2	3.7	8.7	7.7	4.0	8.2	3.9	21.2	7.4	16.3	33.8	10.0	4.2	11.8	22.2	2.7	2.5	2.7	7.2	11.7	7.8	0.4	3.6	11.0	17.6	2.8	2.1	4.4	0.0	0.1	0.1	0.2	3.4	4.8	0.0	0.1	0.0	0.5	0.2	0.0	0.0	1.3	0.3	1.3	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.2	0.1	1.1	0.3	9.9	0.9	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.0	10.4	3.1	0.5	0.0	2.7	0.0	9.6	0.0	0.0	0.0	0.6	0.0	0.0	12.4	0.5	4.9	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	7.0	107.7	0.4	17.6	10.8	2.1	4.7	0.7	0.3	0.2	1.0	3.6	0.4	0.2	1.0	11.0	2.8	3.1	0.6	0.0	4.4	22.1	40.3	86.2	38.8	25.8	15.0	28.1	25.0	14.2	22.2
GIT1		ENSG00000108262	"GIT ArfGAP 1"	Q9Y2X7	17	29573469-29594054	"Plasma proteins, Predicted intracellular proteins"		"GTPase activation"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004059, HPA004186"	Enhanced		Supported	"Focal adhesion sites,Mitochondria,Cytosol"			53000	"Focal adhesion sites, Cytosol"	Mitochondria	"HPA004059: AB_1078966, HPA004186: AB_1078967"	"unprognostic (3.66e-1)"	"unprognostic (4.46e-2)"	"unprognostic (3.24e-2)"	"unprognostic (6.30e-3)"	"unprognostic (1.46e-1)"	"unprognostic (1.08e-1)"	"prognostic unfavourable (2.54e-6)"	"unprognostic (3.00e-3)"	"unprognostic (2.79e-1)"	"unprognostic (5.23e-2)"	"unprognostic (2.12e-2)"	"unprognostic (3.08e-1)"	"unprognostic (8.48e-2)"	"unprognostic (5.56e-2)"	"unprognostic (7.30e-2)"	"unprognostic (2.10e-1)"	"unprognostic (1.69e-1)"	13.0	8.5	34.0	11.1	38.1	8.0	9.4	18.9	43.4	7.8	9.8	15.6	2.2	11.6	10.0	5.3	13.2	14.0	10.2	12.2	41.5	16.4	7.0	3.7	12.0	12.6	19.2	21.8	13.6	14.3	10.2	8.1	13.8	15.0	8.4	6.9	7.8	11.9	10.3	10.0	20.2	10.9	8.7	11.9	11.1	9.5	42.9	19.8	10.8	11.0	4.5	9.7	9.8	7.5	1.8	4.7	3.0	6.0	5.6	4.9	3.6	17.1	28.8	14.2	25.2	11.3	7.2	16.5	8.5	8.4	10.3	9.2	11.6	6.4	13.0	13.7	11.1	28.4	14.9	21.9	5.3	16.8	17.8	9.4	14.1	10.4	13.8	11.8	7.7	8.7	25.2	11.8	18.5	19.0	7.6	11.3	7.3	17.7	37.3	16.0	10.5	6.9	28.4	19.0	19.5	9.3	9.5	29.9	25.6	12.0	28.0	42.0	13.7	15.8	23.5	9.8	14.2	21.5	17.1	9.4	12.9	14.2	16.1	10.2	16.5	0.3	3.6	3.0	4.7	6.0	2.2	1.8	4.5	4.9	4.7	1.7	3.7	2.7	1.2	5.6	3.7	4.0	2.9	3.6	34.0	38.1	18.9	43.4	41.5	16.4	19.2	21.8	15.0	19.8
GPBP1L1	SP192	ENSG00000159592	"GC-rich promoter binding protein 1 like 1"	Q9HC44	1	45627304-45688113	"Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA028593	Approved		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"				Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"HPA028593: AB_10602906"	"unprognostic (1.39e-1)"	"unprognostic (8.41e-2)"	"unprognostic (1.44e-3)"	"unprognostic (6.60e-2)"	"unprognostic (6.35e-2)"	"unprognostic (1.97e-3)"	"unprognostic (2.42e-3)"	"unprognostic (9.79e-2)"	"unprognostic (3.91e-2)"	"unprognostic (1.94e-3)"	"unprognostic (1.12e-2)"	"unprognostic (4.11e-1)"	"unprognostic (1.25e-2)"	"unprognostic (6.63e-2)"	"unprognostic (4.51e-1)"	"unprognostic (7.56e-3)"	"unprognostic (6.13e-2)"	29.9	20.5	16.9	21.2	23.7	24.9	25.2	24.4	18.6	27.4	36.9	33.3	29.7	31.6	26.3	23.8	34.8	22.5	19.7	23.9	17.3	17.0	30.2	38.9	28.3	29.1	33.2	12.4	24.7	46.9	24.4	36.6	25.7	22.1	26.4	37.2	29.8	33.5	35.3	29.6	31.0	58.0	25.7	28.2	30.6	26.2	33.2	27.2	40.5	37.7	30.3	35.4	32.5	27.5	13.5	17.8	29.8	22.1	20.0	20.0	15.4	15.8	9.8	17.1	18.1	20.2	19.7	23.4	12.6	21.0	18.3	23.1	9.8	17.8	22.0	16.5	17.3	16.6	18.7	19.0	23.3	25.1	13.3	28.6	11.4	15.2	27.9	28.4	26.5	14.3	41.7	14.3	41.0	23.1	24.3	19.6	20.8	8.5	25.2	25.7	24.3	11.2	16.6	22.3	16.2	21.0	15.7	21.1	14.1	20.8	30.8	32.1	14.0	33.6	19.6	13.2	13.9	14.2	19.1	19.2	17.8	16.3	13.9	23.8	13.8	16.4	16.6	29.8	17.8	21.2	18.9	13.5	17.6	17.4	17.8	11.5	19.4	18.9	17.7	20.0	22.1	10.2	20.0	15.4	16.9	23.7	24.4	18.6	17.3	17.0	33.2	12.4	22.1	27.2
GUCA1C	GCAP3	ENSG00000138472	"Guanylate cyclase activator 1C"	O95843	3	108907792-108953895	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	4	"heart muscle: 10.2;pancreas: 31.0;retina: 15.7"	"Cell line enriched"	"Detected in single"	84	"RPTEC TERT1: 17.6"	"Cancer enriched"	"Detected in single"	7	"pancreatic cancer: 0.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA041597	Uncertain		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA041597: AB_10795501"						"unprognostic (7.56e-2)"					"unprognostic (6.56e-2)"							0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.2	0.7	0.0	0.5	0.0	0.0	0.0	0.7	0.0	0.7	31.0	0.0	0.2	0.0	0.5	0.0	0.0	15.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.7	0.0	0.0	0.0	0.0	0.0	2.8	1.9	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.2	0.7	0.0	0.7	0.0	0.5	0.0
HAUS4	"C14orf94, FLJ20424"	ENSG00000092036	"HAUS augmin like complex subunit 4"	Q9H6D7	14	22946228-22957161	"Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA029803, HPA071195"	Approved		Supported	"Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"		"HPA029803: AB_10601428, HPA071195: "	"unprognostic (8.47e-3)"	"unprognostic (3.52e-1)"	"unprognostic (6.47e-2)"	"unprognostic (7.59e-2)"	"unprognostic (3.08e-2)"	"unprognostic (1.73e-1)"	"unprognostic (7.54e-2)"	"unprognostic (4.32e-3)"	"unprognostic (2.92e-2)"	"unprognostic (2.87e-2)"	"unprognostic (7.70e-2)"	"unprognostic (8.66e-2)"	"unprognostic (3.00e-2)"	"unprognostic (6.94e-2)"	"unprognostic (3.16e-1)"	"unprognostic (1.96e-1)"	"prognostic unfavourable (2.24e-4)"	17.2	16.7	11.0	28.8	15.0	29.8	22.3	9.9	15.6	20.3	24.0	13.8	22.3	15.3	17.8	20.7	25.4	16.9	30.6	19.5	12.3	8.3	16.8	17.9	24.0	30.6	17.7	9.2	33.8	29.1	17.5	9.8	12.1	13.4	19.1	16.9	14.2	22.0	19.2	14.4	21.7	24.9	23.3	17.6	24.5	19.3	12.2	17.4	33.7	23.2	17.2	21.2	18.9	19.5	14.0	35.3	34.5	28.2	7.8	15.4	15.3	25.6	17.5	20.2	20.0	14.9	18.7	30.4	12.9	17.2	14.1	19.9	12.5	30.7	49.6	6.2	7.7	26.0	10.7	15.4	11.9	13.4	8.1	16.7	12.3	30.5	13.6	21.4	27.8	12.7	29.9	6.0	18.4	24.5	11.6	24.8	15.1	19.8	23.3	19.0	10.6	17.8	22.4	24.3	19.1	12.2	14.1	8.1	13.2	18.5	19.2	11.3	16.7	17.3	13.5	12.9	16.7	9.3	11.3	26.3	22.6	23.0	6.1	24.2	7.3	2.1	28.2	5.8	5.8	18.3	7.8	14.0	10.9	8.3	35.3	11.6	15.4	11.8	34.5	7.8	11.3	9.9	14.6	15.3	11.0	15.0	9.9	15.6	12.3	8.3	17.7	9.2	13.4	17.4
HENMT1	"C1orf59, FLJ30525, HEN1"	ENSG00000162639	"HEN methyltransferase 1"	Q5T8I9	1	108648290-108661526	"Enzymes, Predicted intracellular proteins"	"RNA-mediated gene silencing"	"Methyltransferase, RNA-binding, Transferase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.8;testis: 45.2"	"Cell line enhanced"	"Detected in many"		"MOLT-4: 23.9;NB-4: 26.7;THP-1: 20.0;U-937: 35.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in single"	16	"cerebellum: 18.1"	"HPA028464, HPA028497"	Uncertain		Approved	"Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"		"HPA028464: AB_10600103, HPA028497: AB_10601552"	"unprognostic (1.82e-1)"	"prognostic favourable (2.56e-4)"	"prognostic favourable (9.95e-4)"	"unprognostic (2.92e-3)"	"unprognostic (1.91e-1)"	"unprognostic (3.88e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.49e-1)"	"unprognostic (7.01e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.95e-1)"	"unprognostic (1.19e-1)"	"prognostic unfavourable (2.48e-5)"	"unprognostic (2.53e-1)"	"unprognostic (2.43e-1)"	"unprognostic (2.18e-1)"	"unprognostic (1.65e-1)"	3.5	2.2	6.7	5.1	10.2	7.7	5.5	3.6	11.6	6.1	4.4	4.2	1.4	3.4	2.8	3.4	1.9	1.8	4.5	3.1	9.5	10.1	1.8	1.4	4.9	9.8	8.2	5.6	3.8	1.5	0.6	3.9	3.8	10.7	2.7	6.6	1.3	2.4	2.6	2.0	2.6	5.2	2.5	6.9	8.0	3.2	45.2	2.5	10.3	1.7	1.2	7.3	5.5	1.6	5.4	10.6	18.2	12.0	22.9	28.8	15.9	5.9	3.0	0.2	0.0	0.2	0.2	0.0	1.4	0.5	3.5	0.5	8.9	9.4	0.0	3.3	2.7	0.0	0.0	0.0	2.2	1.9	0.0	15.1	11.5	0.0	3.1	8.9	13.5	2.9	0.1	0.7	0.0	0.7	0.0	6.8	0.1	15.1	23.9	26.7	8.8	1.3	10.4	0.0	0.5	0.0	6.5	14.9	0.0	12.8	3.6	0.0	0.0	20.0	0.1	0.0	11.8	6.4	0.0	4.1	5.2	0.0	0.0	35.2	0.1	16.0	8.8	18.2	28.8	10.1	26.0	5.4	14.2	26.0	10.6	2.9	11.8	21.7	8.6	22.9	12.0	8.5	13.1	15.9	6.7	10.2	3.6	11.6	9.5	10.1	8.2	5.6	10.7	2.5
HRASLS	"H-REV107, HRASLS1"	ENSG00000127252	"HRAS like suppressor"		3	193241125-193277738	"Predicted membrane proteins"				"Evidence at transcript level"	"Evidence at transcript level"				"Group enriched"	"Detected in many"	7	"skeletal muscle: 40.9;testis: 42.1"	"Cell line enhanced"	"Detected in some"		"HAP1: 8.5;NTERA-2: 7.4;PC-3: 16.5;RH-30: 7.2;SCLC-21H: 15.0;U-2 OS: 9.1;U-251 MG: 11.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	7	"neutrophil: 1.7"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 1.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA051179	Uncertain		Approved	"Focal adhesion sites,Cytosol"				"Focal adhesion sites"	Cytosol	"HPA051179: "	"unprognostic (3.01e-2)"	"unprognostic (4.21e-2)"	"unprognostic (7.93e-3)"	"unprognostic (4.82e-3)"	"unprognostic (2.79e-1)"	"unprognostic (1.87e-1)"	"unprognostic (9.97e-3)"	"unprognostic (9.68e-3)"	"unprognostic (1.84e-1)"	"unprognostic (3.55e-1)"	"unprognostic (1.77e-4)"	"unprognostic (5.09e-2)"	"unprognostic (1.38e-5)"	"unprognostic (1.61e-2)"	"prognostic favourable (4.36e-4)"	"unprognostic (2.98e-3)"	"unprognostic (1.13e-2)"	0.6	1.1	1.8	0.2	3.1	0.1	1.0	0.6	3.3	0.5	0.6	1.7	0.0	0.1	0.6	3.1	2.4	0.5	0.2	4.3	2.0	1.1	0.6	0.6	0.5	0.1	1.5	2.1	0.6	0.8	0.5	0.7	0.1	2.4	0.5	0.1	3.1	6.1	0.5	40.9	1.7	0.6	0.7	0.6	0.6	0.6	42.1	1.7	0.2	3.7	6.2	0.2	0.5	0.6	0.0	0.2	1.7	0.1	0.0	0.0	6.2	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.1	0.0	1.5	0.3	0.0	0.1	0.0	0.1	0.0	0.0	8.5	0.2	0.4	0.0	3.8	4.4	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	7.4	16.5	0.0	7.2	0.0	2.4	0.0	15.0	2.8	1.0	2.2	0.0	4.3	0.0	0.1	0.0	9.1	0.0	11.5	0.0	0.0	0.0	4.7	0.0	2.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	6.2	1.8	3.1	0.6	3.3	2.0	1.1	1.5	2.1	2.4	1.7
HSH2D	"ALX, FLJ14886, HSH2"	ENSG00000196684	"Hematopoietic SH2 domain containing"	Q96JZ2	19	16134028-16158575	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 47.4;lymphoid tissue: 33.8"	"Cell line enhanced"	"Detected in some"		"HL-60: 13.4;HMC-1: 18.5;NB-4: 43.6;RPMI-8226: 19.6;U-937: 42.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in all"		"basophil: 47.4"	"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA036616			Approved	"Plasma membrane,Focal adhesion sites,Cytosol"				"Plasma membrane"	"Focal adhesion sites, Cytosol"	"HPA036616: AB_10671962"	"unprognostic (1.69e-1)"	"unprognostic (2.97e-2)"	"prognostic unfavourable (9.46e-6)"	"unprognostic (1.06e-1)"	"unprognostic (5.50e-3)"	"unprognostic (5.21e-3)"	"unprognostic (9.35e-2)"	"unprognostic (4.78e-2)"	"unprognostic (4.21e-3)"	"unprognostic (9.96e-2)"	"unprognostic (1.57e-2)"	"unprognostic (2.22e-2)"	"prognostic unfavourable (6.49e-6)"	"unprognostic (9.17e-3)"	"unprognostic (6.18e-2)"	"unprognostic (3.21e-2)"	"prognostic favourable (3.47e-5)"	1.2	1.1	1.2	31.5	1.1	19.2	1.2	1.1	1.1	1.4	8.9	0.0	5.2	5.5	1.1	6.2	2.0	1.5	10.3	1.2	1.1	1.1	1.3	1.5	6.0	16.7	1.0	0.0	1.1	4.8	0.9	3.7	2.3	0.3	2.2	4.0	1.0	8.8	5.2	1.1	1.1	12.1	0.7	1.1	21.8	5.4	1.1	0.0	8.5	1.7	2.4	33.8	4.7	1.1	14.5	6.0	47.4	8.4	19.0	4.3	3.6	4.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.7	6.8	12.9	0.2	0.0	0.2	0.0	0.1	0.0	0.7	0.0	0.2	0.1	0.8	0.0	13.4	18.5	0.0	0.0	0.0	0.0	0.0	0.0	12.2	0.0	2.8	0.0	43.6	0.0	0.0	0.9	0.0	19.6	0.1	1.8	0.0	0.0	0.0	0.4	0.1	0.1	5.0	0.0	0.0	0.0	0.0	0.0	1.9	12.6	7.1	0.0	42.8	0.0	47.4	3.7	23.0	4.3	5.0	3.9	14.5	1.9	2.8	6.0	8.6	1.8	2.3	43.7	19.0	8.4	1.8	2.9	3.6	1.2	1.1	1.1	1.1	1.1	1.1	1.0	0.0	0.3	0.0
IGFLR1	"FLJ22573, TMEM149, U2AF1L4"	ENSG00000126246	"IGF like family receptor 1"	Q9H665	19	35738801-35742453	"Predicted intracellular proteins, Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 121.2;liver: 46.2;lymphoid tissue: 40.7"	"Cell line enhanced"	"Detected in many"		"HMC-1: 21.9;Karpas-707: 16.7;U-266/70: 22.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"plasmacytoid DC: 121.2"	"Lineage enriched"	"Detected in all"	4	"dendritic cells: 121.2"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			HPA012369	Uncertain		Approved	"Focal adhesion sites"	"Intracellular and membrane"			"Focal adhesion sites"		"HPA012369: AB_1858095"	"unprognostic (5.97e-3)"	"prognostic favourable (6.55e-4)"	"unprognostic (1.94e-1)"	"unprognostic (5.42e-2)"	"unprognostic (8.31e-3)"	"unprognostic (2.34e-4)"	"unprognostic (6.71e-2)"	"unprognostic (1.74e-2)"	"unprognostic (1.87e-2)"	"prognostic favourable (1.59e-5)"	"unprognostic (1.44e-3)"	"unprognostic (3.52e-1)"	"unprognostic (8.72e-12)"	"unprognostic (2.74e-1)"	"unprognostic (1.22e-1)"	"unprognostic (2.29e-1)"	"unprognostic (3.32e-3)"	5.3	7.3	4.5	17.8	7.6	10.1	4.1	2.0	5.3	3.1	5.0	3.8	0.0	5.6	2.6	4.7	3.4	4.5	5.9	5.8	4.5	3.1	17.0	46.2	8.5	40.7	7.7	1.6	4.5	6.9	1.1	3.4	3.8	5.6	4.0	5.4	2.2	7.4	1.8	3.9	4.6	8.4	3.5	5.4	20.2	6.3	3.5	4.5	14.6	10.0	3.2	19.3	8.0	4.9	22.3	121.2	28.6	26.5	18.1	17.4	16.3	1.3	6.4	2.2	5.3	0.7	1.1	1.3	1.5	0.7	1.2	3.1	1.9	1.5	2.8	2.1	0.4	1.0	1.3	1.3	0.6	2.0	3.2	9.8	2.6	6.7	1.9	1.3	21.9	1.8	0.8	2.2	0.5	1.2	3.0	16.7	0.3	5.4	3.1	10.3	1.6	1.7	3.8	2.1	5.1	1.0	2.3	1.6	3.0	2.1	1.5	1.1	2.3	5.3	0.3	2.7	1.3	1.7	2.4	22.1	4.6	1.7	3.2	3.8	2.1	16.2	26.5	23.6	13.3	22.2	15.2	22.3	15.4	12.6	33.9	21.8	13.9	11.1	28.6	18.1	15.5	121.2	17.4	16.3	4.5	7.6	2.0	5.3	4.5	3.1	7.7	1.6	5.6	4.5
IGSF5	JAM4	ENSG00000183067	"Immunoglobulin superfamily member 5"	Q9NSI5	21	39745407-39802096	"Predicted membrane proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"heart muscle: 5.8"	"Cell line enhanced"	"Detected in many"		"T-47d: 10.6"	"Cancer enhanced"	"Detected in some"		"testis cancer: 2.3"					"Cell type enriched"	"Detected in single"	5	"neutrophil: 2.2"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 2.2"					"Low region specificity"	"Detected in all"			HPA057282	Uncertain		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA057282: "	"unprognostic (1.06e-1)"	"unprognostic (2.53e-1)"	"unprognostic (7.06e-2)"	"unprognostic (9.73e-5)"	"unprognostic (1.56e-2)"	"unprognostic (3.15e-1)"		"unprognostic (1.41e-1)"	"unprognostic (2.18e-2)"	"unprognostic (2.09e-1)"	"unprognostic (8.35e-2)"	"unprognostic (9.61e-2)"	"unprognostic (4.01e-1)"	"unprognostic (4.18e-1)"	"unprognostic (3.75e-2)"	"unprognostic (6.89e-2)"	"unprognostic (1.07e-2)"	0.0	2.0	0.9	0.0	3.4	0.1	1.3	0.1	0.7	1.1	0.3			0.2	0.9	3.4	0.0	0.9	0.3	5.8	1.2	2.3	0.3	0.3	0.1	0.2	1.3		1.5	2.5	0.3	1.5	4.3		2.4	0.9		0.9	0.4	0.0	0.6	0.1	0.4	0.7	0.3	0.6	1.5			0.8		0.2	0.5	0.2	0.4	0.3	2.2	0.4	0.0	0.4	0.0	1.3	0.7	4.4	1.1	4.4	3.5	1.1	0.8	1.2	1.2	1.9	0.7	1.3	1.4	1.2	1.6	1.2	1.5	2.9	2.5	2.2	2.1	1.3	3.2	0.5	2.7	1.8	0.6	3.2	5.3	2.8	3.2	0.6	2.5	0.9	1.7	1.5	0.3	0.6	2.4	0.8	0.7	2.0	0.8	1.8	1.9	2.0	0.5	1.2	2.9	1.7	10.6	1.1	0.4	1.9	2.2	0.9	1.8	0.9	0.8	0.9	1.1	1.4	1.9	0.1	0.4	0.4	0.4	0.0	0.2	0.1	0.3	0.1	0.1	0.4	0.1	0.2	2.2	0.0	0.1	0.3	0.0	0.0										
IL1RL1	"DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1"	ENSG00000115602	"Interleukin 1 receptor like 1"	Q01638	2	102311502-102352037	"Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"kidney: 49.7;lung: 77.2;placenta: 95.0"	"Group enriched"	"Detected in some"	6	"HHSteC: 54.1;HMC-1: 80.5;HUVEC TERT2: 39.3"	"Cancer enhanced"	"Detected in many"		"thyroid cancer: 7.9"	"Group enriched"	"Detected in many"	5	"basal ganglia: 11.4;cerebral cortex: 6.6;hippocampal formation: 5.6;midbrain: 3.8;pons and medulla: 14.6"	"Group enriched"	"Detected in some"	59	"basophil: 17.1;eosinophil: 17.0"	"Lineage enriched"	"Detected in single"	59	"granulocytes: 17.1"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA007406, HPA007917"	Uncertain		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"	"Secreted to blood"	19074133	1700000	"Plasma membrane"	"Focal adhesion sites, Cytosol"	"HPA007406: AB_1079128, HPA007917: AB_1079129"	"unprognostic (7.25e-2)"	"unprognostic (9.72e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.28e-2)"	"unprognostic (5.28e-2)"	"unprognostic (1.98e-2)"	"unprognostic (3.25e-3)"	"unprognostic (2.07e-1)"	"unprognostic (2.77e-1)"	"unprognostic (4.50e-2)"	"unprognostic (8.58e-2)"	"unprognostic (9.74e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.32e-2)"	"unprognostic (1.60e-2)"	"unprognostic (1.17e-1)"	"unprognostic (4.60e-3)"	10.7	7.5	1.4	2.0	11.4	0.9	6.9	0.5	6.6	2.6	3.1	0.1	0.1	1.3	1.7	0.9	2.7	0.8	7.8	16.6	5.6	1.8	49.7	6.2	77.2	1.4	3.8	0.0	0.7	2.8	0.8	1.8	95.0	14.6	1.9	2.3	1.0	0.7	5.7	2.8	1.1	2.0	3.3	5.0	1.0	6.7	0.8	0.3	0.0	5.6	0.7	0.9	6.0	2.6	0.0	0.0	17.1	0.0	0.2	0.2	0.0	0.1	0.0	0.1	0.0	3.3	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.3	0.0	1.3	0.1	0.0	0.0	9.5	0.1	0.1	54.1	0.4	80.5	1.1	0.3	1.3	8.7	39.3	0.1	0.1	0.1	0.0	0.1	1.7	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	3.2	0.1	0.1	0.7	0.1	0.0	0.0	0.0	0.1	0.1	0.1	17.1	0.0	17.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.4	11.4	0.5	6.6	5.6	1.8	3.8	0.0	14.6	0.3
ILK		ENSG00000166333	"Integrin linked kinase"	Q13418	11	6603708-6610874	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004041, HPA048437"	Enhanced		Supported	"Nucleoplasm,Cell Junctions,Focal adhesion sites"			130000000	"Cell Junctions, Focal adhesion sites"	Nucleoplasm	"CAB004041: AB_2127050, HPA048437: "	"unprognostic (1.78e-1)"	"unprognostic (2.26e-2)"	"unprognostic (5.26e-2)"	"unprognostic (2.12e-2)"	"unprognostic (7.57e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.19e-3)"	"unprognostic (5.25e-3)"	"unprognostic (1.49e-2)"	"unprognostic (9.65e-2)"	"unprognostic (2.64e-1)"	"unprognostic (8.12e-2)"	"prognostic favourable (2.44e-4)"	"unprognostic (4.01e-3)"	"unprognostic (9.27e-2)"	"unprognostic (2.42e-1)"	"unprognostic (6.36e-3)"	20.9	17.6	11.0	22.3	11.9	7.5	37.0	9.4	14.6	40.2	75.1	14.7	41.9	13.5	75.4	25.2	35.7	33.2	41.1	35.1	11.1	9.2	21.6	15.1	21.9	18.9	11.5	14.0	24.2	22.3	20.4	10.9	22.2	11.5	39.9	24.6	19.3	19.4	89.9	18.5	12.4	22.2	103.5	10.6	20.2	33.2	14.2	11.0	8.2	17.5	14.1	13.6	60.8	25.9	19.5	45.9	76.5	49.4	45.3	25.8	63.7	23.8	18.4	29.1	10.0	44.9	31.9	13.2	35.1	69.4	41.6	50.8	19.2	28.1	9.0	9.3	57.4	19.2	16.2	29.7	41.8	15.7	14.8	12.9	17.6	14.9	30.1	10.3	14.8	30.6	14.0	28.1	21.5	39.6	11.8	10.7	54.2	17.9	9.1	17.7	18.3	21.6	9.6	15.2	9.5	30.5	19.1	5.0	11.4	16.6	23.0	19.3	16.0	11.8	45.8	52.2	23.6	21.6	17.0	7.8	4.8	12.6	38.7	15.6	24.3	48.3	49.4	76.5	25.8	47.9	25.1	19.5	23.3	24.4	45.9	17.1	14.7	18.5	31.7	45.3	44.4	18.5	25.7	63.7	11.0	11.9	9.4	14.6	11.1	9.2	11.5	14.0	11.5	11.0
ITGAV	"CD51, MSK8, VNRA, VTNR"	ENSG00000138448	"Integrin subunit alpha V"	P06756	2	186590065-186680901	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RT4: 75.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 7.7"	"Group enriched"	"Detected in many"	4	"granulocytes: 7.7;monocytes: 2.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002499, HPA004856"	Supported		Approved	"Focal adhesion sites,Cytosol"			750000	"Focal adhesion sites, Cytosol"		"CAB002499: AB_563594, HPA004856: AB_1846316"	"unprognostic (4.03e-2)"	"unprognostic (5.17e-3)"	"unprognostic (1.22e-2)"	"unprognostic (5.22e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.18e-1)"	"prognostic unfavourable (2.08e-4)"	"unprognostic (1.48e-2)"	"unprognostic (6.95e-2)"	"unprognostic (2.89e-1)"	"prognostic unfavourable (5.07e-4)"	"unprognostic (5.84e-2)"	"unprognostic (2.67e-2)"	"prognostic unfavourable (1.05e-6)"	"unprognostic (2.61e-1)"	"unprognostic (9.11e-2)"	"unprognostic (8.07e-2)"	23.2	22.1	17.9	18.3	21.8	3.1	25.8	16.7	23.1	22.9	13.6	23.4	11.6	8.4	26.0	11.4	14.2	14.5	25.2	40.7	16.8	12.3	51.5	9.5	20.6	7.6	24.2	11.6	35.4	18.7	65.0	11.0	29.6	22.1	16.5	11.9	83.4	17.9	15.9	13.1	21.5	10.1	29.6	33.0	12.1	17.3	11.2	17.0	7.8	33.1	10.9	11.1	17.6	17.9	0.3	0.9	7.7	2.3	0.4	1.1	0.5	9.7	11.7	7.8	24.9	28.7	19.4	29.7	19.2	15.5	6.8	6.8	10.2	33.8	0.0	37.9	21.6	12.3	3.9	18.1	9.8	1.9	3.5	2.3	15.4	14.0	11.3	1.6	1.4	14.1	8.6	15.2	12.9	16.2	2.2	4.9	18.1	3.8	0.9	1.3	5.9	5.9	0.0	15.9	1.3	17.6	75.3	1.6	4.8	22.2	6.9	8.1	5.4	4.5	49.1	42.2	13.2	8.6	16.2	1.2	2.0	1.1	17.0	0.6	20.8	7.7	1.1	1.6	1.0	2.3	0.7	0.3	0.5	0.8	0.9	0.1	0.5	0.5	0.5	0.4	1.2	0.4	1.1	0.5	17.9	21.8	16.7	17.3	16.8	12.3	24.2	11.6	22.1	17.0
ITGB1	"CD29, FNRB, GPIIA, MDF2, MSK12"	ENSG00000150093	"Integrin subunit beta 1"	P05556	10	32900319-33005792	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003434, HPA059297, HPA069003"	Enhanced		Supported	"Endoplasmic reticulum,Plasma membrane,Focal adhesion sites"			540000000	"Plasma membrane, Focal adhesion sites"	"Endoplasmic reticulum"	"CAB003434: AB_303570, HPA059297: , HPA069003: "	"unprognostic (3.07e-2)"	"prognostic unfavourable (5.01e-4)"	"unprognostic (8.67e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.87e-2)"	"unprognostic (1.60e-2)"	"prognostic unfavourable (3.36e-6)"	"unprognostic (3.22e-1)"	"unprognostic (2.36e-3)"	"unprognostic (3.68e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.02e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.08e-2)"	95.2	30.6	13.7	32.1	19.7	9.7	107.7	6.5	14.8	55.1	61.3	17.0	80.2	20.2	84.2	56.2	59.9	45.0	49.8	68.7	15.0	14.4	47.3	85.8	55.4	34.5	23.0	11.1	47.4	37.4	17.6	35.2	83.3	19.5	53.1	32.2	18.6	30.3	76.2	58.0	19.5	42.3	109.3	30.1	59.8	45.4	26.9	18.8	12.7	36.8	27.6	19.4	92.7	47.4	31.3	9.1	4.3	27.1	21.9	68.4	26.2	47.4	69.7	37.6	41.7	90.9	78.3	32.8	159.7	92.6	76.1	69.6	15.6	111.2	12.8	28.9	133.9	33.2	11.3	90.9	84.9	12.6	9.2	15.4	33.2	18.2	64.0	3.4	15.3	79.3	49.7	80.0	32.6	93.4	10.6	5.7	125.4	7.8	5.9	3.5	8.4	35.4	3.9	27.9	2.3	108.5	13.8	8.9	22.3	49.8	8.5	35.8	11.4	12.4	104.5	98.0	56.9	69.6	53.2	5.2	1.1	7.2	72.2	14.6	38.4	1.6	9.8	4.3	25.5	17.8	6.0	31.3	54.6	37.5	9.1	8.6	7.1	19.1	2.3	21.9	27.1	3.7	68.4	26.2	13.7	19.7	6.5	14.8	15.0	14.4	23.0	11.1	19.5	18.8
JAK2	JTK10	ENSG00000096968	"Janus kinase 2"	O60674	9	4984390-5128183	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Immunity, Innate immunity"	"Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"ASC diff: 18.9;HDLM-2: 26.7;HEL: 54.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 40.8"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 40.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013089, HPA040820, HPA043870"	Approved		Supported	"Nucleoplasm,Plasma membrane,Focal adhesion sites"				Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"CAB013089: AB_2533647, HPA040820: , HPA043870: "	"unprognostic (2.24e-3)"	"unprognostic (2.76e-2)"	"unprognostic (1.50e-2)"	"unprognostic (7.67e-2)"	"unprognostic (5.50e-2)"	"unprognostic (3.09e-2)"	"unprognostic (1.48e-1)"	"unprognostic (7.36e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.49e-3)"	"unprognostic (1.58e-1)"	"unprognostic (1.72e-2)"	"unprognostic (3.85e-1)"	"unprognostic (4.53e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.37e-3)"	19.8	8.8	11.5	19.0	10.5	19.0	17.7	14.7	14.4	17.8	10.6	7.0	10.3	7.2	14.8	13.6	12.4	13.4	14.6	27.6	10.3	6.7	7.7	5.6	16.1	19.4	7.0	10.5	15.9	6.7	10.1	7.5	12.0	10.0	12.0	7.4	9.4	7.2	7.4	14.4	19.0	12.3	10.4	11.7	21.5	14.1	10.1	9.0	13.6	8.6	6.5	13.5	13.9	15.6	2.1	9.6	40.8	7.5	3.4	2.1	2.5	2.5	1.4	1.4	2.5	18.9	4.9	0.4	3.4	2.9	2.6	1.7	0.1	0.8	0.1	0.8	2.0	0.8	1.5	2.1	1.9	26.7	0.5	54.8	2.9	0.7	3.9	3.7	2.8	4.0	0.9	1.1	1.8	2.4	3.9	6.4	4.7	0.9	0.9	5.2	1.3	1.7	1.9	2.7	0.7	2.0	1.3	1.6	0.9	1.0	1.5	1.0	0.7	6.5	5.0	4.0	1.3	4.1	2.4	1.2	2.2	0.5	5.2	1.8	2.0	40.8	7.5	13.4	2.1	7.3	1.7	2.1	1.6	1.2	9.6	1.9	0.9	1.1	7.1	3.4	5.8	3.6	1.6	2.5	11.5	10.5	14.7	14.4	10.3	6.7	7.0	10.5	10.0	9.0
KLF11	"MODY7, TIEG2, Tieg3"	ENSG00000172059	"Kruppel like factor 11"	O14901	2	10042849-10054836	"Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Diabetes mellitus, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 25.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA058276			Supported	"Nucleoplasm,Nuclear bodies,Focal adhesion sites,Cytosol"				Nucleoplasm	"Nuclear bodies, Focal adhesion sites, Cytosol"	"HPA058276: "	"unprognostic (9.66e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.59e-1)"	"unprognostic (1.06e-2)"	"unprognostic (3.02e-3)"	"unprognostic (2.63e-3)"	"unprognostic (6.34e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.04e-1)"	"unprognostic (3.17e-3)"	"unprognostic (3.08e-2)"	"unprognostic (2.48e-3)"	"unprognostic (8.96e-2)"	"unprognostic (3.44e-1)"	"unprognostic (1.07e-2)"	"unprognostic (9.24e-2)"	28.7	9.1	2.5	7.0	3.5	11.8	33.1	8.2	4.4	12.9	13.0	5.1	10.8	3.5	12.8	11.7	8.3	11.2	11.6	19.4	2.9	2.3	12.7	27.9	14.6	15.9	5.5	2.4	13.7	38.3	7.3	2.4	9.9	3.4	13.9	4.7	9.2	11.3	10.9	14.0	19.1	7.7	30.4	3.5	16.1	10.2	16.7	2.7	1.5	9.1	8.5	5.6	11.1	42.7	2.9	6.6	1.7	12.7	5.4	2.7	3.8	3.7	1.8	4.4	0.3	3.0	5.4	10.6	4.3	4.4	2.5	2.6	4.2	8.7	0.0	7.8	5.2	0.8	3.7	3.3	1.6	25.5	2.9	1.9	5.3	0.8	3.0	7.7	12.4	8.4	12.5	4.7	1.3	2.1	5.1	17.2	2.5	4.4	0.0	1.4	7.0	3.7	4.1	0.1	7.2	6.0	4.6	5.6	3.5	6.6	13.7	12.7	3.2	10.6	6.1	10.9	9.2	8.2	1.4	15.7	18.6	10.1	2.8	2.1	5.8	0.0	6.9	1.7	2.6	11.0	0.8	2.8	1.7	1.8	6.6	2.9	0.5	1.0	0.2	5.4	12.7	0.3	2.7	3.8	2.5	3.5	8.2	4.4	2.9	2.3	5.5	2.4	3.4	2.7
LASP1	"Lasp-1, MLN50"	ENSG00000002834	"LIM and SH3 protein 1"	Q14847	17	38869859-38921770	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Ion transport, Transport"	Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 124.5"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA012072, CAB022049"	Enhanced		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"			26000000	"Plasma membrane, Cytosol"	"Focal adhesion sites"	"CAB022049: , HPA012072: AB_1852714"	"unprognostic (1.23e-1)"	"unprognostic (2.09e-2)"	"unprognostic (1.77e-1)"	"prognostic unfavourable (4.57e-4)"	"unprognostic (1.47e-1)"	"unprognostic (3.03e-2)"	"prognostic unfavourable (2.41e-4)"	"unprognostic (1.06e-3)"	"unprognostic (2.24e-1)"	"unprognostic (9.60e-2)"	"unprognostic (9.87e-3)"	"unprognostic (1.01e-1)"	"unprognostic (9.65e-3)"	"unprognostic (1.29e-3)"	"unprognostic (3.95e-2)"	"unprognostic (1.60e-3)"	"unprognostic (4.53e-2)"	51.2	20.0	23.8	40.3	22.4	45.4	35.5	15.5	25.7	23.6	57.4	16.3	18.7	54.4	23.4	24.1	22.4	20.8	48.3	15.2	18.4	23.3	33.1	47.5	33.3	44.2	20.0	14.3	28.4	30.1	10.1	17.6	40.0	16.1	18.9	38.6	24.2	22.4	24.1	10.7	18.3	124.5	21.3	12.2	43.1	39.5	13.9	12.9	40.5	18.3	18.7	33.7	22.0	28.3	6.4	13.9	34.0	19.9	17.3	16.5	13.1	34.8	72.7	21.3	18.8	31.3	34.0	36.7	43.9	42.9	46.3	34.0	21.7	38.0	15.9	36.7	67.8	55.6	9.6	33.4	40.5	11.6	5.2	7.6	21.0	37.7	29.7	17.5	23.1	30.1	11.7	39.2	11.1	31.0	12.9	5.3	64.3	11.5	20.8	27.0	10.6	18.2	11.8	11.3	20.1	56.8	30.7	3.2	7.8	26.1	27.4	22.7	43.3	21.4	54.1	27.8	40.5	32.4	26.6	13.7	18.1	12.3	29.3	15.8	33.4	9.9	14.8	16.8	16.5	17.1	11.3	6.4	8.4	11.0	13.9	6.3	7.2	10.9	34.0	17.3	19.9	10.7	10.7	13.1	23.8	22.4	15.5	25.7	18.4	23.3	20.0	14.3	16.1	12.9
LDB3	"CMD1C, KIAA0613, PDLIM6, ZASP"	ENSG00000122367	"LIM domain binding 3"	O75112	10	86668449-86736068	"Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cardiomyopathy, Disease mutation, Myofibrillar myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	21	"heart muscle: 213.9;skeletal muscle: 329.7;tongue: 110.3"	"Cell line enhanced"	"Detected in some"		"HSkMC: 6.0;SCLC-21H: 9.7;SK-MEL-30: 4.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"							HPA048955	Enhanced		Supported	"Nucleoplasm,Focal adhesion sites,Cytosol"			450000	"Focal adhesion sites, Cytosol"	Nucleoplasm	"HPA048955: "	"unprognostic (1.60e-1)"	"unprognostic (9.01e-2)"	"unprognostic (4.87e-2)"	"unprognostic (6.92e-2)"	"unprognostic (5.55e-2)"	"unprognostic (1.50e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.36e-1)"	"unprognostic (2.79e-2)"	"unprognostic (7.61e-2)"	"unprognostic (2.54e-3)"	"unprognostic (3.55e-2)"	"unprognostic (4.72e-4)"	"unprognostic (3.07e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.62e-2)"	"unprognostic (3.16e-1)"	6.4	0.4	0.9	1.3	1.6	0.2	0.5	0.1	1.3	2.8	2.3	0.0	4.9	0.4	4.2	9.9	9.9	1.3	1.0	213.9	1.7	1.0	0.3	0.2	0.4	0.2	2.6	0.0	1.5	0.3	0.3	0.1	0.5	0.0	4.4	0.8	4.7	7.6	3.1	329.7	0.3	1.2	3.6	6.7	0.2	0.7	0.5	0.0	0.0	2.8	110.3	10.2	1.9	0.9	0.9	0.6	1.8	0.4	0.6	0.6	0.0	0.3	0.3	0.4	3.2	0.4	0.1	0.3	0.4	0.3	0.1	0.2	0.3	0.3	0.3	0.6	0.0	0.4	0.2	0.0	0.1	0.9	0.8	0.7	0.9	0.1	0.1	0.1	1.7	6.0	0.5	0.1	0.0	0.0	0.3	1.9	0.3	1.6	0.4	0.2	0.4	0.3	0.0	2.0	0.1	0.0	1.1	9.7	1.8	0.3	0.2	4.7	0.3	0.2	0.0	0.3	0.5	0.4	0.1	0.2	0.6	0.4	0.8	0.3	0.5	1.8	0.4	0.4	0.4	0.3	0.4	0.3	0.3	0.3	0.2	0.9	0.5	0.6	1.4	0.6	0.4	0.6	0.3	0.0	0.9	1.6	0.1	0.6	1.7	1.0	2.6	0.0	0.0	0.0
LIMA1	EPLIN	ENSG00000050405	"LIM domain and actin binding 1"	Q9UHB6	12	50175788-50283546	"Predicted intracellular proteins"	"Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"	Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 83.2"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in all"	5	"cerebellum: 73.6"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023871, HPA052645"	Enhanced		Enhanced	"Plasma membrane,Actin filaments,Focal adhesion sites,Cytosol"			160000	"Plasma membrane, Actin filaments"	"Focal adhesion sites, Cytosol"	"HPA023871: AB_1852875, HPA052645: AB_2681898"	"unprognostic (6.22e-2)"	"unprognostic (9.39e-3)"	"unprognostic (8.13e-2)"	"unprognostic (1.42e-1)"	"unprognostic (8.08e-2)"	"prognostic unfavourable (1.76e-6)"	"unprognostic (1.63e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.28e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.28e-3)"	"unprognostic (6.27e-2)"	"prognostic favourable (2.79e-4)"	"unprognostic (7.12e-2)"	"unprognostic (9.26e-3)"	"unprognostic (1.46e-1)"	"unprognostic (1.43e-1)"	50.3	19.8	6.6	22.3	6.8	0.9	34.1	73.6	6.6	30.9	49.2	10.4	21.3	35.2	31.1	22.1	25.0	18.0	31.1	12.6	6.6	5.1	29.3	11.1	23.3	11.8	7.2	4.1	21.1	12.4	12.4	18.6	42.0	15.4	28.2	42.8	20.7	27.0	22.1	10.5	16.3	90.5	33.8	10.4	23.6	30.3	11.8	6.0	12.1	17.0	20.7	18.0	41.8	21.4	0.6	4.4	1.3	2.1	5.8	13.6	2.7	24.0	0.7	7.7	11.3	35.4	35.6	29.1	60.5	42.6	48.7	39.0	9.1	35.4	1.0	5.6	83.2	27.4	6.9	55.8	42.7	15.3	7.3	10.0	2.7	3.2	22.7	3.6	14.3	23.8	16.5	17.1	49.3	17.1	7.0	4.9	15.6	4.1	4.4	1.1	3.9	3.3	4.4	18.8	0.3	11.3	28.7	5.7	12.4	8.2	16.7	25.9	7.9	2.2	26.6	20.9	16.1	19.3	9.8	2.7	0.3	4.4	22.7	4.0	8.9	0.1	0.2	1.3	6.4	1.0	2.5	0.1	8.1	7.8	4.4	0.6	3.3	5.9	0.1	5.8	2.1	1.1	13.6	2.7	6.6	6.8	73.6	5.6	6.6	5.1	7.2	4.1	15.4	6.0
LIMD1		ENSG00000144791	"LIM domains containing 1"	Q9UGP4	3	45555394-45686338	"Plasma proteins, Predicted intracellular proteins"	"RNA-mediated gene silencing, Transcription, Transcription regulation"	Repressor	"Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA064220			Supported	"Nucleoplasm,Focal adhesion sites"				"Nucleoplasm, Focal adhesion sites"		"HPA064220: "	"unprognostic (2.77e-1)"	"unprognostic (3.22e-2)"	"unprognostic (5.43e-2)"	"unprognostic (7.78e-2)"	"unprognostic (6.53e-2)"	"unprognostic (2.07e-2)"	"unprognostic (9.44e-2)"	"unprognostic (1.53e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.42e-1)"	"unprognostic (6.88e-2)"	"unprognostic (2.11e-3)"	"prognostic favourable (6.73e-5)"	"unprognostic (8.02e-2)"	"unprognostic (3.06e-2)"	"unprognostic (2.86e-2)"	"unprognostic (6.61e-3)"	12.6	7.0	4.8	14.9	5.5	6.2	13.9	2.5	6.0	10.2	9.7	8.1	13.0	8.4	14.4	12.0	10.4	9.6	10.9	11.5	5.1	4.1	8.3	16.6	24.8	17.1	9.2	2.2	7.6	24.5	11.3	5.5	11.7	9.4	12.1	9.2	20.2	19.1	8.2	25.2	8.3	12.2	12.5	6.8	16.4	11.4	6.2	6.4	20.3	17.9	10.7	24.9	12.9	18.9	6.7	8.8	4.1	5.5	1.1	1.6	1.0	7.3	14.0	5.1	6.9	4.5	8.9	10.3	7.1	10.0	7.6	6.7	6.6	3.9	0.9	4.7	6.5	5.0	10.9	5.8	6.3	15.5	6.7	8.2	11.1	5.4	4.6	7.3	10.6	3.7	4.8	11.3	6.0	6.6	6.8	23.2	7.5	4.9	8.9	4.6	8.3	13.5	4.4	6.0	11.2	4.0	13.2	2.4	4.6	6.0	10.9	7.2	6.6	6.6	11.8	8.4	7.7	8.4	7.5	22.2	28.5	3.7	18.2	6.7	9.1	4.1	1.4	1.4	1.6	3.1	1.0	3.9	1.3	1.4	1.4	6.7	1.4	1.4	1.6	1.1	5.5	8.8	1.3	1.0	4.8	5.5	2.5	6.0	5.1	4.1	9.2	2.2	9.4	6.4
LIMS1	"PINCH, PINCH1"	ENSG00000169756	"LIM zinc finger domain containing 1"	P48059	2	108534355-108687246	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 88.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											"HPA058455, HPA061230"	Approved		Supported	"Focal adhesion sites,Cytosol"			130000000	Cytosol	"Focal adhesion sites"	"HPA058455: , HPA061230: "	"unprognostic (1.79e-1)"	"unprognostic (8.82e-3)"	"unprognostic (5.66e-2)"	"unprognostic (1.17e-2)"	"unprognostic (1.52e-1)"	"unprognostic (4.23e-2)"	"unprognostic (1.08e-3)"	"unprognostic (1.09e-1)"	"unprognostic (8.96e-2)"	"unprognostic (1.18e-1)"	"unprognostic (5.95e-3)"	"unprognostic (2.09e-1)"	"prognostic unfavourable (7.88e-4)"	"unprognostic (7.51e-2)"	"unprognostic (8.60e-3)"	"unprognostic (1.43e-2)"	"unprognostic (2.11e-1)"	39.3	26.3	7.8	18.3	13.3	14.9	21.5	3.9	9.6	18.1	16.9	14.4	38.2	8.3	21.9	21.7	18.4	16.9	16.5	20.2	8.0	7.5	20.8	18.0	26.3	21.2	13.3	4.6	18.3	10.6	6.6	13.6	19.0	10.8	15.8	9.5	11.0	13.8	43.6	54.0	11.2	17.9	18.8	16.7	24.3	13.0	9.3	10.7	20.2	13.1	15.0	25.5	21.1	16.1	4.4	14.2	45.6	34.0	8.8	20.9	29.6	9.2	10.4	4.1	4.9	6.8	10.0	19.9	10.4	12.0	8.1	8.3	18.0	20.1	9.0	31.9	13.3	6.0	6.2	10.7	10.8	22.2	11.1	47.2	7.4	9.5	15.7	8.8	88.1	9.7	9.9	21.4	17.7	29.2	16.6	12.6	24.9	7.6	8.4	6.5	8.1	10.7	10.8	14.3	7.3	15.4	16.8	7.5	10.1	16.4	7.0	7.3	3.6	8.3	39.2	36.8	16.8	8.1	21.3	12.3	16.3	12.8	30.7	10.0	9.3	38.3	16.9	45.6	4.3	28.7	7.8	4.4	18.5	5.7	14.2	3.5	5.0	1.8	8.0	8.8	34.0	1.8	20.9	29.6	7.8	13.3	3.9	9.6	8.0	7.5	13.3	4.6	10.8	10.7
LIMS2	"PINCH-2, PINCH2"	ENSG00000072163	"LIM zinc finger domain containing 2"	Q7Z4I7	2	127638381-127681786	"Disease related genes, Predicted intracellular proteins"			"Disease mutation, Limb-girdle muscular dystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 114.4"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 11.8;fHDF/TERT166: 13.0;HHSteC: 15.6;MOLT-4: 17.7;TIME: 37.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 17.1"	"Group enriched"	"Detected in many"	14	"B-cells: 17.1;T-cells: 8.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA058340	Enhanced		Supported	"Focal adhesion sites"				"Focal adhesion sites"		"HPA058340: "	"unprognostic (2.51e-2)"	"unprognostic (1.25e-1)"	"unprognostic (5.82e-3)"	"unprognostic (4.51e-2)"	"unprognostic (9.25e-2)"	"unprognostic (3.49e-1)"	"prognostic favourable (6.53e-7)"	"unprognostic (3.98e-2)"	"unprognostic (3.73e-1)"	"unprognostic (2.29e-1)"	"unprognostic (3.78e-2)"	"unprognostic (8.86e-2)"	"unprognostic (3.33e-1)"	"unprognostic (4.60e-3)"	"unprognostic (3.64e-2)"	"unprognostic (1.77e-1)"	"unprognostic (4.00e-2)"	21.9	4.4	3.4	16.7	4.5	0.2	17.9	1.5	5.8	31.7	83.5	4.6	18.1	6.5	49.9	17.4	28.3	23.8	31.8	40.2	4.2	1.8	11.7	8.0	20.1	4.9	3.7	4.3	8.2	2.9	2.6	2.8	11.6	6.4	30.6	6.6	20.4	8.0	45.1	12.5	5.7	16.9	114.4	4.0	21.6	25.6	6.8	2.7	11.5	9.3	6.5	4.5	65.1	44.9	17.1	0.8	0.3	0.2	0.0	8.2	1.9	0.3	0.7	0.2	0.0	2.1	0.5	0.2	8.6	11.8	9.3	8.6	2.3	0.0	0.0	5.0	13.0	0.0	0.1	0.0	1.9	0.0	0.3	0.0	5.5	1.6	15.6	0.0	0.0	0.1	0.0	3.6	0.1	6.4	0.0	0.0	4.3	0.0	17.7	0.4	0.6	1.1	4.0	0.8	0.4	0.6	0.0	0.0	0.1	1.6	0.8	0.3	0.3	0.0	37.1	0.0	6.2	7.9	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.1	0.0	0.1	0.2	0.0	10.7	3.9	0.8	0.1	17.1	8.2	3.3	0.3	0.0	0.1	0.8	5.2	1.9	3.4	4.5	1.5	5.8	4.2	1.8	3.7	4.3	6.4	2.7
LIMS3		ENSG00000256977	"LIM zinc finger domain containing 3"	P0CW19	2	109898428-109924868	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"blood: 11.9;endometrium 1: 9.7"	"Cell line enhanced"	"Detected in many"		"HEL: 9.6;HMC-1: 29.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"eosinophil: 11.9"	"Low lineage specificity"	"Detected in many"											HPA058455	Uncertain		Approved	"Focal adhesion sites,Cytosol"				Cytosol	"Focal adhesion sites"	"HPA058455: "										"unprognostic (2.23e-2)"								1.2	2.8	0.5	2.2	0.5	0.0	1.0	0.8	0.5	1.0	0.7	0.3	4.2	0.2	9.7	2.8	1.2	7.1	0.9	2.6	0.5	0.5	2.6	0.6	0.8	2.8	0.6	0.3	2.2	0.7	0.3	2.4	5.6	0.3	1.0	0.8	0.6	2.2	0.6	3.0	0.8	0.5	1.2	0.6	0.6	0.7	3.7	0.3	0.3	1.0	0.3	0.3	2.6	0.7	0.7	2.5	11.9	5.5	1.1	6.2	8.0	0.0	0.1	1.2	1.5	0.5	0.4	0.0	1.5	0.0	0.2	0.6	1.5	0.0	0.0	4.6	0.3	0.8	0.0	1.8	1.3	2.3	0.0	9.6	0.4	0.9	1.4	1.7	29.2	2.1	1.1	1.1	1.3	2.4	2.0	1.6	3.2	0.1	0.0	0.2	1.5	0.5	1.7	3.1	1.0	0.8	1.5	0.4	3.5	3.9	0.0	0.7	0.0	0.5	7.1	6.3	5.8	3.2	0.3	0.0	0.0	1.8	0.8	0.0	1.9	4.7	3.3	11.9	0.9	5.5	1.5	0.7	5.0	1.7	2.5	0.2	0.9	0.3	0.7	1.1	5.2	0.2	6.2	8.0	0.5	0.5	0.8	0.5	0.5	0.5	0.6	0.3	0.3	0.3
LIMS4	LIMS3L	ENSG00000256671	"LIM zinc finger domain containing 4"	P0CW20	2	110446640-110473075	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 2.6;HHSteC: 2.5;hTEC/SVTERT24-B: 4.8;HUVEC TERT2: 2.8;U-138 MG: 5.2"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA058455	Uncertain		Uncertain	"Focal adhesion sites,Cytosol"				Cytosol	"Focal adhesion sites"	"HPA058455: "										"unprognostic (2.12e-1)"								4.0	4.1	0.0	0.3	0.0	0.6	1.5	0.0	0.3	0.3	0.6			0.3	4.1	0.3	0.3	3.7	0.3	3.5	0.0	0.0	5.5	2.7	0.8	0.3	0.0		1.9	2.2	0.3	0.8	0.6		0.3	0.3		0.3	0.3	5.6	0.4	0.3	0.3	0.0	0.3	0.3	1.3			1.1		0.3	0.3	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.4	2.6	0.2	0.6	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	4.8	0.0	2.8	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.2	0.0	0.2	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
LMLN	"Gp63, LMNL1, Msp"	ENSG00000185621	"Leishmanolysin like peptidase"	Q96KR4	3	197960200-198043720	"Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell cycle, Cell division, Mitosis"	"Hydrolase, Metalloprotease, Protease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016481, HPA028844"	Uncertain		Supported	"Focal adhesion sites,Cytosol"				Cytosol	"Focal adhesion sites"	"HPA016481: AB_1852955, HPA028844: AB_10602347"	"unprognostic (2.54e-1)"	"unprognostic (3.15e-1)"	"unprognostic (7.63e-2)"	"prognostic favourable (6.77e-4)"	"unprognostic (1.14e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.07e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.31e-1)"	"unprognostic (6.36e-2)"	"unprognostic (2.98e-1)"	"unprognostic (4.82e-3)"	"unprognostic (8.78e-2)"	"unprognostic (7.65e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.63e-1)"	3.9	4.9	5.2	2.5	11.0	2.3	4.5	6.1	9.1	6.2	3.5	5.8	14.3	2.2	4.8	20.3	3.5	9.3	5.1	5.9	5.7	7.4	6.6	3.7	8.1	3.5	5.6	8.9	6.5	6.1	8.8	15.0	3.9	11.6	4.6	4.1	5.4	4.2	11.7	3.7	6.5	2.3	4.0	5.5	3.0	3.9	27.0	4.4	1.2	7.6	3.0	2.6	3.5	3.7	1.9	1.9	0.8	2.4	1.8	2.4	1.2	6.5	2.5	3.0	3.5	5.9	8.3	2.5	3.4	3.1	6.2	5.1	2.4	2.4	2.1	16.0	2.4	2.5	2.8	2.7	9.0	0.3	2.0	1.2	2.1	1.8	3.7	3.7	1.8	3.9	6.1	7.7	5.0	2.7	6.3	4.0	5.9	4.9	2.2	3.2	3.3	6.0	2.5	0.7	2.2	6.4	1.7	4.8	1.4	4.8	4.3	3.4	11.1	2.8	5.7	7.6	1.1	9.2	5.7	7.1	13.8	0.6	10.9	6.4	6.9	0.2	0.6	0.5	1.2	2.4	1.7	1.9	0.8	1.6	1.9	1.1	2.2	2.4	0.8	1.8	0.9	0.5	0.0	1.2	5.2	11.0	6.1	9.1	5.7	7.4	5.6	8.9	11.6	4.4
LPP		ENSG00000145012	"LIM domain containing preferred translocation partner in lipoma"	Q93052	3	188153284-188890671	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"smooth muscle: 127.8;urinary bladder: 105.1"	"Cell line enhanced"	"Detected in many"		"Daudi: 28.8;EFO-21: 35.8;U-698: 59.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 18.0"	"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA011133, HPA017342"	Enhanced		Enhanced	"Focal adhesion sites,Cytosol"			520000	"Focal adhesion sites, Cytosol"		"HPA011133: AB_1853247, HPA017342: AB_1853249"	"unprognostic (1.50e-1)"	"unprognostic (4.97e-3)"	"unprognostic (1.41e-1)"	"unprognostic (2.18e-1)"	"unprognostic (1.86e-1)"	"unprognostic (4.05e-1)"	"unprognostic (2.43e-3)"	"unprognostic (7.97e-2)"	"unprognostic (2.17e-1)"	"unprognostic (5.56e-2)"	"unprognostic (3.44e-3)"	"unprognostic (2.10e-1)"	"unprognostic (2.57e-3)"	"unprognostic (2.25e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.82e-3)"	"unprognostic (1.48e-1)"	19.6	4.2	2.7	29.5	2.8	3.1	12.5	3.0	2.7	42.2	29.9	2.1	19.6	5.0	68.6	14.9	59.7	10.0	37.9	9.3	2.6	2.8	10.9	5.3	11.4	6.0	2.8	1.6	26.1	4.4	4.7	3.2	5.2	3.0	37.7	12.8	8.5	7.0	28.4	11.6	5.9	17.2	127.8	3.2	9.5	12.1	30.7	1.5	5.1	5.4	4.2	7.8	105.1	38.3	5.9	4.9	18.0	4.5	4.3	5.0	1.4	7.5	7.0	5.1	3.4	11.1	11.4	5.5	4.9	6.3	3.6	2.4	12.6	3.6	28.8	35.8	11.2	3.2	1.5	3.3	9.1	3.1	1.7	1.4	5.4	3.3	4.7	0.6	1.7	8.1	4.7	8.1	7.0	6.1	0.0	0.6	6.3	2.4	1.4	0.6	2.0	2.3	1.8	3.8	0.1	4.0	8.0	0.3	0.0	10.6	3.5	6.0	2.7	2.4	13.1	8.4	6.5	6.0	12.2	0.0	1.1	59.7	4.2	1.3	7.6	0.8	4.5	1.9	5.0	4.2	3.2	2.9	4.3	3.6	2.4	5.9	2.3	2.9	18.0	4.3	4.0	4.9	1.6	1.4	2.7	2.8	3.0	2.7	2.6	2.8	2.8	1.6	3.0	1.5
LPXN	LDPL	ENSG00000110031	Leupaxin	O60711	11	58526871-58578220	"Predicted intracellular proteins"	"Cell adhesion, Transcription, Transcription regulation"	Activator		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 42.0;lymphoid tissue: 75.1"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 39.3;HMC-1: 65.8;Karpas-707: 56.4;U-2197: 39.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043741, CAB046478, HPA061441"	Enhanced		Supported	"Nuclear speckles,Focal adhesion sites,Cytosol"				"Focal adhesion sites"	"Nuclear speckles, Cytosol"	"CAB046478: AB_10603113, HPA043741: AB_2678647, HPA061441: AB_2684518"	"unprognostic (1.61e-3)"	"unprognostic (6.91e-2)"	"unprognostic (6.54e-2)"	"prognostic favourable (8.81e-4)"	"unprognostic (5.16e-2)"	"unprognostic (2.07e-3)"	"unprognostic (2.16e-2)"	"unprognostic (8.87e-3)"	"unprognostic (5.18e-2)"	"unprognostic (3.96e-2)"	"unprognostic (2.39e-2)"	"unprognostic (3.05e-1)"	"unprognostic (3.60e-3)"	"unprognostic (1.91e-1)"	"unprognostic (5.25e-2)"	"unprognostic (2.55e-1)"	"unprognostic (2.41e-3)"	16.3	5.6	5.1	34.2	4.7	4.2	5.1	3.5	4.9	4.4	6.7	9.0	4.1	5.1	6.5	5.9	3.8	4.7	7.2	3.9	5.2	5.1	6.3	7.1	19.7	37.2	6.3	2.5	6.6	5.6	3.9	4.8	2.6	5.0	5.7	9.6	6.2	7.6	5.1	2.1	3.7	16.0	4.7	11.4	32.2	5.7	5.9	4.9	75.1	6.8	4.4	52.9	11.2	3.9	19.9	36.5	3.8	19.1	20.1	42.0	20.9	0.3	0.4	0.4	0.7	1.5	1.9	0.2	9.8	39.3	2.4	4.4	0.0	1.0	28.7	0.4	11.9	0.3	0.3	26.7	10.3	12.4	0.1	1.3	0.2	0.1	2.6	7.7	65.8	1.4	0.6	33.9	4.4	15.8	0.3	56.4	19.9	0.2	27.1	9.7	0.3	8.9	0.4	0.5	24.7	1.6	13.7	0.2	0.3	0.4	0.6	3.9	0.5	2.2	15.4	6.2	1.8	39.6	8.8	3.6	3.5	28.2	14.3	7.0	14.0	1.7	19.1	3.1	28.2	11.0	42.0	19.9	29.0	32.4	36.5	11.5	22.6	26.8	3.8	20.1	5.6	33.1	38.7	20.9	5.1	4.7	3.5	4.9	5.2	5.1	6.3	2.5	5.0	4.9
LRCH4	"LRN, LRRN1"	ENSG00000077454	"Leucine rich repeats and calponin homology domain containing 4"	O75427	7	100574011-100586153	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 44.8;NB-4: 69.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA037667, HPA037668"	Enhanced		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"				"Nucleoplasm, Focal adhesion sites, Cytosol"		"HPA037667: AB_10671882, HPA037668: AB_10672910"	"unprognostic (2.41e-1)"	"unprognostic (2.53e-2)"	"prognostic unfavourable (1.61e-7)"	"unprognostic (8.32e-3)"	"unprognostic (2.76e-2)"	"unprognostic (3.96e-3)"	"unprognostic (8.98e-3)"	"unprognostic (3.72e-2)"	"unprognostic (2.52e-1)"	"unprognostic (5.51e-2)"	"unprognostic (2.63e-3)"	"unprognostic (7.81e-2)"	"unprognostic (1.95e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.40e-2)"	"unprognostic (7.96e-2)"	"unprognostic (1.26e-2)"	11.4	15.2	14.5	32.0	25.7	52.7	13.8	19.7	22.2	12.0	14.0	16.4	11.8	22.0	12.3	9.6	14.4	14.0	15.9	10.2	16.2	9.1	16.1	12.2	20.8	39.1	25.8	13.1	23.7	17.3	8.9	22.8	26.4	19.2	14.6	7.2	18.3	23.5	13.0	15.8	15.0	27.8	8.1	25.7	54.5	14.9	43.3	23.1	31.1	20.0	6.8	25.2	9.9	12.0	5.9	6.2	24.2	8.4	1.4	7.3	2.9	7.8	4.4	4.4	4.0	2.6	2.0	8.4	7.6	3.4	4.5	3.6	7.3	11.4	5.6	8.5	2.2	6.7	2.1	3.2	1.2	5.6	5.9	6.5	5.2	3.5	8.4	11.2	44.8	3.4	3.4	3.7	2.1	4.5	8.0	11.7	3.1	14.7	12.8	69.2	4.6	5.2	14.3	3.6	6.9	3.4	2.7	5.7	8.6	3.6	11.6	8.8	7.8	24.4	7.0	6.1	11.0	8.4	4.5	11.9	5.6	5.1	4.7	27.7	10.4	12.6	8.4	11.9	5.2	6.8	4.7	4.7	5.1	5.9	6.2	5.9	7.3	5.9	24.2	1.4	4.7	5.9	5.2	2.9	14.5	25.7	19.7	22.2	16.2	9.1	25.8	13.1	19.2	23.1
METTL27	WBSCR27	ENSG00000165171	"Methyltransferase like 27"	Q8N6F8	7	73834590-73842535	"Disease related genes, Predicted intracellular proteins"			"Williams-Beuren syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 9.4;RPMI-8226: 39.9;T-47d: 11.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"T-reg: 9.2"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			HPA022420	Uncertain		Supported	"Focal adhesion sites"				"Focal adhesion sites"		"HPA022420: AB_2304370"	"unprognostic (6.70e-2)"	"unprognostic (1.98e-1)"	"prognostic unfavourable (1.73e-4)"	"unprognostic (1.38e-2)"	"unprognostic (2.66e-2)"	"unprognostic (4.39e-2)"	"unprognostic (4.81e-3)"	"unprognostic (1.20e-1)"	"unprognostic (3.23e-1)"	"unprognostic (2.27e-1)"	"unprognostic (4.98e-2)"	"unprognostic (1.33e-1)"	"prognostic favourable (1.10e-6)"	"unprognostic (1.86e-1)"	"unprognostic (2.15e-2)"	"unprognostic (6.49e-2)"	"unprognostic (1.24e-2)"	5.7	2.7	1.5	1.4	2.6	0.3	5.2	4.2	3.9	10.2	3.6	3.8	14.5	3.3	5.3	4.4	5.8	9.3	12.4	0.9	1.4	1.3	9.2	2.7	4.7	6.0	1.2	6.0	5.2	11.1	10.0	4.0	8.7	2.8	8.0	1.3	2.4	20.3	12.4	2.3	2.0	4.5	1.3	1.3	5.1	1.7	10.6	0.8	3.0	6.6	0.9	3.1	4.3	3.6	2.4	1.4	2.0	3.4	0.0	9.2	0.3	6.2	7.7	0.0	0.6	1.2	3.4	1.3	0.0	0.1	0.2	0.2	0.4	9.4	1.5	1.4	1.3	0.6	0.0	2.5	0.1	1.0	0.1	0.0	2.3	2.3	1.3	0.0	0.0	1.4	0.6	4.0	1.9	1.5	0.1	1.3	0.9	1.7	0.0	0.0	0.1	2.0	0.4	1.7	39.9	2.1	1.2	0.7	0.2	0.8	0.7	0.7	11.7	0.3	1.7	2.5	0.6	4.8	2.5	1.8	0.6	0.0	0.5	0.0	0.7	0.0	1.0	2.0	0.1	3.4	0.0	2.4	0.6	0.0	1.4	1.0	1.2	0.8	1.0	0.0	0.8	1.0	9.2	0.3	1.5	2.6	4.2	3.9	1.4	1.3	1.2	6.0	2.8	0.8
MISP	"C19orf21, Caprice, DKFZp686H18209, MISP1"	ENSG00000099812	"Mitotic spindle positioning"	Q8IVT2	19	751126-764318	"Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis"	Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"gallbladder: 24.6;intestine: 63.8"	"Cell line enhanced"	"Detected in some"		"A549: 37.1;HaCaT: 27.5;hTCEpi: 25.8;MCF7: 18.9;SK-BR-3: 41.8"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 133.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA049511, HPA062232"	Enhanced		Enhanced	"Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"		"HPA049511: AB_2680798, HPA062232: AB_2684719"	"unprognostic (7.48e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.99e-2)"	"unprognostic (1.02e-1)"	"unprognostic (6.50e-2)"	"unprognostic (1.78e-3)"	"unprognostic (1.64e-2)"	"unprognostic (8.64e-2)"	"unprognostic (1.49e-1)"	"unprognostic (2.56e-3)"	"unprognostic (2.09e-1)"	"unprognostic (1.19e-3)"	"unprognostic (6.78e-3)"	"unprognostic (2.29e-1)"	"unprognostic (4.80e-1)"	"unprognostic (5.27e-2)"	0.5	0.1	0.3	7.9	0.3	0.0	0.7	0.2	0.2	1.5	42.8	0.2	0.2	45.9	0.7	0.8	0.4	2.4	24.6	0.2	0.5	0.2	6.9	0.4	6.8	0.2	0.3	0.3	2.2	2.0	0.0	4.2	2.1	0.2	2.2	13.0	0.2	0.5	0.5	0.2	0.3	63.8	0.7	0.2	0.2	5.8	0.2	0.2	0.3	0.2	0.8	0.2	1.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.0	37.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	12.7	13.6	3.2	3.6	0.0	27.5	0.0	11.5	0.0	0.0	0.0	0.0	14.6	3.9	0.0	0.0	0.5	0.0	25.8	0.1	1.4	0.0	0.0	0.1	0.0	18.9	0.0	0.2	0.0	7.6	0.0	0.1	0.3	9.3	10.3	0.4	0.1	13.1	41.8	0.0	9.1	0.0	0.0	0.0	4.7	0.5	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.2	0.2	0.5	0.2	0.3	0.3	0.2	0.2
MMP28	"EPILYSIN, MM28, MMP-25, MMP-28"	ENSG00000271447	"Matrix metallopeptidase 28"	Q9H239	17	35756249-35795707	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	9	"HaCaT: 28.1"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 7.2;naive CD8 T-cell: 5.9"	"Lineage enriched"	"Detected in many"	5	"T-cells: 7.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA057288, HPA057890"			Approved	"Nucleoplasm,Focal adhesion sites"	"Secreted to extracellular matrix"			Nucleoplasm	"Focal adhesion sites"	"HPA057288: , HPA057890: "	"unprognostic (7.99e-3)"	"unprognostic (3.27e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.01e-1)"	"unprognostic (7.52e-2)"	"unprognostic (1.63e-1)"	"unprognostic (6.90e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.99e-1)"	"prognostic unfavourable (6.28e-6)"	"unprognostic (9.37e-2)"	"unprognostic (1.31e-1)"	"unprognostic (8.87e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.76e-2)"	"unprognostic (3.27e-3)"	8.0	1.6	1.8	2.7	3.7	0.5	4.3	0.0	5.1	1.7	7.3	1.6	1.4	3.0	3.2	4.8	4.3	1.5	12.3	0.5	2.8		0.8	0.2	10.3	0.4	0.0	2.9	0.1	1.3	0.5	0.0	0.7	1.3	2.9	4.1	2.7	0.1	2.1	0.6	4.5	9.3	4.3	0.2	0.6	7.2	13.4	0.2	0.0	4.2	4.4	2.5	5.5	2.2	1.1	1.5	0.1	0.2	1.3	7.2	0.9	0.1	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.1	0.7	0.0	28.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.1	0.0	0.0	0.0	2.5	0.0	0.1	0.2	0.0	0.1	0.0	0.2	0.1	0.2	0.0	0.2	0.6	0.0	0.0	0.0	1.6	0.2	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	2.0	1.1	0.4	1.7	0.1	0.9	7.2	5.9	0.1	1.3	0.2	1.5	0.0	0.9										
MTSS1L	"ABBA, ABBA-1, LOC92154"	ENSG00000132613	"MTSS1L, I-BAR domain containing"	Q765P7	16	70661204-70686066	"Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 105.5"	"Cell line enhanced"	"Detected in many"		"Hep G2: 61.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"MAIT T-cell: 2.4;plasmacytoid DC: 2.3"	"Group enriched"	"Detected in many"	7	"dendritic cells: 2.3;T-cells: 2.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA048531, HPA066469"	Approved		Supported	"Focal adhesion sites"				"Focal adhesion sites"		"HPA048531: , HPA066469: AB_2685671"	"prognostic unfavourable (2.85e-4)"	"unprognostic (8.85e-2)"	"unprognostic (7.01e-2)"	"unprognostic (5.99e-2)"	"unprognostic (3.21e-1)"	"unprognostic (2.98e-1)"	"unprognostic (1.86e-1)"	"unprognostic (1.82e-1)"	"unprognostic (5.30e-2)"	"unprognostic (1.31e-1)"	"unprognostic (5.59e-3)"	"unprognostic (3.88e-1)"	"unprognostic (2.92e-3)"	"unprognostic (9.87e-2)"	"unprognostic (9.92e-2)"	"unprognostic (6.74e-2)"	"unprognostic (2.25e-2)"	17.2	13.4	61.9	11.1	47.6	4.9	6.4	68.3	105.5	22.5	15.5	59.5	4.1	8.1	29.5	4.1	27.4	17.5	15.8	16.8	70.3	45.6	6.8	21.7	12.9	5.5	50.2	38.7	14.5	7.9	7.7	5.2	19.0	40.7	15.5	5.2	11.8	16.1	21.6	37.2	15.8	7.8	31.6	53.5	19.2	6.7	6.2	53.3	8.2	4.5	5.2	4.8	20.8	10.0	0.3	2.3	0.2	0.1	0.0	2.4	0.4	13.6	32.8	8.2	8.5	6.8	6.8	31.2	20.6	25.7	17.7	14.7	13.2	8.8	0.1	7.4	32.2	28.6	8.9	9.0	6.8	0.2	11.9	4.7	28.0	61.0	60.7	7.0	0.2	28.1	19.6	8.2	28.5	5.8	17.8	0.3	15.6	33.8	6.7	36.1	7.2	6.9	14.4	15.4	0.0	15.5	20.5	19.4	13.0	44.0	19.2	5.7	14.7	13.8	8.7	13.8	15.7	12.5	12.8	5.0	1.2	0.2	12.5	0.2	4.7	0.0	0.1	0.2	0.1	0.0	2.4	0.2	0.0	0.0	0.2	0.3	0.0	0.5	0.0	0.0	0.0	2.3	0.0	0.4	61.9	47.6	68.3	52.3	70.3	45.6	50.2	38.7	40.7	53.3
MYO5A	"GS1, MYH12, MYO5, MYR12"	ENSG00000197535	"Myosin VA"	Q9Y4I1	15	52307283-52529050	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Protein transport, Transport"	"Actin-binding, Calmodulin-binding, Motor protein, Myosin"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 34.5;parathyroid gland: 47.6"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 58.9;RPMI-8226: 39.9"	"Cancer enhanced"	"Detected in all"		"melanoma: 25.2"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001356	Enhanced		Approved	"Focal adhesion sites,Centriolar satellite"				"Focal adhesion sites, Centriolar satellite"		"HPA001356: AB_1079441"	"unprognostic (1.54e-1)"	"unprognostic (1.78e-1)"	"unprognostic (6.95e-2)"	"unprognostic (2.29e-2)"	"unprognostic (1.97e-2)"	"unprognostic (3.91e-2)"	"unprognostic (2.30e-2)"	"unprognostic (6.65e-2)"	"unprognostic (7.89e-2)"	"unprognostic (4.74e-2)"	"unprognostic (9.36e-3)"	"unprognostic (1.71e-1)"	"unprognostic (5.63e-3)"	"unprognostic (3.79e-3)"	"unprognostic (1.24e-1)"	"unprognostic (7.16e-2)"	"prognostic unfavourable (4.22e-4)"	8.4	7.1	16.6	9.5	27.5	15.7	5.5	27.4	34.5	6.2	4.4	7.8	0.4	3.3	4.2	3.2	5.0	3.6	7.3	4.6	15.9	15.4	4.6	2.7	7.3	11.2	15.6	17.6	5.4	4.3	47.6	10.5	5.2	29.3	4.5	5.2	9.9	4.0	3.4	4.1	10.4	3.9	7.7	10.1	7.3	4.1	4.6	7.1	3.1	6.8	2.7	10.3	7.3	4.2	2.3	5.2	6.3	4.4	0.7	4.5	1.9	5.4	9.6	5.1	6.1	5.2	6.4	5.5	9.9	9.0	5.3	4.2	0.9	2.2	5.2	2.6	11.8	4.5	11.7	10.2	6.6	29.4	2.7	4.8	2.5	1.1	2.7	2.5	4.7	4.2	6.4	7.8	15.5	30.8	0.1	58.9	10.2	9.6	2.2	0.3	2.3	7.7	4.1	8.2	39.9	4.4	3.9	3.8	2.2	9.2	7.6	18.0	4.0	2.8	14.7	10.7	4.6	5.0	9.6	6.1	13.5	6.3	11.7	7.3	15.4	0.9	4.4	5.4	2.9	3.6	4.5	2.3	2.9	1.9	5.2	1.6	0.5	1.0	6.3	0.7	2.6	3.1	4.1	1.9	16.6	27.5	27.4	34.5	15.9	15.4	15.6	17.6	29.3	7.1
NOB1	"ART-4, MST158, NOB1P, PSMD8BP1"	ENSG00000141101	"NIN1/PSMD8 binding protein 1 homolog"	Q9ULX3	16	69741867-69754940	"Predicted intracellular proteins"		"Endonuclease, Hydrolase, Nuclease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA041522, HPA049430, HPA067411"	Approved		Approved	"Focal adhesion sites,Cytosol"				Cytosol	"Focal adhesion sites"	"HPA041522: , HPA049430: , HPA067411: "	"unprognostic (5.11e-2)"	"unprognostic (4.49e-2)"	"unprognostic (3.15e-1)"	"unprognostic (8.61e-3)"	"unprognostic (9.45e-2)"	"prognostic unfavourable (4.21e-5)"	"prognostic unfavourable (8.16e-4)"	"unprognostic (3.26e-2)"	"unprognostic (3.04e-1)"	"unprognostic (7.51e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.16e-2)"	"unprognostic (1.23e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.16e-1)"	18.2	31.6	9.9	14.5	18.0	17.4	18.9	13.4	16.2	18.8	19.4	12.5	12.4	20.3	21.3	15.5	25.4	29.2	19.0	13.3	9.6	9.7	18.4	23.4	13.3	21.3	12.9	7.5	37.5	68.5	13.9	10.1	13.1	13.5	21.5	12.7	13.0	20.4	14.8	26.3	25.1	15.5	18.0	10.1	21.5	20.5	11.6	15.4	23.7	28.9	25.8	29.0	25.6	18.4	21.0	20.3	2.0	15.0	24.5	26.1	17.3	14.6	32.2	7.6	21.5	16.9	26.7	15.1	11.8	16.5	22.2	20.2	36.4	24.2	32.8	18.4	13.1	21.9	20.8	26.4	13.1	8.2	24.3	12.7	15.2	46.7	30.0	23.5	10.8	33.8	22.5	25.5	32.6	18.6	29.0	10.2	11.0	38.4	29.5	47.2	23.3	19.2	32.8	7.8	41.4	16.4	14.4	19.8	9.8	37.1	13.1	18.4	14.2	21.3	14.1	15.1	13.7	13.7	19.2	16.8	12.8	57.7	15.1	21.5	16.6	0.1	15.0	2.0	17.6	12.7	24.6	19.4	21.4	16.1	20.3	21.0	23.1	21.0	0.7	24.5	9.5	10.5	26.1	17.3	9.9	18.0	13.4	16.2	9.6	9.7	12.9	7.5	13.5	15.4
NUP214	"CAIN, CAN, D9S46E, N214"	ENSG00000126883	"Nucleoporin 214"	P35658	9	131125561-131234670	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport"		"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 131.5"	"Cell line enhanced"	"Detected in all"		"K-562: 71.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 43.7;neutrophil: 131.5"	"Group enriched"	"Detected in many"	5	"granulocytes: 131.5;monocytes: 43.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048789			Approved	"Nucleoplasm,Vesicles,Focal adhesion sites"			100000	Nucleoplasm	"Vesicles, Focal adhesion sites"	"HPA048789: "	"unprognostic (1.30e-1)"	"unprognostic (9.51e-3)"	"unprognostic (9.92e-3)"	"unprognostic (1.15e-1)"	"unprognostic (7.42e-2)"	"unprognostic (8.31e-2)"	"unprognostic (1.07e-3)"	"unprognostic (2.10e-2)"	"unprognostic (3.35e-1)"	"unprognostic (4.95e-1)"	"unprognostic (6.60e-3)"	"unprognostic (1.08e-1)"	"prognostic favourable (2.39e-5)"	"unprognostic (5.49e-2)"	"unprognostic (6.84e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.53e-1)"	16.9	10.3	11.5	13.8	13.9	29.4	12.9	13.0	14.4	10.2	11.4	19.8	10.4	9.0	15.0	13.7	16.1	12.1	10.2	9.7	9.5	8.1	19.0	15.1	11.7	13.3	13.2	8.8	14.2	17.0	16.7	16.9	13.0	11.3	11.1	10.8	15.3	13.0	11.1	15.5	17.5	11.7	11.1	14.3	35.8	12.3	63.7	13.3	27.4	11.8	7.6	16.8	10.7	11.2	1.2	16.8	131.5	43.7	1.2	0.8	17.9	6.7	9.6	8.2	4.9	6.6	6.4	8.6	6.0	6.2	7.8	6.3	7.8	4.9	10.9	4.8	8.2	15.4	11.0	7.8	7.6	7.9	5.4	6.8	13.7	15.2	5.8	10.6	7.3	7.0	7.2	10.0	8.1	8.0	71.4	6.3	8.0	12.5	13.9	16.0	8.9	8.5	4.8	10.3	10.9	9.0	6.2	7.0	7.2	10.0	9.2	5.2	12.1	26.4	6.8	13.8	7.8	9.0	9.6	5.5	10.7	10.5	6.7	6.4	8.3	3.5	43.7	17.3	0.7	18.4	0.8	1.2	0.7	0.6	16.8	1.1	0.7	0.7	131.5	1.2	15.0	1.5	0.4	17.9	11.5	13.9	13.0	14.4	9.5	8.1	13.2	8.8	11.3	13.3
PALMD	"C1orf11, FLJ20271, PALML"	ENSG00000099260	Palmdelphin	Q9NP74	1	99645943-99694541	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 84.9;skeletal muscle: 106.9"	"Cell line enhanced"	"Detected in some"		"HUVEC TERT2: 42.5;LHCN-M2: 13.7;TIME: 59.6;U-87 MG: 26.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017959, HPA030549"	Supported		Supported	"Plasma membrane,Actin filaments,Focal adhesion sites"				"Actin filaments"	"Plasma membrane, Focal adhesion sites"	"HPA017959: AB_1854949, HPA030549: "	"unprognostic (1.48e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.05e-2)"	"prognostic favourable (9.42e-4)"	"unprognostic (7.67e-2)"	"prognostic favourable (5.90e-5)"	"unprognostic (1.54e-2)"	"unprognostic (2.10e-1)"	"unprognostic (3.93e-2)"	"unprognostic (1.64e-1)"	"unprognostic (8.32e-2)"	"unprognostic (6.18e-2)"	"unprognostic (5.19e-2)"	"unprognostic (1.63e-2)"	"unprognostic (1.88e-1)"	"unprognostic (2.70e-1)"	"unprognostic (8.08e-2)"	84.9	18.6	8.3	6.2	4.3	0.0	46.4	1.1	3.7	17.1	6.5	3.9	4.0	1.3	18.6	10.1	16.2	8.7	5.3	59.0	5.6	3.4	5.1	20.9	10.6	3.4	3.9	3.8	17.4	2.2	4.4	4.7	16.8	19.0	8.1	2.6	7.9	34.0	4.4	106.9	18.0	3.5	12.2	4.1	2.3	2.8	7.5	2.2	2.1	3.4	48.2	6.2	6.9	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.3	0.7	2.9	0.0	0.1	0.0	0.0	0.0	0.0	5.5	7.1	0.0	0.0	0.0	1.1	0.5	0.0	0.0	42.5	6.0	0.0	13.7	0.1	0.0	0.0	0.0	1.8	0.0	10.6	0.0	0.0	2.2	0.2	0.1	0.0	2.7	0.0	0.6	0.0	59.6	0.0	0.1	4.6	0.0	0.0	0.0	0.0	26.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.3	4.3	1.1	3.7	5.6	3.4	3.9	3.8	19.0	2.2
PARVA	"FLJ10793, FLJ12254, MXRA2"	ENSG00000197702	"Parvin alpha"		11	12377185-12530801	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"				"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 53.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"MAIT T-cell: 4.0;memory CD4 T-cell: 1.3"	"Lineage enriched"	"Detected in single"	40	"T-cells: 4.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005964	Approved		Supported	"Actin filaments,Focal adhesion sites,Cytosol"				"Actin filaments, Focal adhesion sites"	Cytosol	"HPA005964: AB_1079569"	"unprognostic (3.87e-2)"	"unprognostic (7.38e-2)"	"unprognostic (3.30e-2)"	"prognostic favourable (1.76e-4)"	"unprognostic (7.37e-3)"	"unprognostic (1.38e-2)"	"unprognostic (6.78e-2)"	"prognostic unfavourable (8.19e-4)"	"unprognostic (1.76e-2)"	"unprognostic (2.80e-2)"	"unprognostic (1.70e-2)"	"unprognostic (9.82e-2)"	"unprognostic (6.73e-2)"	"unprognostic (6.58e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.82e-2)"	30.5	8.3	7.1	14.4	6.5	0.0	44.0	3.9	8.3	29.2	39.2	3.5	25.8	6.9	40.5	17.6	27.0	17.2	35.2	21.3	6.4	5.3	15.3	10.7	13.2	8.5	5.3	7.8	22.7	16.2	10.1	6.3	16.3	5.5	31.7	16.4	18.3	13.4	35.1	6.4	7.7	13.1	55.9	5.0	8.4	24.2	8.4	2.8	0.4	10.5	8.1	5.0	38.8	33.4	0.0	0.0	0.0	0.0	0.0	4.0	0.1	7.6	7.6	7.1	9.2	36.4	28.3	16.6	29.4	30.3	20.8	19.5	5.6	12.0	0.0	9.8	53.4	4.7	0.0	15.3	24.8	0.1	3.8	0.0	10.8	4.2	28.0	0.0	0.2	22.3	6.2	8.7	13.7	25.8	0.0	0.0	30.9	4.6	0.0	0.0	3.3	6.6	0.0	17.8	0.0	11.5	7.5	1.1	0.0	22.6	9.1	15.1	4.3	0.2	31.9	25.1	10.5	13.5	8.0	0.0	0.0	0.0	13.9	0.0	27.6	0.0	0.0	0.0	0.5	0.0	4.0	0.0	1.3	0.4	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	7.1	6.5	3.9	8.3	6.4	5.3	5.3	7.8	5.5	2.8
PCDHGA2	PCDH-GAMMA-A2	ENSG00000081853	"Protocadherin gamma subfamily A, 2"	Q9Y5H1	5	141338760-141512979	"Plasma proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 9.9;BJ: 5.4;fHDF/TERT166: 6.4;HSkMC: 5.1"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in all"			"HPA008755, HPA010580, HPA038625"	Approved		Approved	"Nucleoplasm,Nucleoli,Vesicles,Plasma membrane,Focal adhesion sites,Cytosol"				"Vesicles, Plasma membrane"	"Nucleoplasm, Nucleoli, Focal adhesion sites, Cytosol"	"HPA008755: AB_1079577, HPA010580: , HPA038625: "	"unprognostic (2.43e-3)"	"unprognostic (2.10e-2)"	"unprognostic (1.32e-2)"	"unprognostic (4.54e-1)"	"unprognostic (2.92e-1)"	"unprognostic (1.14e-1)"	"unprognostic (3.01e-1)"	"unprognostic (2.82e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.01e-2)"	"unprognostic (4.32e-2)"	"unprognostic (8.45e-3)"	"unprognostic (9.68e-3)"	"unprognostic (1.04e-2)"	"unprognostic (1.18e-2)"	"unprognostic (2.23e-4)"	5.1	4.3	6.7	2.1	8.0	0.6	4.2	5.2	12.6	6.6	2.6	4.6	1.0	0.9	6.5	5.7	2.4	5.5	5.5	11.1	6.5	4.6	3.3	2.4	4.6	1.1	6.0	2.3	15.3	8.4	9.2	10.6	2.2	7.8	5.3	1.4	13.8	3.3	5.8	2.6	2.9	1.4	5.2	5.6	1.9	2.1	10.4	3.5	0.0	4.3	1.2	1.1	3.2	5.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.5	0.3	3.9	9.9	0.1	5.4	2.1	0.5	0.9	0.1	0.1	0.1	0.7	6.4	0.2	0.0	0.4	1.3	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	5.1	0.2	0.1	0.3	2.0	0.0	0.1	0.9	0.0	0.0	0.1	0.0	0.1	1.4	0.3	0.2	0.8	0.0	0.3	0.7	0.0	3.6	0.1	0.7	0.0	3.3	0.9	0.5	0.3	0.1	0.0	0.4	0.0	2.3	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	8.0	5.2	7.2	6.5	4.6	6.0	2.3	7.8	3.5
PCDHGB1	PCDH-GAMMA-B1	ENSG00000254221	"Protocadherin gamma subfamily B, 1"	Q9Y5G3	5	141350102-141512979	"Predicted membrane proteins"	"Cell adhesion"			"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Group enriched"	"Detected in many"	6	"brain: 32.2;pituitary gland: 13.7"	"Cell line enhanced"	"Detected in some"		"ASC diff: 14.9;ASC TERT1: 7.7;T-47d: 9.6"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	14	"naive CD8 T-cell: 1.3"	"Lineage enriched"	"Detected in single"	14	"T-cells: 1.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008755, HPA010580, HPA076182"	Uncertain		Approved	"Nucleoplasm,Vesicles,Plasma membrane,Focal adhesion sites,Midbody"				"Vesicles, Plasma membrane"	"Nucleoplasm, Focal adhesion sites, Midbody"	"HPA008755: AB_1079577, HPA010580: , HPA076182: "	"unprognostic (1.53e-2)"	"unprognostic (1.94e-3)"	"unprognostic (3.21e-1)"	"unprognostic (4.38e-3)"	"unprognostic (2.98e-1)"	"unprognostic (8.36e-3)"	"unprognostic (2.37e-1)"	"unprognostic (9.57e-2)"	"unprognostic (8.57e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.44e-2)"	"unprognostic (4.78e-2)"	"unprognostic (6.33e-2)"	"unprognostic (3.15e-2)"	"unprognostic (8.75e-2)"	"unprognostic (1.93e-1)"	"unprognostic (7.63e-3)"	2.3	2.7	8.2	1.4	7.5	1.0	2.1	4.3	32.2	2.5	1.4	9.4	0.1	1.2	3.7	2.0	1.7	1.9	2.1	2.2	7.6	5.7	2.1	1.3	2.4	1.2	5.5	5.0	4.1	2.8	1.4	13.7	1.6	7.0	2.5	1.4	2.6	1.7	3.1	1.1	1.4	1.3	3.0	6.9	1.4	1.2	1.5	5.6	0.0	2.5	0.0	1.2	1.4	1.2	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.1	2.1	1.8	0.0	14.9	7.7	0.1	1.4	3.6	0.5	0.8	0.2	0.5	0.5	4.7	0.5	0.6	0.4	0.2	0.5	0.0	0.9	0.0	0.2	1.3	0.2	0.0	0.1	1.2	0.0	0.0	0.0	0.1	0.2	0.2	3.3	1.9	0.4	0.3	0.2	0.0	0.0	2.8	0.1	0.0	0.0	1.1	0.8	0.0	0.9	0.1	9.6	0.0	1.1	0.2	1.6	1.2	0.0	0.0	2.6	0.3	2.9	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	8.2	7.5	4.3	9.6	7.6	5.7	5.5	5.0	7.0	5.6
PDLIM2		ENSG00000120913	"PDZ and LIM domain 2"	Q96JY6	8	22578279-22598025	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 81.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA003880	Approved		Supported	"Actin filaments,Focal adhesion sites"				"Actin filaments, Focal adhesion sites"		"HPA003880: AB_1855149"	"unprognostic (1.04e-1)"	"unprognostic (3.53e-2)"	"unprognostic (1.80e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.45e-3)"	"unprognostic (9.33e-2)"	"unprognostic (3.69e-2)"	"unprognostic (4.55e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.22e-3)"	"unprognostic (1.52e-1)"	"unprognostic (3.37e-1)"	"prognostic unfavourable (1.37e-7)"	"unprognostic (6.14e-2)"	"unprognostic (8.17e-2)"	"unprognostic (3.47e-2)"	"unprognostic (3.08e-3)"	10.4	7.0	5.4	10.9	5.9	6.0	10.4	16.2	7.9	19.8	27.6	8.4	7.7	17.8	11.1	11.0	41.1	9.0	19.9	10.1	6.3	5.0	20.9	16.4	26.5	17.2	6.9	7.1	13.1	15.6	2.2	5.7	42.3	10.8	11.2	3.2	11.3	12.4	10.0	53.5	48.8	32.2	16.2	10.1	81.6	5.6	8.5	5.0	7.5	5.5	23.4	21.0	12.7	23.2	9.6	12.4	49.3	20.2	8.7	16.4	10.2	22.6	14.0	9.5	16.6	18.7	32.1	10.7	35.8	26.8	25.8	26.1	16.0	3.8	9.3	10.1	32.3	11.6	5.3	24.4	5.0	0.0	3.6	2.9	9.1	11.5	23.8	3.2	22.7	34.2	3.0	12.6	3.5	14.1	0.8	6.1	17.4	11.9	4.1	3.8	7.8	1.4	3.3	1.8	1.0	4.5	4.6	2.9	7.1	7.5	20.5	32.4	7.2	6.6	17.5	28.1	29.0	33.5	16.4	0.1	0.2	3.0	28.9	13.0	20.6	22.7	15.5	49.3	16.4	20.2	14.6	8.4	12.4	16.1	12.4	9.6	8.6	12.2	32.9	8.7	19.4	8.0	12.8	10.2	5.4	5.9	16.2	7.9	6.3	5.0	6.9	7.1	10.8	5.0
PDLIM5	"Enh, LIM"	ENSG00000163110	"PDZ and LIM domain 5"	Q96HC4	4	94451857-94668227	"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 129.6;skeletal muscle: 173.0"	"Low cell line specificity"	"Detected in all"			"Cancer enriched"	"Detected in all"	8	"prostate cancer: 132.0"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in all"	4	"basophil: 51.1"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 51.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013511, HPA016740, HPA020026"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Focal adhesion sites"			2200000	"Nucleoplasm, Plasma membrane, Focal adhesion sites"		"CAB013511: AB_2533388, HPA016740: AB_1855153, HPA020026: AB_1855154"	"unprognostic (6.20e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.81e-2)"	"unprognostic (1.08e-2)"	"unprognostic (6.61e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.46e-2)"	"unprognostic (7.60e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.24e-1)"	"unprognostic (2.11e-2)"	"unprognostic (3.15e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.04e-1)"	11.6	4.8	6.2	4.2	6.1	8.7	9.8	3.4	5.8	12.7	11.0	3.7	7.1	5.6	37.5	12.9	14.0	10.2	11.0	129.6	5.3	5.2	12.9	13.9	5.6	5.3	5.4	4.5	10.3	8.1	3.4	6.8	18.9	10.2	15.3	5.4	12.6	15.3	12.5	173.0	5.6	15.8	22.1	4.9	7.0	5.6	5.5	3.7	1.0	5.3	52.9	9.5	17.7	7.1	3.2	5.6	51.1	12.2	2.7	3.9	3.8	8.6	25.7	10.0	3.9	22.1	15.2	3.9	21.2	17.6	12.2	9.8	23.7	19.3	3.4	21.7	21.2	9.0	13.6	19.8	20.4	6.1	5.7	12.7	16.8	8.9	31.9	4.1	11.4	20.4	17.5	29.1	22.7	27.3	5.4	3.8	25.8	8.5	4.2	1.4	3.4	10.8	2.0	7.4	3.1	13.6	27.8	5.0	6.7	11.5	26.5	5.9	3.1	1.3	34.2	31.8	5.0	13.7	12.8	2.6	3.4	3.5	17.3	3.0	7.4	51.1	6.8	5.9	3.8	11.8	3.1	3.2	3.7	3.9	5.6	2.5	2.5	3.2	6.8	2.7	12.2	1.9	3.4	3.8	6.2	6.1	3.4	3.9	5.3	5.2	5.4	4.5	10.2	3.7
PDLIM7	ENIGMA	ENSG00000196923	"PDZ and LIM domain 7"	Q9NR12	5	177483394-177497606	"Predicted intracellular proteins"	"Differentiation, Osteogenesis"	"Developmental protein"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 159.6"	"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"basophil: 27.2;eosinophil: 20.5;neutrophil: 80.6"	"Lineage enriched"	"Detected in many"	10	"granulocytes: 80.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018794, HPA048815"	Approved		Enhanced	"Actin filaments,Focal adhesion sites"			7600000	"Actin filaments, Focal adhesion sites"		"HPA018794: AB_1855155, HPA048815: AB_2680530"	"unprognostic (7.70e-3)"	"unprognostic (3.75e-2)"	"unprognostic (9.27e-3)"	"prognostic unfavourable (5.45e-4)"	"unprognostic (1.40e-1)"	"unprognostic (3.48e-2)"	"unprognostic (9.18e-3)"	"prognostic unfavourable (4.07e-4)"	"unprognostic (5.01e-2)"	"unprognostic (3.10e-1)"	"unprognostic (7.24e-2)"	"unprognostic (1.88e-1)"	"prognostic unfavourable (6.19e-10)"	"unprognostic (6.72e-3)"	"unprognostic (3.02e-1)"	"unprognostic (1.93e-1)"	"unprognostic (3.68e-2)"	12.4	5.6	3.7	21.1	9.3	12.5	8.3	0.5	5.9	54.6	76.0	3.2	42.6	9.0	85.0	35.8	33.9	35.5	52.3	11.1	3.8	5.0	8.3	2.4	11.6	8.9	3.5	5.8	28.2	3.1	2.1	10.3	11.5	5.6	42.0	7.6	17.6	9.1	61.7	159.6	5.3	16.5	129.5	3.1	12.7	27.0	11.7	2.4	3.7	5.4	24.9	6.5	67.8	19.6	1.8	4.8	80.6	8.4	0.4	1.4	3.9	24.8	4.9	23.7	18.7	6.4	11.8	24.1	47.6	26.0	27.1	19.5	9.6	22.5	4.5	49.2	29.1	12.0	3.9	32.3	6.3	6.2	5.7	14.6	16.3	9.0	17.6	7.8	49.3	25.7	5.4	21.7	10.4	16.2	10.8	3.2	19.6	19.2	1.4	17.2	16.4	21.4	29.0	21.2	2.8	18.1	5.1	3.6	7.8	18.6	3.5	9.1	5.1	7.0	58.3	32.7	35.5	12.4	43.4	0.8	0.9	5.3	15.5	8.4	7.4	27.2	8.4	20.5	0.9	3.9	1.1	1.8	0.6	1.4	4.8	1.0	0.6	0.7	80.6	0.4	4.9	0.3	1.2	3.9	3.7	9.3	0.5	5.9	3.8	5.0	3.5	5.8	5.6	2.4
PLEC	"EBS1, PCN, PLEC1, PLTN"	ENSG00000178209	Plectin	Q15149	8	143915147-143976734	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Cancer-related genes, Disease mutation, Epidermolysis bullosa, Limb-girdle muscular dystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 144.9"	"Cell line enhanced"	"Detected in many"		"PC-3: 72.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003847, HPA025967, HPA029906"	Enhanced		Enhanced	"Intermediate filaments,Focal adhesion sites,Cytosol"			7100000	"Intermediate filaments, Cytosol"	"Focal adhesion sites"	"CAB003847: AB_562198, HPA025967: AB_10601671, HPA029906: AB_10602279"	"unprognostic (1.02e-1)"	"unprognostic (1.37e-3)"	"prognostic unfavourable (4.29e-4)"	"unprognostic (2.09e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.76e-3)"	"prognostic unfavourable (5.33e-4)"	"unprognostic (1.72e-3)"	"unprognostic (1.13e-2)"	"unprognostic (2.85e-3)"	"unprognostic (5.48e-2)"	"prognostic unfavourable (7.98e-6)"	"unprognostic (2.30e-1)"	"unprognostic (4.04e-2)"	"unprognostic (6.58e-2)"	"unprognostic (5.58e-3)"	20.9	11.0	15.9	16.5	13.3	27.9	13.1	15.0	20.7	20.7	17.7	14.6	16.7	13.1	20.2	16.8	25.1	18.2	29.0	23.4	18.9	10.7	11.2	10.9	16.6	15.0	9.9	13.0	18.0	14.0	8.8	12.0	24.2	13.2	17.5	9.8	13.0	17.8	14.8	144.9	36.4	24.1	24.7	11.0	16.9	21.4	6.7	12.7	16.3	9.2	44.2	24.5	20.2	19.2	1.5	3.4	0.8	4.1	0.7	2.9	3.2	16.3	51.2	3.3	4.1	6.0	13.4	11.7	24.0	10.7	6.4	3.6	7.1	17.1	1.6	18.7	35.1	19.4	2.2	33.6	2.5	12.2	1.8	6.2	52.0	5.8	9.5	2.0	5.2	15.4	6.6	17.2	33.6	7.4	3.0	5.3	7.4	28.7	1.2	3.4	2.2	72.1	0.3	9.4	4.4	10.7	30.3	3.4	3.4	40.9	8.7	3.9	10.7	2.4	23.8	24.8	44.9	21.8	28.4	0.8	0.6	1.2	23.6	2.6	35.2	0.0	4.1	0.2	1.4	3.8	2.8	1.4	2.7	2.0	3.4	1.5	2.0	1.1	0.8	0.7	2.7	2.8	2.9	3.2	15.9	13.3	15.0	17.3	18.9	10.7	9.9	13.0	13.2	12.7
PPFIA1	"LIP.1, LIPRIN"	ENSG00000131626	"PTPRF interacting protein alpha 1"	Q13136	11	70270700-70385312	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"A-431: 78.4;SK-MEL-30: 45.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017032, HPA042271"	Uncertain		Supported	"Focal adhesion sites,Cytosol"				Cytosol	"Focal adhesion sites"	"CAB017032: , HPA042271: "	"unprognostic (1.89e-1)"	"unprognostic (1.28e-2)"	"unprognostic (6.27e-2)"	"unprognostic (9.92e-2)"	"unprognostic (1.18e-1)"	"prognostic unfavourable (5.58e-4)"	"unprognostic (7.20e-3)"	"unprognostic (2.20e-1)"	"unprognostic (3.02e-2)"	"unprognostic (5.45e-3)"	"prognostic unfavourable (8.26e-4)"	"unprognostic (1.14e-1)"	"prognostic favourable (3.76e-4)"	"unprognostic (1.09e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.80e-1)"	"unprognostic (2.14e-2)"	28.9	18.6	20.9	17.5	20.8	20.8	40.5	22.8	24.1	15.9	18.3	27.7	18.5	15.5	26.2	20.4	19.4	16.9	23.9	19.3	19.7	12.0	18.1	15.5	25.4	15.9	18.9	17.8	21.0	17.7	21.2	34.1	24.9	20.7	13.8	16.3	21.9	19.0	18.5	38.7	24.2	17.8	18.4	30.0	14.7	15.6	29.8	22.5	17.0	25.2	10.0	13.6	18.7	18.6	2.6	2.8	10.0	4.8	1.1	2.2	1.0	78.4	10.6	9.7	6.6	9.1	5.7	10.3	9.2	7.5	11.5	7.6	20.0	7.0	7.3	12.0	7.4	11.4	8.2	7.9	9.9	4.9	5.7	5.9	11.1	6.4	9.3	7.7	7.2	7.2	12.7	14.7	12.1	7.4	9.9	6.0	9.9	10.7	5.3	4.6	5.8	9.1	6.1	24.5	6.4	5.6	10.8	9.5	6.4	13.7	17.3	45.1	11.6	8.2	10.1	11.5	9.0	15.9	9.7	7.3	4.6	10.3	9.5	5.4	13.4	0.0	3.6	1.7	1.3	1.9	2.2	2.6	2.2	1.9	2.8	2.3	1.7	1.0	10.0	1.1	4.8	2.8	2.1	1.0	20.9	20.8	22.8	21.4	19.7	12.0	18.9	17.8	20.7	22.5
PTK2	"FADK, FAK, FAK1, PPP1R71"	ENSG00000169398	"Protein tyrosine kinase 2"	Q05397	8	140657900-141002216	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	Angiogenesis	"Developmental protein, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001842, CAB004036, HPA029671"	Approved		Supported	"Vesicles,Focal adhesion sites,Cytosol"			32000	"Focal adhesion sites"	"Vesicles, Cytosol"	"CAB004036: AB_2269034, HPA001842: AB_1855891, HPA029671: AB_10610288"	"prognostic unfavourable (3.21e-4)"	"unprognostic (3.86e-2)"	"unprognostic (1.95e-1)"	"prognostic unfavourable (9.11e-4)"	"unprognostic (1.93e-1)"	"unprognostic (2.28e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.97e-1)"	"unprognostic (2.96e-2)"	"unprognostic (1.06e-2)"	"unprognostic (2.38e-1)"	"unprognostic (2.80e-2)"	"unprognostic (2.94e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.53e-1)"	"unprognostic (2.90e-2)"	22.6	20.4	36.0	14.4	42.3	3.1	19.3	20.5	40.8	24.9	17.9	55.7	23.5	14.5	20.2	29.9	14.6	18.7	18.4	20.0	43.5	23.9	22.3	17.0	21.5	13.0	41.4	31.4	19.4	18.2	33.1	13.0	42.1	30.0	19.2	20.7	11.0	21.9	25.5	17.9	13.5	16.3	21.9	38.0	12.2	17.5	21.2	46.1	2.8	22.5	10.2	14.0	22.2	17.8	8.6	7.2	1.8	3.9	5.2	5.7	4.1	14.6	23.4	32.5	11.7	13.7	14.7	21.0	14.5	20.2	13.6	13.4	10.2	12.2	8.9	33.0	18.6	17.4	19.1	33.3	20.6	0.1	8.9	19.7	12.9	14.0	18.7	0.0	9.4	10.0	16.4	17.0	24.0	40.1	19.8	0.2	18.2	25.5	0.2	0.2	12.6	26.2	13.1	17.8	0.4	28.7	33.5	12.9	16.1	22.7	7.3	14.7	17.2	0.3	24.2	13.4	25.3	15.8	16.3	0.0	0.1	0.9	17.4	0.1	18.1	1.8	3.9	0.0	0.3	1.6	0.0	6.8	0.8	0.1	5.3	8.6	5.7	2.0	1.7	5.2	0.9	7.2	0.2	4.1	36.0	42.3	20.5	40.8	43.5	23.9	41.4	31.4	30.0	46.1
PWWP2A	KIAA1935	ENSG00000170234	"PWWP domain containing 2A"	Q96N64	5	160061801-160119423	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 52.7"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA046733, HPA058233"			Supported	"Nucleoplasm,Focal adhesion sites"				Nucleoplasm	"Focal adhesion sites"	"HPA046733: , HPA058233: "	"unprognostic (1.03e-1)"	"unprognostic (2.67e-1)"	"unprognostic (5.13e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.18e-2)"	"unprognostic (7.86e-3)"	"unprognostic (1.40e-3)"	"unprognostic (6.24e-2)"	"unprognostic (2.42e-2)"	"unprognostic (7.08e-2)"	"unprognostic (7.25e-2)"	"unprognostic (8.24e-3)"	"prognostic unfavourable (3.70e-4)"	"unprognostic (2.23e-1)"	"unprognostic (3.88e-2)"	"unprognostic (1.08e-1)"	"prognostic favourable (3.51e-4)"	8.4	9.3	9.5	12.7	22.3	11.9	9.1	52.7	16.0	14.4	13.6	19.9	5.3	9.6	10.8	7.2	8.7	9.5	8.1	7.4	15.9	8.8	10.3	8.6	9.8	12.0	25.2	8.9	10.5	10.5	10.6	15.1	11.2	17.0	11.9	14.7	10.3	8.8	8.4	7.0	14.7	10.6	9.3	13.8	12.5	11.8	6.3	21.3	18.6	9.8	5.8	11.4	10.7	10.1	6.0	2.9	6.0	4.4	1.1	4.9	0.9	10.6	5.1	13.4	11.4	14.9	11.7	18.9	8.5	7.0	7.6	7.8	16.6	20.8	17.2	13.1	6.5	7.7	11.6	13.3	12.6	17.8	12.9	12.3	9.5	8.5	11.4	12.4	9.4	8.3	6.7	15.3	11.7	12.2	9.4	11.2	12.9	8.9	10.6	12.1	15.7	6.7	16.7	11.9	11.0	9.3	7.6	15.8	11.0	14.4	14.5	15.4	11.2	13.8	16.2	13.3	9.2	9.9	16.5	12.8	11.5	15.3	8.8	12.6	13.1	6.0	4.4	2.4	2.8	2.0	2.2	6.0	3.0	3.3	2.9	3.7	4.9	2.7	5.0	1.1	2.6	2.7	2.5	0.9	9.5	22.3	52.7	16.0	15.9	8.8	25.2	8.9	17.0	21.3
PXN		ENSG00000089159	Paxillin	P49023	12	120210439-120265771	"Predicted intracellular proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 49.5"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003841, HPA051309"	Supported		Enhanced	"Focal adhesion sites,Centrosome,Cytosol"				"Focal adhesion sites"	"Centrosome, Cytosol"	"CAB003841: AB_562188, HPA051309: "	"unprognostic (4.00e-2)"	"unprognostic (1.94e-2)"	"unprognostic (3.51e-2)"	"unprognostic (3.55e-3)"	"prognostic unfavourable (1.09e-4)"	"prognostic unfavourable (3.72e-5)"	"prognostic unfavourable (7.12e-5)"	"prognostic unfavourable (1.73e-4)"	"unprognostic (3.12e-2)"	"unprognostic (9.19e-3)"	"unprognostic (2.66e-2)"	"unprognostic (1.73e-1)"	"unprognostic (2.12e-2)"	"unprognostic (3.35e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.75e-2)"	35.4	26.2	17.9	26.7	16.5	31.6	45.9	15.5	18.6	25.0	29.0	12.4	31.7	25.6	27.6	30.9	16.0	29.8	31.8	26.2	18.0	7.6	27.6	13.1	35.8	42.9	15.7	8.1	14.8	16.3	17.6	13.9	34.0	15.8	24.9	23.5	24.7	22.1	40.1	98.5	19.7	34.7	44.4	20.3	34.0	20.6	19.8	14.4	9.9	26.7	22.8	11.6	30.1	45.7	0.5	7.6	49.5	12.3	14.4	26.3	14.5	32.6	16.2	5.8	5.8	11.7	30.4	39.3	27.6	24.1	22.5	11.9	18.9	20.5	2.2	18.2	28.1	23.3	4.0	50.3	18.0	1.8	3.6	0.4	11.9	6.7	16.9	0.5	0.7	14.8	33.0	23.6	26.8	40.0	5.7	3.7	44.0	21.6	2.0	0.7	8.2	56.3	4.8	9.6	2.0	23.1	31.4	9.5	2.8	24.8	7.6	14.9	18.8	2.7	52.7	15.7	17.2	19.5	32.9	4.0	2.2	0.8	45.1	4.9	30.6	9.8	12.3	13.4	26.3	4.4	14.2	0.5	12.1	17.2	7.6	0.4	9.6	12.8	49.5	14.4	0.2	1.2	9.1	14.5	17.9	16.5	15.5	18.6	18.0	7.6	15.7	8.1	15.8	14.4
RAB24		ENSG00000169228	"RAB24, member RAS oncogene family"	Q969Q5	5	177301198-177303744	"Predicted intracellular proteins"	"Autophagy, Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HDLM-2: 54.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA034945			Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA034945: "	"unprognostic (1.03e-2)"	"unprognostic (6.81e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.59e-1)"	"unprognostic (7.86e-2)"	"prognostic favourable (6.22e-4)"	"prognostic unfavourable (7.56e-5)"	"unprognostic (1.28e-1)"	"unprognostic (1.78e-2)"	"unprognostic (9.66e-2)"	"unprognostic (1.43e-3)"	"unprognostic (2.79e-2)"	"prognostic unfavourable (2.54e-7)"	"unprognostic (3.97e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.75e-1)"	"unprognostic (1.12e-2)"	13.6	19.7	18.3	19.9	20.9	24.6	16.8	25.0	24.2	12.1	13.7	7.5	25.3	15.3	10.9	23.6	21.0	11.9	12.4	12.7	15.4	18.0	16.6	15.2	14.2	15.5	13.1	22.0	16.9	31.4	16.2	26.0	15.6	19.8	15.3	11.0	14.1	23.2	20.8	27.1	19.5	15.6	14.5	10.6	27.6	12.8	5.7	13.1	5.9	18.8	15.1	19.9	11.0	15.9	7.5	14.5	38.0	42.0	7.9	5.1	10.2	2.9	7.7	5.1	10.2	8.3	7.3	10.7	9.0	11.2	11.1	13.5	9.3	3.9	3.1	11.0	7.1	2.7	6.9	9.7	6.2	54.3	5.5	10.8	7.8	7.9	17.6	6.8	9.8	12.2	7.9	11.8	8.3	6.8	8.0	17.2	7.8	11.0	2.5	19.6	3.3	7.9	1.5	8.5	12.2	7.4	5.1	6.6	9.0	2.8	5.5	23.1	9.9	17.1	7.4	3.9	6.4	9.0	7.7	13.1	6.2	4.0	7.4	11.0	8.2	8.7	21.4	38.0	5.1	42.0	4.4	7.5	2.5	4.2	14.5	6.8	2.8	4.4	33.0	7.9	40.7	3.2	2.1	10.2	18.3	20.9	25.0	24.2	15.4	18.0	13.1	22.0	19.8	13.1
RAET1E	"bA350J20.7, LETAL, ULBP4"	ENSG00000164520	"Retinoic acid early transcript 1E"	Q8TD07	6	149883375-149898102	"Predicted intracellular proteins, Predicted membrane proteins"	Immunity			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 39.7;lymphoid tissue: 22.5;tongue: 19.8"	"Cell line enhanced"	"Detected in some"		"HBEC3-KT: 15.5;HeLa: 21.4;hTCEpi: 15.5;SiHa: 7.4;U-87 MG: 6.7"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 3.9"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"											HPA054022			Supported	"Focal adhesion sites,Cytosol"	"Intracellular and membrane"			"Focal adhesion sites"	Cytosol	"HPA054022: "	"unprognostic (1.67e-2)"	"unprognostic (2.10e-1)"	"unprognostic (3.49e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.36e-1)"	"unprognostic (2.71e-2)"	"unprognostic (1.36e-3)"	"unprognostic (4.80e-4)"	"unprognostic (1.11e-1)"	"unprognostic (3.39e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.69e-1)"	"unprognostic (7.47e-5)"	"unprognostic (2.41e-2)"	"unprognostic (3.18e-2)"	"unprognostic (3.17e-2)"	"unprognostic (1.06e-1)"	1.6	0.5	0.2	0.5	0.2	0.0	1.4	0.2	0.2	10.4	0.3	0.2	0.2	0.2	0.8	0.6	39.7	0.6	0.2	0.2	0.2	0.0	2.8	0.2	0.6	0.2	0.2	0.2	0.6	0.2	0.1	0.2	0.5	0.2	0.4	0.3	0.2	7.0	0.2	0.7	14.6	0.3	0.3	0.2	0.6	0.2	0.5	0.3	0.3	0.2	19.8	22.5	1.3	12.6	0.6	0.4	2.3	0.6	0.5	0.7	0.1	1.5	0.9	0.0	0.0	0.1	1.3	0.1	0.1	0.9	0.1	0.3	0.0	3.7	0.0	2.1	3.0	1.6	0.0	15.5	0.2	0.4	0.0	0.0	21.4	0.0	0.0	0.0	0.0	0.3	15.5	0.9	3.2	0.1	0.0	1.3	0.9	0.1	0.0	0.0	0.0	0.8	0.0	0.0	0.2	0.3	0.7	0.2	0.0	7.4	2.0	0.0	1.1	0.0	2.9	1.1	0.4	0.1	0.9	0.0	0.0	0.0	6.7	0.3	0.0	2.0	0.6	0.4	0.4	0.3	0.2	0.2	0.6	0.3	0.1	0.6	0.7	0.4	2.3	0.5	0.2	0.4	0.3	0.1	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.3
RALA	RAL	ENSG00000006451	"RAS like proto-oncogene A"	P11233	7	39623483-39708124	"Predicted intracellular proteins, RAS pathway related proteins"	"Cell cycle, Cell division, Exocytosis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HUVEC TERT2: 76.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047037, HPA065232"	Approved		Supported	"Plasma membrane,Focal adhesion sites"				"Plasma membrane"	"Focal adhesion sites"	"HPA047037: , HPA065232: "	"unprognostic (1.20e-3)"	"unprognostic (1.03e-2)"	"unprognostic (2.91e-1)"	"unprognostic (7.73e-3)"	"unprognostic (1.98e-2)"	"unprognostic (9.14e-2)"	"prognostic unfavourable (5.32e-5)"	"unprognostic (7.71e-2)"	"unprognostic (2.17e-1)"	"prognostic favourable (7.46e-4)"	"prognostic unfavourable (6.30e-4)"	"unprognostic (3.32e-1)"	"unprognostic (4.95e-3)"	"unprognostic (5.38e-2)"	"unprognostic (7.15e-2)"	"unprognostic (2.79e-1)"	"unprognostic (2.95e-2)"	19.2	25.2	24.7	14.3	24.6	4.8	24.4	16.1	22.0	18.4	22.3	17.2	8.0	23.5	15.7	15.5	44.9	15.0	20.0	13.8	24.7	20.2	15.9	15.4	30.3	14.8	27.6	18.9	17.4	11.6	12.8	14.2	23.7	20.3	12.9	23.6	9.1	18.5	12.7	16.8	19.5	25.5	15.7	36.0	16.0	24.4	12.2	21.9	19.9	13.8	31.0	28.9	15.2	20.8	13.3	16.3	21.5	11.2	15.7	20.4	11.5	19.7	4.5	11.2	9.7	21.4	17.8	7.7	17.3	25.1	15.8	17.6	11.3	9.7	10.1	6.5	13.4	20.5	15.8	11.3	27.3	9.7	7.5	7.9	7.4	8.3	34.7	13.7	11.3	14.0	13.8	28.1	40.1	76.6	15.8	6.8	16.0	6.4	9.7	16.3	31.4	9.0	12.1	10.1	8.8	16.1	9.2	20.1	19.5	10.7	17.2	11.8	16.0	15.1	24.5	9.3	8.3	11.7	12.3	12.1	9.3	12.4	10.5	14.3	16.9	21.5	9.8	11.0	9.7	11.2	12.0	11.5	15.7	12.4	16.3	13.3	20.4	17.9	4.5	15.7	8.6	10.6	19.7	11.5	24.7	24.6	16.1	20.8	24.7	20.2	27.6	18.9	20.3	21.9
RAPGEF4	"cAMP-GEFII, CGEF2"	ENSG00000091428	"Rap guanine nucleotide exchange factor 4"	Q8WZA2	2	172735274-173052893	"Predicted intracellular proteins"	Exocytosis	"Guanine-nucleotide releasing factor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 29.6;brain: 70.9"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 17.6;SCLC-21H: 6.8;U-266/70: 9.0;U-266/84: 17.6"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in all"	4	"amygdala: 68.3;basal ganglia: 31.5;cerebral cortex: 55.3;hippocampal formation: 70.9;olfactory region: 23.8"	"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004388, HPA028968"	Approved		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"CAB004388: AB_670916, HPA028968: "	"unprognostic (1.87e-1)"	"unprognostic (4.22e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.98e-3)"	"unprognostic (4.53e-2)"	"unprognostic (1.20e-2)"	"unprognostic (4.45e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.16e-1)"	"unprognostic (3.23e-1)"	"prognostic favourable (1.32e-4)"	"unprognostic (6.32e-2)"	"unprognostic (1.46e-3)"	"unprognostic (1.97e-2)"	"unprognostic (6.18e-2)"	"unprognostic (5.70e-2)"	"unprognostic (2.93e-1)"	3.3	29.6	68.3	1.6	31.5	0.6	5.2	10.9	55.3	4.9	1.5	5.4	1.0	2.1	6.6	2.7	2.3	2.9	3.7	5.7	70.9	10.2	3.8	24.6	5.4	1.7	10.0	23.8	9.7	2.0	3.2	2.4	2.3	8.6	3.5	1.7	11.3	1.7	2.9	1.4	10.6	1.8	4.3	2.9	0.9	5.4	3.7	11.5	0.0	4.3	0.9	1.8	4.2	1.2	0.4	0.6	1.4	0.6	0.6	0.7	0.1	0.1	0.1	2.6	0.4	0.0	0.2	0.1	0.9	0.5	0.1	0.2	0.0	3.0	0.0	0.2	0.0	0.5	2.2	0.6	0.3	0.1	4.7	0.4	2.2	0.0	0.0	2.9	0.7	0.0	0.7	0.0	0.0	2.8	0.0	17.6	0.1	0.0	0.2	0.2	0.3	0.3	0.0	0.6	0.0	0.0	5.2	6.8	2.5	0.1	0.0	0.9	0.1	0.1	0.8	0.1	0.3	0.0	0.2	9.0	17.6	0.0	0.3	0.1	0.1	1.4	0.4	0.4	0.3	0.4	0.6	0.4	0.4	0.3	0.3	0.4	0.6	0.7	1.0	0.6	0.6	0.6	0.3	0.1	68.3	31.5	10.9	55.3	70.9	10.2	10.0	23.8	8.6	11.5
RASAL2	nGAP	ENSG00000075391	"RAS protein activator like 2"	Q9UJF2	1	178094141-178484147	"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"		"GTPase activation"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 29.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 2.1"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018805, HPA020453"	Enhanced		Approved	"Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"		"HPA018805: AB_1856085, HPA020453: AB_1856086"	"unprognostic (5.55e-3)"	"unprognostic (6.49e-2)"	"unprognostic (2.65e-1)"	"unprognostic (6.33e-2)"	"unprognostic (3.40e-2)"	"unprognostic (5.59e-2)"	"unprognostic (5.91e-2)"	"unprognostic (1.72e-2)"	"unprognostic (2.91e-1)"	"unprognostic (2.92e-2)"	"unprognostic (3.16e-3)"	"unprognostic (2.03e-1)"	"unprognostic (1.06e-2)"	"unprognostic (4.98e-2)"	"unprognostic (2.45e-1)"	"unprognostic (8.36e-2)"	"prognostic unfavourable (2.05e-4)"	13.5	3.8	4.2	2.8	5.1	0.4	7.1	2.7	8.5	9.5	4.2	3.7	4.2	2.4	10.9	5.5	24.4	5.8	9.0	15.5	3.8	5.9	7.1	2.7	9.2	1.5	4.0	6.5	6.3	5.0	6.1	6.7	21.2	5.6	5.0	4.3	10.7	9.6	4.5	8.3	7.5	3.3	7.1	3.8	2.9	3.7	9.0	2.7	0.0	5.0	13.1	4.8	5.6	13.2	2.1	0.5	1.4	0.6	0.3	0.1	0.0	16.1	5.3	7.0	2.3	4.7	6.4	9.7	8.1	7.9	6.9	5.2	8.5	8.6	0.0	13.5	7.9	13.6	5.6	12.9	6.4	0.0	3.1	0.0	5.6	3.3	5.6	2.3	0.3	20.1	2.5	8.2	29.6	6.2	0.5	0.0	9.5	1.6	0.0	1.9	5.2	1.0	0.1	2.8	0.0	3.7	2.1	5.4	2.6	6.3	4.9	4.9	5.7	2.6	11.7	9.2	9.3	9.5	10.8	3.5	0.0	0.0	7.2	1.2	6.5	1.4	0.4	0.1	0.1	0.3	0.0	0.6	0.0	0.0	0.2	2.1	0.1	0.1	0.8	0.3	0.6	0.5	0.0	0.0	4.2	5.1	2.7	7.1	3.8	5.9	4.0	6.5	5.6	2.7
RELN	"PRO1598, RL"	ENSG00000189056	Reelin	P78509	7	103471784-103989516	"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"	"Developmental protein, Hydrolase, Protease, Serine protease"	"Disease mutation, Epilepsy, Lissencephaly"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"brain: 73.4;liver: 35.8"	"Cell line enhanced"	"Detected in some"		"Hep G2: 33.6;PC-3: 6.8;SCLC-21H: 8.2;SH-SY5Y: 8.9;TIME: 19.5"	"Cancer enhanced"	"Detected in many"		"liver cancer: 5.7"	"Region enriched"	"Detected in many"	11	"cerebellum: 73.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA046512			Approved	"Plasma membrane,Focal adhesion sites"	"Secreted to extracellular matrix"		59000000	"Focal adhesion sites"	"Plasma membrane"	"HPA046512: "	"unprognostic (1.42e-1)"	"unprognostic (2.93e-3)"	"unprognostic (4.31e-2)"	"unprognostic (1.29e-4)"	"unprognostic (1.30e-1)"	"unprognostic (6.95e-2)"	"unprognostic (1.85e-1)"	"unprognostic (8.35e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.48e-2)"	"unprognostic (3.31e-3)"	"unprognostic (3.86e-1)"	"unprognostic (2.02e-2)"	"unprognostic (1.43e-2)"	"unprognostic (3.03e-1)"	"unprognostic (1.35e-1)"	"unprognostic (3.06e-2)"	2.7	5.9	5.7	1.2	5.3	0.5	6.3	73.4	6.7	2.9	2.1	0.8	0.0	1.1	1.0	3.0	1.7	4.4	1.9	3.2	5.7	5.3	1.2	35.8	1.6	7.9	1.8	2.5	1.3	1.0	0.3	0.8	0.4	5.1	1.2	2.1	10.6	1.1	2.1	0.4	1.1	1.9	2.4	3.2	1.1	0.8	1.5	0.0	0.0	2.6	1.7	0.9	1.7	2.5	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.0	0.0	0.0	3.6	0.0	1.2	0.0	0.1	0.0	0.0	2.4	0.0	33.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.8	0.0	1.4	0.0	0.0	0.0	8.2	8.9	0.0	0.0	0.0	0.0	0.0	19.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.7	5.3	73.4	6.7	5.7	5.3	1.8	2.5	5.1	0.0
REXO2	"CGI-114, DKFZP566E144, SFN"	ENSG00000076043	"RNA exonuclease 2"	Q9Y3B8	11	114439386-114450279	"Predicted intracellular proteins"		"Exonuclease, Hydrolase, Nuclease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038450, HPA038451"	Enhanced		Supported	"Nucleoli,Focal adhesion sites,Mitochondria"			390000	Mitochondria	"Nucleoli, Focal adhesion sites"	"HPA038450: AB_10672516, HPA038451: AB_10697391"	"unprognostic (3.26e-3)"	"unprognostic (2.36e-2)"	"prognostic favourable (6.51e-4)"	"unprognostic (6.84e-3)"	"unprognostic (5.80e-3)"	"unprognostic (1.06e-1)"	"unprognostic (1.40e-3)"	"unprognostic (1.78e-1)"	"unprognostic (8.18e-3)"	"unprognostic (2.49e-2)"	"unprognostic (2.17e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.73e-2)"	"unprognostic (6.75e-2)"	"unprognostic (1.23e-1)"	"unprognostic (7.69e-2)"	"prognostic unfavourable (6.70e-4)"	21.8	31.1	13.5	15.8	14.2	16.2	30.0	14.9	12.6	31.4	36.0	11.2	24.0	8.4	38.4	24.8	33.5	17.7	23.9	64.3	13.3	10.5	35.7	28.6	20.1	13.9	17.0	13.1	28.5	27.7	61.2	24.9	45.0	15.3	32.0	17.7	11.6	61.6	22.8	27.8	22.7	15.8	44.6	15.7	18.6	31.5	29.6	14.5	9.9	20.0	25.2	15.2	34.9	40.6	15.5	28.6	19.0	7.9	18.1	30.5	12.2	27.4	16.0	6.2	16.6	49.9	53.0	14.8	46.5	36.4	23.5	30.0	41.9	47.0	15.1	46.9	41.1	17.5	13.9	41.2	38.9	14.6	10.8	16.6	22.1	26.0	65.6	12.1	5.3	36.6	39.5	29.7	31.6	42.0	30.7	9.3	52.6	6.5	8.8	15.2	19.1	28.3	7.8	20.2	54.9	33.7	22.3	11.0	6.9	21.4	16.5	19.6	33.6	6.3	39.7	30.3	36.3	23.3	28.5	7.3	8.7	25.5	20.9	28.6	16.1	19.0	6.0	8.8	14.3	7.9	16.5	15.5	21.6	17.9	7.8	11.7	19.9	16.1	1.5	18.1	7.9	28.6	30.5	12.2	13.5	14.2	14.9	12.6	13.3	10.5	17.0	13.1	15.3	14.5
RTN4R	NOGOR	ENSG00000040608	"Reticulon 4 receptor"	Q9BZR6	22	20241415-20283246	"Disease related genes, Predicted membrane proteins"		Receptor	"Disease mutation, Schizophrenia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 12.0;brain: 33.2"	"Cell line enhanced"	"Detected in many"		"NB-4: 20.0;REH: 28.2;SCLC-21H: 17.2;SK-MEL-30: 13.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 12.0"	"Lineage enriched"	"Detected in many"	9	"T-cells: 12.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB012443			Supported	"Plasma membrane,Actin filaments,Focal adhesion sites"			1300000	"Plasma membrane, Focal adhesion sites"	"Actin filaments"	"CAB012443: "	"unprognostic (1.28e-1)"	"unprognostic (1.28e-2)"	"unprognostic (8.29e-2)"	"unprognostic (6.58e-2)"	"unprognostic (3.49e-1)"	"prognostic unfavourable (7.73e-4)"	"unprognostic (2.19e-1)"	"unprognostic (1.56e-1)"	"unprognostic (3.44e-1)"	"unprognostic (8.90e-3)"	"unprognostic (1.21e-2)"	"unprognostic (9.89e-2)"	"unprognostic (1.80e-2)"	"unprognostic (1.34e-2)"	"unprognostic (1.30e-1)"	"unprognostic (5.02e-2)"	"unprognostic (3.07e-1)"	0.8	1.1	10.9	1.2	7.0	1.3	0.7	33.2	24.6	0.8	1.7	1.2	0.3	3.9	4.9	0.5	0.9	1.3	0.6	1.4	8.8	3.1	0.9	4.0	1.7	1.1	1.4	6.8	1.1	2.7	0.6	1.6	1.1	4.9	1.2	0.6	0.7	1.3	1.2	0.8	5.2	1.8	0.7	2.8	5.9	2.3	1.1	0.5	0.1	1.1	0.4	0.7	0.7	0.7	0.1	1.3	0.0	0.0	0.7	12.0	1.7	4.1	2.0	1.2	3.0	0.0	0.0	0.6	0.4	0.0	0.3	0.1	3.2	1.1	0.2	1.4	0.0	6.8	0.7	1.7	0.0	0.1	7.3	0.1	1.8	0.4	0.7	0.1	0.2	0.0	2.2	0.0	0.2	0.0	0.2	0.2	0.0	5.8	2.1	20.0	4.7	3.6	28.2	0.0	0.2	0.2	1.7	17.2	2.8	2.0	1.4	13.4	1.6	0.5	0.0	0.2	8.1	0.0	0.1	0.0	0.5	0.5	0.2	4.1	0.0	0.0	0.0	0.0	5.1	0.0	12.0	0.0	4.5	5.1	0.2	0.1	2.7	5.7	0.0	0.7	0.0	1.3	3.1	1.7	10.9	7.0	33.2	20.1	8.8	3.1	1.4	6.8	4.9	0.5
SCN9A	"ETHA, Nav1.7, NE-NA, NENA, PN1"	ENSG00000169432	"Sodium voltage-gated channel alpha subunit 9"	Q15858	2	166195185-166376001	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ: 17.3;BJ hTERT+: 12.9;HHSteC: 14.9"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	17	"plasmacytoid DC: 18.6"	"Lineage enriched"	"Detected in single"	24	"dendritic cells: 18.6"	"Region enriched"	"Detected in some"	5	"hypothalamus: 10.9"	"Low region specificity"	"Detected in many"			"CAB013679, HPA061843"	Uncertain		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"				"Plasma membrane, Actin filaments, Focal adhesion sites"		"CAB013679: , HPA061843: "	"unprognostic (2.10e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.13e-1)"	"unprognostic (8.98e-5)"	"unprognostic (1.47e-3)"	"unprognostic (9.43e-3)"	"unprognostic (2.28e-2)"	"unprognostic (2.24e-1)"	"unprognostic (2.23e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.27e-1)"	"prognostic unfavourable (2.30e-5)"	"unprognostic (1.69e-3)"	"unprognostic (6.74e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.46e-1)"	6.6	4.2	3.8	2.8	9.1	4.2	2.7	0.9	4.4	1.8	10.2	0.5	0.1	1.4	0.9	3.8	2.6	1.2	5.8	2.9	2.8	15.9	4.8	8.3	4.5	3.5	4.1	2.3	2.1	4.8	0.6	11.3	9.2	7.3	2.0	7.0	1.7	1.8	1.9	0.9	1.8	4.2	5.2	2.5	12.4	1.7	16.2	0.4	10.3	1.4	1.9	1.2	3.6	1.8	0.0	18.6	0.7	0.1	0.4	0.0	0.0	0.0	1.9	0.1	0.0	7.5	6.5	0.0	17.3	12.9	4.0	1.4	0.5	0.1	0.0	0.0	2.1	0.0	5.0	0.6	6.7	0.0	1.6	1.3	1.5	1.4	14.9	0.0	0.0	0.4	0.2	6.9	1.3	0.8	4.3	5.0	0.6	0.0	2.6	0.0	1.5	0.5	0.7	2.5	6.5	1.8	7.3	0.8	7.3	0.0	0.0	0.3	0.2	0.0	0.0	0.0	1.1	0.1	0.3	0.1	0.0	0.0	2.5	0.0	1.4	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.7	0.4	0.1	18.6	0.0	0.0	3.8	9.1	0.9	4.4	2.8	15.9	4.1	2.3	7.3	0.4
SDC1	"CD138, SDC, SYND1, syndecan"	ENSG00000115884	"Syndecan 1"	P18827	2	20200797-20225433	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 113.2;placenta: 228.8"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 60.9;hTCEpi: 56.3;U-251 MG: 58.0;U-266/70: 60.1;U-266/84: 126.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	17	"memory B-cell: 3.9"	"Lineage enriched"	"Detected in single"	40	"B-cells: 3.9"	"Group enriched"	"Detected in some"	4	"cerebellum: 10.7;olfactory region: 5.9"	"Not detected"	"Not detected"			"CAB002424, HPA006185, HPA067477"	Enhanced		Supported	"Focal adhesion sites"	"Secreted to blood"	63100000	1600000	"Focal adhesion sites"		"CAB002424: AB_442050, HPA006185: AB_1857705, HPA067477: "	"prognostic unfavourable (2.22e-4)"	"unprognostic (6.80e-3)"	"unprognostic (6.80e-2)"	"unprognostic (7.84e-2)"	"prognostic unfavourable (5.02e-4)"	"unprognostic (1.15e-1)"	"unprognostic (4.02e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.70e-1)"	"unprognostic (3.66e-1)"	"unprognostic (2.27e-3)"	"unprognostic (1.79e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.94e-2)"	"unprognostic (4.27e-1)"	"unprognostic (1.62e-2)"	"unprognostic (1.52e-1)"	0.8	3.4	0.5	5.4	0.6	0.0	4.5	0.8	0.7	21.4	18.3	0.5	3.5	14.3	2.3	8.7	103.7	1.6	55.3	0.3	0.4	0.5	68.5	113.2	15.8	6.3	1.9	0.4	1.6	7.0	0.6	0.6	228.8	0.7	13.3	6.2	1.5	16.0	5.2	0.5	69.5	21.9	4.3	0.4	3.7	16.3	2.6	0.4	1.5	3.5	62.3	48.4	30.0	37.7	3.9	0.0	0.0	0.0	0.0	0.0	0.5	30.8	17.3	5.5	13.8	1.5	0.2	17.3	8.6	8.3	8.1	6.8	3.6	18.8	0.0	3.2	6.1	30.4	2.4	60.9	5.4	0.1	1.6	0.0	1.6	18.5	1.3	1.3	0.1	0.8	56.3	7.2	17.3	0.8	0.7	12.1	4.3	18.4	0.0	0.3	4.9	33.5	0.6	2.0	23.3	10.3	46.3	1.6	12.8	6.5	43.9	1.9	4.3	0.3	1.3	32.1	10.3	1.1	58.0	60.1	126.7	0.1	9.6	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.6	0.8	0.7	0.4	0.5	1.9	0.4	0.7	0.4
SENP1		ENSG00000079387	"SUMO1/sentrin specific peptidase 1"	Q9P0U3	12	48042898-48106308	"Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Hydrolase, Protease, Thiol protease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 60.2"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011765, HPA046491"			Supported	"Nucleoplasm,Focal adhesion sites"				Nucleoplasm	"Focal adhesion sites"	"HPA011765: AB_1079907, HPA046491: "	"unprognostic (2.66e-2)"	"unprognostic (6.51e-2)"	"unprognostic (3.14e-1)"	"unprognostic (5.69e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.09e-1)"	"prognostic unfavourable (7.72e-5)"	"unprognostic (6.48e-2)"	"unprognostic (2.44e-3)"	"unprognostic (8.20e-3)"	"unprognostic (2.57e-1)"	"unprognostic (2.23e-1)"	"prognostic unfavourable (8.37e-4)"	"unprognostic (7.61e-2)"	"unprognostic (3.02e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.28e-1)"	5.7	3.3	3.0	9.0	4.0	8.4	5.2	5.3	3.2	5.5	4.9	3.8	3.5	3.4	6.2	4.3	5.7	5.2	3.8	3.6	2.7	3.3	3.8	3.9	4.3	7.3	3.0	2.3	6.2	4.4	6.1	11.4	8.1	3.0	4.4	4.7	5.1	20.0	4.7	6.8	6.6	4.5	5.8	4.3	6.4	4.5	60.2	3.6	15.0	5.2	4.8	8.3	5.7	6.3	5.3	3.8	7.1	2.6	3.8	5.5	2.3	7.0	9.1	11.3	8.5	3.4	5.0	8.4	7.6	8.5	13.1	10.6	11.1	11.4	19.2	6.6	6.9	6.9	14.0	6.7	13.3	17.4	6.3	16.8	8.8	5.3	5.6	15.6	11.4	4.1	5.5	11.7	10.5	6.8	14.7	9.1	6.8	5.6	19.5	5.0	10.3	6.9	18.4	12.0	9.4	3.6	8.6	11.9	8.2	11.0	6.7	4.5	10.6	7.5	6.2	11.1	9.9	6.5	8.0	9.5	15.3	18.7	6.8	36.3	5.0	2.0	1.8	7.1	4.3	2.6	5.5	2.4	4.2	3.9	3.3	5.3	3.6	4.1	3.8	3.8	2.0	3.8	5.0	2.3	3.0	4.0	5.3	3.2	2.7	3.3	3.0	2.3	3.0	3.6
SHROOM4	KIAA1202	ENSG00000158352	"Shroom family member 4"	Q9ULL8	X	50591647-50814302	"Disease related genes, Predicted intracellular proteins"		"Actin-binding, Developmental protein"	"Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 27.3"	"Cell line enhanced"	"Detected in some"		"EFO-21: 6.0;HUVEC TERT2: 22.8;RH-30: 4.4;RPTEC TERT1: 4.9;TIME: 8.6;WM-115: 4.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	10	"basophil: 1.6"	"Lineage enriched"	"Detected in single"	17	"granulocytes: 1.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010089, HPA010565"	Uncertain		Approved	"Vesicles,Focal adhesion sites"				"Focal adhesion sites"	Vesicles	"HPA010089: , HPA010565: AB_1079961"	"unprognostic (2.55e-2)"	"unprognostic (1.43e-1)"	"unprognostic (5.56e-2)"	"prognostic unfavourable (8.37e-4)"	"unprognostic (1.34e-1)"	"unprognostic (1.60e-2)"	"unprognostic (4.30e-3)"	"unprognostic (4.55e-2)"	"unprognostic (2.13e-1)"	"unprognostic (2.93e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.14e-1)"	"prognostic unfavourable (4.66e-4)"	"unprognostic (7.30e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.74e-2)"	"unprognostic (2.75e-1)"	13.1	3.5	5.9	3.6	12.1	2.4	10.1	1.9	7.7	6.4	2.9	27.3	1.6	2.4	6.8	3.6	5.2	4.3	5.7	8.5	8.3	4.8	9.7	1.9	21.4	1.9	15.9	6.5	2.5	1.9	3.6	3.7	15.3	13.0	3.6	3.0	4.8	3.5	3.7	6.0	3.2	2.6	7.4	19.7	2.1	2.4	1.5	15.8	0.0	6.3	6.7	2.1	4.8	4.4	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	1.4	0.1	0.0	6.0	0.7	0.6	3.7	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.4	0.0	0.0	0.4	22.8	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	4.4	0.0	4.9	2.1	0.1	0.0	0.0	0.7	1.3	0.0	0.1	8.6	0.0	0.0	0.0	0.6	0.4	0.0	0.0	1.2	0.2	4.4	1.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	5.9	12.1	1.9	7.7	8.3	4.8	15.9	6.5	13.0	15.8
SIKE1	"FLJ21168, SIKE"	ENSG00000052723	"Suppressor of IKBKE 1"	Q9BRV8	1	114769479-114780685	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA024177, HPA025726"	Supported		Approved	"Vesicles,Focal adhesion sites"				"Focal adhesion sites"	Vesicles	"HPA024177: AB_1848798, HPA025726: AB_1848800"	"unprognostic (1.38e-1)"	"unprognostic (1.90e-1)"	"unprognostic (3.53e-2)"	"unprognostic (4.52e-3)"	"unprognostic (4.10e-1)"	"unprognostic (6.04e-2)"	"unprognostic (3.37e-3)"	"unprognostic (2.11e-1)"	"unprognostic (1.72e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.94e-2)"	"unprognostic (7.91e-2)"	"unprognostic (2.38e-2)"	"unprognostic (3.86e-2)"	"unprognostic (9.06e-2)"	"unprognostic (2.95e-3)"	"unprognostic (1.05e-1)"	18.3	15.4	14.5	17.4	15.9	15.3	16.4	23.5	16.3	18.3	17.3	14.5	14.2	16.7	17.2	13.4	18.1	14.3	13.4	20.3	14.2	15.1	24.4	22.2	12.3	19.7	21.1	11.2	17.2	17.5	15.4	22.5	17.1	23.2	15.2	17.3	9.3	17.2	13.9	21.1	21.9	17.5	16.4	19.2	20.6	14.5	11.8	17.9	26.0	19.3	17.1	21.2	17.2	14.2	8.1	9.8	12.3	7.6	9.2	10.3	5.3	8.4	2.4	11.2	10.7	13.6	10.8	12.0	7.0	6.6	10.3	13.9	7.4	4.5	15.8	6.9	5.9	8.2	12.3	8.4	14.0	10.6	7.2	8.7	7.5	7.6	12.8	9.8	7.1	10.5	9.7	7.4	12.0	9.2	13.3	10.2	7.8	37.6	17.3	8.8	25.4	7.3	10.4	23.1	8.0	7.5	7.7	8.5	9.6	11.1	10.9	12.7	6.6	33.1	6.5	8.6	11.4	14.3	9.7	8.6	7.4	15.5	12.3	15.0	18.4	12.3	6.0	7.4	8.6	6.4	10.3	7.9	8.0	7.4	7.8	8.1	9.3	9.9	4.0	9.2	7.6	9.8	6.2	5.3	14.5	15.9	23.5	16.3	14.2	15.1	21.1	11.2	23.2	17.9
SLC16A8	"MCT3, REMP"	ENSG00000100156	"Solute carrier family 16 member 8"	O95907	22	38078134-38084093	"Plasma proteins, Predicted membrane proteins, Transporters"	"Symport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"retina: 70.9"	"Cell line enhanced"	"Detected in some"		"BEWO: 5.9;SiHa: 6.4;T-47d: 7.7;U-266/70: 11.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA075017	Enhanced		Approved	"Intermediate filaments,Focal adhesion sites"				"Focal adhesion sites"	"Intermediate filaments"	"HPA075017: "	"unprognostic (1.22e-2)"	"unprognostic (2.25e-2)"	"unprognostic (5.07e-6)"	"unprognostic (2.99e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.84e-2)"	"unprognostic (2.99e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.76e-1)"	"unprognostic (1.63e-2)"	"unprognostic (1.32e-2)"	"unprognostic (2.34e-4)"	"unprognostic (7.69e-2)"	"unprognostic (1.15e-1)"	"unprognostic (4.06e-1)"	"unprognostic (9.71e-5)"	1.6	2.6	1.9	0.8	5.1	1.2	0.8	0.8	3.3	0.8	0.8	0.8	0.8	0.5	1.3	0.8	1.1	1.2	2.7	2.9	2.7	2.9	0.8	0.8	0.8	0.9	2.8	0.8	0.8	2.1	0.0	2.6	0.8	1.3	4.0	0.0	70.9	10.0	0.8	1.9	4.2	0.8	0.8	3.7	1.8	2.3	2.0	0.8	0.8	0.9	0.8	0.8	1.6	0.8	0.0	0.0	0.0	0.0	0.5	0.6	0.0	1.3	0.7	1.1	0.2	0.0	0.0	5.9	0.5	0.0	0.0	0.0	1.2	3.5	0.4	1.7	0.0	0.8	0.0	0.0	0.0	0.0	1.8	0.3	1.0	0.1	0.2	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.1	1.6	0.0	3.9	0.0	0.0	1.4	0.1	2.0	0.0	0.0	0.0	4.4	1.9	0.3	6.4	0.3	0.9	7.7	0.2	0.0	0.0	3.5	0.3	0.0	11.3	1.6	0.1	0.0	0.2	0.2	0.0	0.0	0.0	0.3	0.0	0.4	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	1.9	5.1	0.8	1.2	2.7	2.9	2.8	0.8	1.3	0.8
SLC4A7	"NBC3, SBC2, SLC4A6"	ENSG00000033867	"Solute carrier family 4 member 7"	Q9Y6M7	3	27372721-27484420	"Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Symport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 48.5"	"Cell line enhanced"	"Detected in all"		"hTERT-HME1: 37.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB022494, HPA035857"	Enhanced		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"				"Plasma membrane"	"Focal adhesion sites, Cytosol"	"CAB022494: , HPA035857: AB_10795135"	"unprognostic (2.94e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.80e-3)"	"unprognostic (1.91e-1)"	"unprognostic (8.48e-3)"	"unprognostic (2.68e-1)"	"unprognostic (6.79e-4)"	"unprognostic (4.13e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.83e-1)"	"unprognostic (8.58e-3)"	"prognostic unfavourable (7.91e-6)"	"unprognostic (1.09e-2)"	"unprognostic (6.68e-2)"	"unprognostic (1.93e-1)"	"unprognostic (7.26e-2)"	14.5	5.0	3.2	10.5	4.6	3.3	17.0	4.0	4.8	10.8	38.2	5.0	8.8	48.5	8.1	12.6	8.4	6.5	12.5	9.3	5.0	3.8	15.3	3.7	9.3	10.3	4.8	1.9	9.0	3.3	2.4	4.4	5.6	4.5	10.3	6.9	20.0	8.3	8.4	5.6	5.6	43.4	18.2	5.8	9.7	7.8	6.1	5.5	6.8	6.3	14.7	15.5	15.0	14.9	1.8	2.0	0.1	0.9	2.4	3.9	0.7	5.8	10.9	9.9	4.6	4.6	8.3	7.1	20.0	9.3	7.7	6.0	3.0	3.0	13.4	1.7	7.7	2.5	9.4	9.7	12.3	11.3	3.1	6.1	7.5	3.2	8.0	13.8	5.4	6.6	4.2	11.7	37.8	12.6	4.0	4.7	15.8	2.1	13.8	3.2	6.5	10.9	9.4	7.9	2.6	18.1	4.2	2.5	6.2	9.1	6.8	3.1	15.4	5.4	8.8	18.2	5.1	12.5	15.4	1.8	1.9	7.7	15.9	9.8	8.3	0.0	0.5	0.0	3.0	0.6	2.0	1.2	3.8	3.9	1.4	1.8	1.5	2.7	0.1	2.4	0.9	2.0	3.2	0.7	3.2	4.6	4.0	4.8	5.0	3.8	4.8	1.9	4.5	5.5
SMIM11A	"C21orf51, FAM165B, SMIM11"	ENSG00000205670	"Small integral membrane protein 11A"	P58511	21	34375480-34407866	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"											HPA051321	Uncertain		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA051321: "	"unprognostic (2.62e-2)"	"unprognostic (4.28e-2)"			"unprognostic (1.27e-1)"		"unprognostic (5.86e-3)"	"unprognostic (1.90e-1)"	"unprognostic (1.66e-1)"	"unprognostic (3.04e-1)"		"unprognostic (4.48e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.74e-1)"		"unprognostic (8.84e-2)"	"unprognostic (4.83e-3)"	2.1	6.7	7.8	1.4	7.4	1.0	5.0	4.4	9.5	2.9	4.1			2.2	4.3	6.0	1.4	6.3	4.8	8.8	6.9	6.1	5.1	4.5	5.0	3.3	6.7		5.0	3.8	5.2	4.1	2.4		3.7	6.2		4.8	2.9	16.4	2.6	4.6	3.7	6.5	3.7	17.0	1.7			12.1		5.0	4.3	2.2	4.6	6.5	6.3	4.8	3.4	11.8	3.6	7.5	8.8	0.0	5.9	6.2	5.2	0.0	0.0	4.6	5.7	6.0	6.1	7.5	14.5	4.2	0.3	5.6	0.0	0.1	8.4	26.9	16.9	3.1	0.0	3.6	4.7	3.9	7.2	0.1	8.9	0.0	4.8	10.2	13.5	12.3	3.7	5.6	2.2	3.8	12.4	17.4	4.8	7.1	20.5	2.6	2.4	5.3	10.4	0.1	8.5	12.2	15.5	5.0	0.0	14.1	1.7	4.0	10.1	10.5	12.8	5.1	4.3	6.8	6.9	0.3	3.0	6.3	1.8	4.8	2.7	4.6	3.4	5.0	6.5	2.5	4.6	2.5	0.7	3.4	1.2	1.2	11.8	3.6										
SMIM11B		ENSG00000273590	"Small integral membrane protein 11B"	Q8TCY0	21	7744962-7777853	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"blood: 19.7"	"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"											HPA051321	Uncertain		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA051321: "					"unprognostic (1.99e-1)"					"unprognostic (1.78e-1)"				"unprognostic (1.35e-1)"				2.2	1.9		1.4		1.4	2.5		0.6	1.8	1.0			2.3	2.8	4.9	1.5	0.3	1.1	5.8			4.0	4.0	0.3	2.2			3.4	0.9	0.0		0.2		1.8	0.0		1.1	2.1	5.4	0.8	0.7	0.9		0.8	1.7	0.0			1.1		0.4	1.2		19.7	11.2	10.3	11.6	9.5	17.6	10.5	13.9	0.5	8.4	17.1	12.9	15.9	10.2	7.9	11.2	5.5	6.4	0.5	3.9	12.1	4.7	11.0	2.0	15.9	12.4	2.4	4.5	9.3	19.8	10.4	8.2	13.5	21.5	8.7	15.7	8.9	6.2	10.4	3.6	23.0	20.1	7.3	5.8	10.3	16.2	12.4	0.1	9.4	5.2	17.4	17.8	3.3	15.4	0.8	15.9	7.4	12.8	6.6	6.7	9.2	0.4	6.6	3.5	2.4	10.3	8.9	18.8	11.5	28.4	9.0	5.0	11.6	10.3	14.1	8.7	16.1	16.0	14.7	14.8	11.2	19.7	17.6	15.7	3.1	9.5	9.1	10.8	13.9	10.5										
SNX32	"FLJ30934, SNX6B"	ENSG00000172803	"Sorting nexin 32"	Q86XE0	11	65833641-65856896	"Predicted intracellular proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 16.6"	"Cell line enhanced"	"Detected in some"		"HHSteC: 6.0;HSkMC: 7.8;REH: 2.5;SH-SY5Y: 3.0;U-266/70: 9.1"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"B-cells: 1.0;dendritic cells: 1.2;T-cells: 3.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041775	Uncertain		Uncertain	"Cell Junctions,Focal adhesion sites"				"Cell Junctions, Focal adhesion sites"		"HPA041775: AB_10797268"	"unprognostic (6.74e-4)"	"unprognostic (1.06e-1)"	"unprognostic (1.67e-2)"	"unprognostic (4.50e-5)"	"unprognostic (1.00e-1)"	"unprognostic (9.28e-2)"	"unprognostic (7.30e-2)"	"unprognostic (9.17e-3)"	"unprognostic (2.70e-1)"	"unprognostic (2.87e-1)"	"unprognostic (5.08e-2)"	"unprognostic (1.52e-1)"	"unprognostic (3.64e-4)"	"unprognostic (2.14e-1)"	"unprognostic (1.14e-1)"	"unprognostic (9.80e-2)"	"unprognostic (5.36e-2)"	0.8	1.0	9.0	1.1	16.6	1.3	1.3	3.5	16.1	1.6	2.2	1.6	0.0	3.4	2.0	1.3	0.9	2.5	2.8	0.9	10.2	5.0	0.9	0.7	0.8	1.0	3.6	10.9	1.3	0.8	0.8	0.3	0.9	3.4	0.8	1.9	0.1	0.7	0.9	0.6	1.1	1.5	2.0	1.8	0.9	0.9	3.5	3.7	0.0	0.7	0.0	1.3	1.0	0.2	1.0	1.2	0.2	0.3	0.1	3.0	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	6.0	0.0	0.6	7.8	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.5	0.3	0.1	0.0	2.5	0.0	2.2	0.1	0.0	0.0	3.0	0.0	0.0	1.7	0.0	0.4	0.0	0.3	0.0	0.0	0.0	9.1	1.5	0.0	0.7	0.0	0.3	0.0	0.1	0.0	1.2	0.3	3.0	0.3	1.6	1.2	1.2	1.0	1.4	0.6	0.2	0.1	0.0	0.7	1.2	0.4	9.0	16.6	3.5	15.4	10.2	5.0	3.6	10.9	3.4	3.7
SORBS1	"CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12"	ENSG00000095637	"Sorbin and SH3 domain containing 1"	Q9BX66	10	95311771-95561414	"Predicted intracellular proteins"	Transport			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"smooth muscle: 126.5"	"Cell line enhanced"	"Detected in many"		"CACO-2: 14.9;HMC-1: 26.0;SK-MEL-30: 22.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"basophil: 7.6;eosinophil: 2.2"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 7.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA027559, HPA043084"	Enhanced		Supported	"Focal adhesion sites,Centrosome"				"Focal adhesion sites"	Centrosome	"HPA027559: AB_10600812, HPA043084: AB_2678307"	"prognostic favourable (2.84e-4)"	"unprognostic (3.53e-1)"	"unprognostic (1.89e-1)"	"unprognostic (7.85e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.98e-2)"	"unprognostic (5.30e-2)"	"unprognostic (1.95e-2)"	"unprognostic (1.65e-2)"	"unprognostic (3.17e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.40e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.80e-1)"	"unprognostic (2.55e-2)"	"unprognostic (5.01e-3)"	95.0	6.4	23.0	16.4	21.6	1.8	23.5	16.8	22.5	14.9	70.2	18.7	22.1	8.1	41.8	12.5	45.0	25.1	28.9	83.7	20.9	8.3	5.9	14.7	8.7	1.4	13.4	14.1	9.8	7.3	17.5	3.5	9.9	19.2	42.0	20.0	6.4	7.2	65.7	46.4	6.3	15.5	126.5	20.6	2.9	40.0	5.5	19.3	0.0	4.0	12.7	1.2	63.9	31.4	0.1	0.0	7.6	1.2	0.6	1.0	0.2	0.7	0.6	6.3	1.6	2.3	0.1	0.9	0.2	0.0	0.2	0.0	14.9	5.6	0.0	1.2	0.1	0.3	1.1	0.2	0.1	1.7	2.3	3.6	0.2	8.9	0.8	0.0	26.0	0.4	0.2	0.3	0.1	2.6	5.9	1.2	0.6	0.4	0.0	0.3	2.9	1.4	0.5	2.1	0.2	7.0	9.8	2.7	2.0	0.9	0.3	22.3	1.2	0.2	0.2	0.0	2.2	0.1	1.2	0.8	0.2	0.1	2.7	0.2	6.3	7.6	0.2	2.2	0.7	1.2	1.0	0.1	0.3	0.4	0.0	0.1	0.3	0.1	0.2	0.6	0.2	0.0	0.5	0.2	23.0	21.6	16.8	20.7	20.9	8.3	13.4	14.1	19.2	19.3
SORBS3	"SCAM-1, SH3D4, vinexin"	ENSG00000120896	"Sorbin and SH3 domain containing 3"	O60504	8	22544986-22575788	"Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA015849	Approved		Approved	"Focal adhesion sites,Cytosol"			6600	Cytosol	"Focal adhesion sites"	"HPA015849: AB_1857365"	"unprognostic (6.15e-3)"	"unprognostic (2.09e-2)"	"unprognostic (2.34e-1)"	"unprognostic (3.90e-3)"	"unprognostic (1.72e-1)"	"unprognostic (9.30e-2)"	"unprognostic (2.51e-2)"	"unprognostic (2.44e-2)"	"unprognostic (5.83e-3)"	"unprognostic (1.70e-1)"	"prognostic favourable (4.88e-4)"	"unprognostic (4.21e-2)"	"unprognostic (3.08e-3)"	"unprognostic (7.41e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.65e-1)"	"prognostic unfavourable (1.53e-5)"	52.2	22.6	25.0	16.8	23.2	3.3	56.5	31.4	27.0	49.3	28.9	21.9	19.2	19.6	40.6	32.0	27.5	33.8	42.8	32.8	27.3	12.8	28.1	41.8	38.9	28.7	21.3	18.0	49.0	21.7	27.0	24.1	43.3	22.8	38.0	23.7	45.8	36.6	34.5	29.5	32.0	34.5	41.9	24.1	28.6	20.4	36.0	21.2	3.4	29.7	36.2	15.7	38.4	44.7	0.8	5.6	0.4	3.2	4.0	17.4	3.3	22.4	28.3	15.5	17.4	25.1	33.6	15.8	23.1	35.9	27.1	16.9	28.7	10.1	0.1	15.8	36.0	19.4	23.2	21.1	14.1	15.8	10.1	1.9	16.0	13.1	28.6	0.2	0.1	21.1	15.8	9.4	13.9	20.9	4.9	0.7	19.2	8.8	1.9	0.7	5.4	11.9	21.5	10.5	2.1	12.3	4.4	0.9	13.9	11.3	2.7	14.3	4.7	8.0	32.5	24.1	17.3	17.5	16.2	0.4	0.6	3.0	14.1	5.3	16.3	0.0	1.6	0.4	8.6	3.2	17.4	0.6	9.4	9.9	5.6	0.8	9.7	5.6	0.4	4.0	0.7	1.9	0.4	3.3	25.0	23.2	31.4	27.0	27.3	12.8	21.3	18.0	22.8	21.2
TADA1	"ADA1, hADA1, HFI1, STAF42, TADA1L"	ENSG00000152382	"Transcriptional adaptor 1"	Q96BN2	1	166856510-166876327	"Predicted intracellular proteins"	"Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028651	Approved		Supported	"Nucleoplasm,Focal adhesion sites,Cytosol"				Nucleoplasm	"Focal adhesion sites, Cytosol"	"HPA028651: AB_10602476"	"unprognostic (9.53e-3)"	"unprognostic (2.31e-1)"	"unprognostic (1.05e-2)"	"unprognostic (4.10e-2)"	"unprognostic (1.55e-1)"	"unprognostic (7.09e-2)"	"unprognostic (5.99e-3)"	"unprognostic (7.31e-2)"	"unprognostic (3.35e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.98e-2)"	"unprognostic (3.64e-2)"	"unprognostic (2.73e-2)"	"unprognostic (6.35e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.26e-2)"	6.5	10.6	13.8	7.1	18.5	17.8	10.2	18.2	20.0	11.3	9.1	17.0	3.4	8.3	10.5	8.6	10.1	9.8	6.6	9.2	13.2	14.6	12.9	28.9	6.7	10.1	11.1	14.3	12.7	7.5	11.3	13.7	12.5	15.0	9.2	10.2	13.4	8.7	8.4	10.7	8.5	9.0	8.5	10.8	7.3	8.0	12.0	10.3	16.7	11.5	7.1	10.9	8.6	7.8	13.4	13.0	8.1	8.2	16.2	19.5	15.1	8.1	7.8	14.8	8.7	4.5	5.7	8.8	4.3	5.2	7.2	6.2	7.1	6.6	15.5	8.4	5.0	6.3	11.9	7.6	5.8	9.8	11.3	5.1	6.7	11.6	6.6	14.4	9.5	4.3	8.8	4.3	10.8	5.9	18.3	9.4	5.6	5.6	17.7	11.5	22.4	8.8	15.0	6.5	19.6	9.6	10.9	9.5	16.6	7.7	10.0	9.0	13.6	15.2	4.3	5.9	6.8	6.4	9.0	13.5	18.3	29.0	4.1	6.6	5.5	1.8	8.1	8.1	14.0	8.2	15.5	13.1	15.2	15.8	13.0	13.4	19.5	15.3	1.3	16.2	6.2	8.5	14.3	15.1	13.8	18.5	18.2	20.0	13.2	14.6	11.1	14.3	15.0	10.3
TAS2R42	"hT2R55, T2R24, T2R55, TAS2R55"	ENSG00000186136	"Taste 2 receptor member 42"	Q7RTR8	12	11185993-11186937	"G-protein coupled receptors, Predicted membrane proteins"	"Sensory transduction, Taste"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in single"		"brain: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Low region specificity"	"Detected in single"			HPA036149	Uncertain		Approved	"Nucleoplasm,Actin filaments,Focal adhesion sites"				"Nucleoplasm, Actin filaments"	"Focal adhesion sites"	"HPA036149: AB_10672080"														"unprognostic (2.45e-2)"	"unprognostic (4.17e-2)"			0.0	0.7	0.2	0.2	0.4	0.0	0.0	1.0	0.2	0.0	0.1			0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.3	0.1	0.6	0.0		0.7	0.0	0.0	0.4	0.0		0.1	0.0		0.1	0.0	0.0	0.3	0.1	0.0	0.0	0.4	0.2	0.4			0.1		0.0	0.0	0.0	0.7	0.4	0.0	0.5	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.5	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.5	0.0	0.0	0.1	0.0	0.5	0.0	0.4	0.7	0.1	0.6	0.4	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0										
TATDN3		ENSG00000203705	"TatD DNase domain containing 3"	Q17R31	1	212791828-212816626	"Predicted intracellular proteins"		"Hydrolase, Nuclease"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA032092	Approved		Approved	"Nucleoplasm,Golgi apparatus,Focal adhesion sites"				Nucleoplasm	"Golgi apparatus, Focal adhesion sites"	"HPA032092: AB_10671086"	"unprognostic (9.81e-2)"	"unprognostic (1.57e-2)"	"unprognostic (1.20e-1)"	"unprognostic (3.17e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.74e-1)"	"unprognostic (9.38e-2)"	"unprognostic (4.16e-2)"	"unprognostic (3.80e-1)"	"unprognostic (3.88e-2)"	"unprognostic (3.34e-3)"	"unprognostic (5.02e-3)"	"prognostic favourable (1.59e-4)"	"unprognostic (1.93e-1)"	"unprognostic (2.44e-1)"	"unprognostic (3.13e-3)"	"unprognostic (2.96e-3)"	13.0	14.8	14.4	10.9	24.7	11.9	11.0	12.5	22.9	7.6	8.8	16.6	6.8	7.0	8.5	15.2	8.3	8.7	8.3	20.7	13.7	15.2	18.3	11.1	8.5	16.2	14.5	18.9	10.1	11.3	12.8	11.9	8.0	22.1	8.0	8.6	11.4	9.4	8.2	29.4	7.4	8.1	11.6	15.5	11.5	11.9	10.5	12.0	11.3	13.1	8.3	10.8	10.6	6.5	15.6	30.1	23.8	24.1	5.3	6.9	8.7	6.6	6.7	5.9	8.6	9.4	14.2	13.5	7.4	8.0	5.9	7.4	1.7	9.5	14.8	7.0	6.3	4.3	7.2	10.0	6.5	9.0	9.2	7.5	5.6	3.2	11.0	17.8	9.3	11.3	7.2	8.0	20.0	8.5	14.5	12.3	6.5	3.1	15.2	5.9	7.8	4.3	8.8	11.1	26.4	6.2	3.4	12.5	10.7	8.1	13.9	16.3	14.8	11.0	5.8	4.5	6.0	9.4	7.2	11.1	17.0	24.5	11.7	14.2	6.8	8.5	15.6	23.8	5.5	23.7	4.9	15.6	6.9	6.6	18.4	12.7	5.5	6.6	17.5	5.3	24.1	30.1	6.4	8.7	14.4	24.7	12.5	22.9	13.7	15.2	14.5	18.9	22.1	12.0
TES	"DKFZP586B2022, TESS-2, TESTIN"	ENSG00000135269	"Testin LIM domain protein"	Q9UGI8	7	116210493-116258783	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"EFO-21: 50.9;hTCEpi: 57.6;SK-BR-3: 57.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"							"Low region specificity"	"Detected in some"			"HPA015269, HPA018123"	Approved		Supported	"Plasma membrane,Cell Junctions,Focal adhesion sites,Cytosol"				"Focal adhesion sites, Cytosol"	"Plasma membrane, Cell Junctions"	"HPA015269: AB_1857899, HPA018123: AB_1857900"	"unprognostic (9.81e-2)"	"unprognostic (5.53e-3)"	"unprognostic (4.79e-2)"	"unprognostic (1.31e-1)"	"unprognostic (4.01e-1)"	"unprognostic (6.08e-3)"	"unprognostic (1.84e-3)"	"unprognostic (4.81e-3)"	"unprognostic (8.81e-3)"	"unprognostic (6.19e-3)"	"prognostic unfavourable (1.20e-5)"	"unprognostic (1.60e-2)"	"prognostic favourable (8.71e-5)"	"unprognostic (1.50e-1)"	"unprognostic (5.47e-2)"	"unprognostic (2.36e-2)"	"unprognostic (3.86e-1)"	12.1	2.9	1.2	36.4	1.5	8.6	22.1	0.8	1.2	42.4	53.1	1.5	43.9	9.3	47.6	21.2	22.6	19.5	15.3	7.9	1.6	1.4	14.3	4.6	16.8	20.3	1.9	0.7	17.1	12.3	3.1	4.2	21.2	3.3	26.1	16.8	5.0	19.0	50.9	5.2	9.1	27.4	84.5	3.0	19.1	25.2	18.4	0.7	17.1	26.3	11.2	18.4	71.6	33.9	26.8	21.9	56.8	39.6	49.0	40.5	34.7	24.2	5.1	5.8	0.0	2.6	6.6	13.7	12.7	6.2	2.3	2.3	12.8	27.0	0.0	50.9	8.8	24.9	3.1	18.6	5.8	12.0	10.0	2.4	12.0	6.3	15.6	11.0	0.0	14.8	57.6	8.2	20.9	6.6	2.4	8.6	0.6	5.0	0.0	0.1	3.8	14.7	0.0	0.0	9.5	24.0	9.3	2.7	25.2	18.5	57.8	14.0	0.0	4.5	11.2	0.1	0.3	18.7	0.1	20.3	9.8	0.2	1.6	5.6	19.2	56.8	20.2	53.4	40.5	32.6	39.0	26.8	31.0	36.6	21.9	23.8	31.0	35.0	10.5	49.0	39.6	5.4	31.5	34.7	1.2	1.5	0.8	1.2	1.6	1.4	1.9	0.7	3.3	0.7
TGFB1I1	"ARA55, Hic-5, TSC-5"	ENSG00000140682	"Transforming growth factor beta 1 induced transcript 1"	O43294	16	31471585-31477960	"Predicted intracellular proteins"	"Differentiation, Wnt signaling pathway"	Activator		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"basophil: 8.8"	"Group enriched"	"Detected in many"	4	"granulocytes: 8.8;T-cells: 2.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB020844	Enhanced		Supported	"Focal adhesion sites,Cytosol"			13000000	"Focal adhesion sites"	Cytosol	"CAB020844: "	"unprognostic (5.80e-2)"	"unprognostic (3.09e-2)"	"unprognostic (5.34e-2)"	"unprognostic (1.18e-1)"	"unprognostic (6.64e-2)"	"unprognostic (9.52e-2)"	"unprognostic (1.89e-1)"	"unprognostic (4.95e-2)"	"unprognostic (4.19e-2)"	"unprognostic (1.71e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.39e-1)"	"prognostic unfavourable (6.06e-8)"	"unprognostic (1.06e-2)"	"unprognostic (6.57e-2)"	"unprognostic (2.25e-2)"	"prognostic unfavourable (7.73e-5)"	16.8	4.1	1.0	14.4	1.4	0.3	18.5	1.2	1.6	42.9	51.1	1.8	22.1	5.8	80.7	22.7	34.1	28.9	36.2	11.8	0.9	0.7	8.6	2.8	11.2	10.6	1.1	1.3	40.3	2.2	5.1	1.8	11.5	2.3	37.7	10.4	11.1	7.1	34.7	5.7	5.9	12.8	71.9	1.8	11.5	19.6	10.9	0.9	0.7	5.8	7.8	3.6	69.9	23.5	1.3	0.5	8.8	0.0	0.0	2.5	2.3	4.3	5.4	9.0	0.0	8.9	16.3	0.1	23.5	22.0	14.7	10.0	2.3	1.5	0.0	22.1	20.1	6.5	1.8	4.3	19.4	0.0	0.0	5.2	10.1	1.2	22.6	0.0	6.7	10.5	6.4	9.1	5.4	9.7	0.5	0.0	17.9	0.0	0.0	0.6	0.4	5.6	0.0	10.7	0.0	4.1	2.2	0.0	6.4	9.1	0.0	4.5	0.0	0.5	26.1	26.5	6.5	7.4	10.2	0.0	0.0	0.0	11.7	0.2	16.3	8.8	0.0	0.1	0.3	0.0	0.5	1.3	1.4	0.2	0.1	0.5	0.2	1.0	0.2	0.0	0.0	0.5	2.5	2.3	1.0	1.4	1.2	1.6	0.9	0.7	1.1	1.3	2.3	0.9
TLE2	"ESG, ESG2, FLJ41188, GRG2"	ENSG00000065717	"Transducin like enhancer of split 2"	Q04725	19	2997638-3047635	"Predicted intracellular proteins"	"Transcription, Transcription regulation, Wnt signaling pathway"	Repressor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 85.3"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 24.7;RT4: 19.6;T-47d: 14.3"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in all"	5	"cerebellum: 85.3"	"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	10	"B-cells: 3.1;T-cells: 3.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049103	Enhanced		Supported	"Nuclear bodies,Focal adhesion sites"				"Nuclear bodies"	"Focal adhesion sites"	"HPA049103: "	"unprognostic (1.87e-3)"	"unprognostic (1.42e-1)"	"unprognostic (2.89e-1)"	"prognostic favourable (2.51e-4)"	"unprognostic (2.23e-1)"	"unprognostic (1.01e-1)"	"unprognostic (9.87e-3)"	"unprognostic (6.40e-3)"	"unprognostic (2.44e-1)"	"unprognostic (1.81e-2)"	"prognostic favourable (2.39e-6)"	"unprognostic (2.12e-1)"	"prognostic favourable (9.49e-6)"	"unprognostic (2.66e-1)"	"unprognostic (5.99e-2)"	"unprognostic (2.60e-1)"	"prognostic favourable (8.88e-4)"	13.4	9.6	9.2	4.6	5.7	1.3	38.3	85.3	16.5	10.9	11.4	4.9	28.6	8.1	15.7	6.6	5.5	13.3	8.5	19.9	5.5	7.6	11.9	3.5	12.5	5.4	8.3	5.3	12.4	16.5	13.8	6.4	7.3	9.7	12.9	4.6	20.6	55.5	27.1	38.5	6.4	5.3	26.2	13.3	10.9	7.4	6.3	4.8	1.1	17.5	5.7	3.2	19.2	27.6	3.1	0.0	0.3	0.0	0.0	3.4	0.7	0.3	1.6	0.1	24.7	3.9	0.6	5.4	0.2	0.0	1.2	0.6	7.6	2.7	0.1	3.5	1.7	4.3	4.1	1.5	0.3	0.7	1.2	0.0	1.8	0.3	5.0	0.0	0.2	5.5	0.7	2.8	0.0	9.9	8.9	0.1	0.1	8.3	0.2	0.1	0.1	1.6	1.9	1.2	2.2	3.2	19.6	1.2	6.4	1.6	12.3	0.6	14.3	0.0	6.5	8.1	8.5	0.4	0.2	0.3	0.2	1.6	0.2	1.8	1.5	0.0	0.0	0.3	3.2	0.0	2.3	3.1	2.0	1.0	0.0	0.5	3.4	2.1	0.0	0.0	0.0	0.0	0.7	0.7	9.2	5.7	85.3	16.5	5.5	7.6	8.3	5.3	9.7	4.8
TLN1	"ILWEQ, TLN"	ENSG00000137076	"Talin 1"	Q9Y490	9	35696948-35732395	"Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002006, HPA004748"	Supported		Supported	"Plasma membrane,Focal adhesion sites,Centriolar satellite,Cytosol"			3600000000	"Focal adhesion sites, Cytosol"	"Plasma membrane, Centriolar satellite"	"CAB002006: , HPA004748: AB_1857760"	"unprognostic (9.71e-2)"	"unprognostic (2.02e-2)"	"prognostic unfavourable (5.56e-4)"	"unprognostic (1.96e-1)"	"unprognostic (5.55e-2)"	"unprognostic (2.52e-1)"	"unprognostic (3.18e-2)"	"unprognostic (5.07e-2)"	"unprognostic (1.94e-1)"	"unprognostic (6.46e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.27e-1)"	"prognostic favourable (7.21e-4)"	"unprognostic (1.36e-1)"	"unprognostic (2.71e-2)"	"unprognostic (7.83e-2)"	"unprognostic (8.83e-3)"	47.4	23.7	10.9	29.3	16.6	25.1	38.1	9.6	11.8	34.7	64.0	18.8	22.8	13.0	57.4	20.6	41.2	38.3	48.4	30.3	11.1	7.1	30.5	36.1	33.0	26.0	17.9	7.3	39.0	12.8	19.6	14.6	30.4	14.4	39.5	15.5	22.8	14.9	43.6	24.5	16.5	27.6	87.0	12.4	54.1	38.2	17.3	14.1	33.4	20.7	12.5	20.7	72.5	49.6	3.3	6.8	12.7	9.2	4.8	7.1	7.1	11.3	19.0	11.8	16.2	40.6	30.9	13.5	31.7	34.9	30.8	27.9	15.7	5.1	13.8	10.5	58.5	6.2	13.8	19.7	22.6	31.1	8.9	31.3	24.7	13.9	25.2	18.9	52.4	37.3	9.4	45.3	21.5	47.2	10.7	14.2	40.6	5.0	12.7	4.9	9.6	14.7	17.1	6.9	8.0	15.4	9.1	2.6	11.3	15.4	8.6	10.1	7.3	13.1	56.9	49.2	19.1	15.0	25.5	4.9	4.8	9.6	38.1	10.2	44.3	6.7	7.0	8.4	7.1	7.8	5.9	3.3	4.2	5.4	5.3	3.2	2.0	4.2	12.7	4.8	9.2	6.8	2.8	7.1	10.9	16.6	9.6	11.8	11.1	7.1	17.9	7.3	14.4	14.1
TLN2	"ILWEQ, KIAA0320"	ENSG00000171914	"Talin 2"	Q9Y4G6	15	62390526-62844631	"Plasma proteins, Predicted intracellular proteins"			"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 36.9"	"Cell line enhanced"	"Detected in many"		"ASC diff: 29.4;hTERT-HME1: 23.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017194, HPA051828, HPA054787"	Enhanced		Supported	"Focal adhesion sites,Cytosol"			81000000	"Focal adhesion sites, Cytosol"		"CAB017194: , HPA051828: , HPA054787: "	"prognostic favourable (6.53e-4)"	"unprognostic (2.61e-1)"	"unprognostic (9.47e-2)"	"unprognostic (8.95e-2)"	"unprognostic (3.74e-1)"	"unprognostic (1.43e-1)"	"unprognostic (8.24e-2)"	"unprognostic (9.94e-2)"	"unprognostic (1.68e-1)"	"unprognostic (6.02e-2)"	"unprognostic (2.81e-2)"	"unprognostic (1.91e-1)"	"prognostic favourable (1.81e-6)"	"prognostic favourable (7.74e-4)"	"unprognostic (1.34e-1)"	"unprognostic (5.79e-2)"	"unprognostic (2.30e-1)"	12.5	3.1	7.0	12.1	7.0	2.3	5.3	5.4	18.9	5.6	24.3	4.0	1.7	3.3	6.5	4.2	3.4	3.2	6.3	8.5	6.8	6.0	36.9	1.8	1.9	1.3	6.2	4.2	7.0	3.3	2.3	3.0	2.4	4.5	3.1	5.4	5.5	5.4	1.6	16.9	1.6	16.6	6.9	9.6	0.8	4.1	3.5	1.3	0.9	29.0	4.5	1.3	4.3	7.0	0.0	0.7	0.0	0.1	0.0	0.1	0.0	0.8	2.6	3.9	4.5	29.4	2.8	4.3	6.5	5.1	6.0	6.0	7.1	0.9	2.2	3.0	11.3	1.1	4.9	1.0	5.3	7.0	0.5	0.2	10.7	4.7	1.0	0.7	0.2	5.1	2.7	8.0	23.9	0.2	0.2	0.1	10.0	3.4	0.3	0.3	6.8	1.9	2.7	9.8	2.7	3.1	5.4	0.9	4.5	5.0	0.5	1.7	1.4	1.7	1.8	10.9	14.8	17.5	16.5	0.1	0.4	1.4	4.9	1.6	13.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	0.0	7.0	7.0	5.4	12.9	6.8	6.0	6.2	4.2	4.5	1.3
TM4SF20	"FLJ22800, TCCE518"	ENSG00000168955	"Transmembrane 4 L six family member 20"	Q53R12	2	227362156-227381995	"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"			"Autism spectrum disorder"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	86	"intestine: 147.8"	"Cell line enhanced"	"Detected in some"		"A549: 7.1;RPMI-8226: 4.4"	"Group enriched"	"Detected in many"	6	"colorectal cancer: 5.0;liver cancer: 4.7;pancreatic cancer: 5.5;stomach cancer: 11.8"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA051838, HPA063184, HPA065531"	Uncertain		Supported	"Plasma membrane,Focal adhesion sites"				"Plasma membrane, Focal adhesion sites"		"HPA051838: , HPA063184: , HPA065531: "	"unprognostic (4.68e-2)"	"unprognostic (1.13e-1)"	"unprognostic (8.75e-2)"		"unprognostic (4.96e-2)"	"unprognostic (2.84e-2)"	"unprognostic (1.63e-1)"	"unprognostic (2.51e-1)"	"unprognostic (2.36e-1)"	"unprognostic (2.95e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.19e-1)"	"unprognostic (3.44e-3)"	"unprognostic (7.76e-2)"	"unprognostic (2.60e-2)"	"unprognostic (3.04e-3)"		0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.1	0.1	46.5	0.0	0.0	73.5	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.9	0.0	0.1	0.0	0.1	0.1	147.8	0.2	0.1	0.1	0.1	1.2	0.0	0.0	0.1	0.0	0.0	0.1	0.1	1.1	1.2	1.1	0.5	1.7	0.7	0.0	0.1	7.1	0.2	0.1	0.0	0.0	1.3	0.8	0.1	0.0	0.0	1.3	0.5	0.2	0.1	0.4	0.2	0.0	0.0	0.1	0.1	0.4	0.0	1.3	0.2	0.0	0.5	0.3	0.0	0.1	0.0	0.0	0.0	0.4	0.8	0.3	0.0	0.1	1.6	0.3	0.1	0.4	0.1	4.4	0.1	0.3	0.6	1.7	1.0	0.1	0.0	0.3	0.1	0.3	0.6	0.3	1.9	0.2	0.5	0.3	0.4	0.2	0.2	0.2	0.8	0.5	0.1	0.7	0.3	0.3	0.7	0.4	0.4	0.0	1.1	0.7	0.5	1.1	1.7	0.1	1.2	0.4	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.0	0.0
TMEM139	FLJ90586	ENSG00000178826	"Transmembrane protein 139"	Q8IV31	7	143279957-143288048	"Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 25.1;kidney: 22.6;placenta: 28.0"	"Cell line enhanced"	"Detected in some"		"A-431: 9.5;CAPAN-2: 17.9;EFO-21: 12.6;RPTEC TERT1: 31.5;SK-BR-3: 11.1;T-47d: 30.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 3.2"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA036982, HPA036983"	Approved		Approved	"Plasma membrane,Focal adhesion sites"				"Plasma membrane"	"Focal adhesion sites"	"HPA036982: AB_2675413, HPA036983: AB_10672275"	"unprognostic (2.58e-1)"	"unprognostic (4.38e-1)"	"unprognostic (6.62e-3)"	"unprognostic (1.41e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.16e-3)"	"unprognostic (2.83e-2)"	"unprognostic (4.90e-2)"	"unprognostic (1.60e-1)"	"unprognostic (2.82e-2)"	"prognostic unfavourable (1.66e-4)"	"unprognostic (2.89e-1)"	"prognostic favourable (3.05e-5)"	"unprognostic (1.73e-1)"	"unprognostic (1.42e-2)"	"unprognostic (2.83e-2)"	"unprognostic (9.08e-3)"	1.5	2.2	0.9	2.8	1.9	0.0	2.1	0.6	1.6	6.3	14.7	6.0	1.5	22.7	1.6	3.5	0.4	4.6	4.8	2.3	1.6	1.1	22.6	7.8	5.5	0.1	4.2	0.7	0.9	9.6	6.4	2.0	28.0	4.8	1.6	2.9	1.4	6.1	2.2	0.1	1.1	25.1	0.4	13.4	0.8	2.0	3.0	2.1	0.1	8.8	0.4	0.7	2.1	2.4	0.5	0.3	0.9	3.2	0.0	2.0	0.4	9.5	0.7	0.1	0.0	0.0	0.0	6.4	0.1	0.0	0.0	0.0	2.2	17.9	0.1	12.6	0.0	8.1	0.0	4.1	0.0	0.1	0.0	0.0	1.1	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.6	0.4	0.0	0.7	0.1	0.1	0.0	31.5	2.4	0.1	0.0	0.4	11.1	0.0	30.3	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.9	0.0	3.2	0.0	0.5	1.3	0.8	0.0	0.0	1.1	0.6	0.0	0.0	2.4	0.3	2.0	0.4	0.9	1.9	0.6	1.6	1.6	1.1	4.2	0.7	4.8	2.1
TMEM260	"C14orf101, FLJ20392"	ENSG00000070269	"Transmembrane protein 260"	Q9NX78	14	56488354-56650606	"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"cervix, uterine: 61.0"	"Low cell line specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003502	Uncertain		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"				"Nucleoplasm, Cytosol"	"Focal adhesion sites"	"HPA003502: AB_1078314"	"unprognostic (4.63e-2)"	"unprognostic (2.41e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.73e-2)"	"unprognostic (2.51e-1)"	"unprognostic (3.58e-2)"	"unprognostic (2.04e-1)"	"prognostic favourable (7.11e-4)"	"unprognostic (7.14e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.95e-3)"	"unprognostic (3.22e-1)"	"unprognostic (2.23e-3)"	"unprognostic (5.81e-2)"	"unprognostic (8.11e-2)"	"unprognostic (1.32e-1)"	"unprognostic (3.84e-2)"	7.8	7.4	7.3	11.0	10.6	3.8	9.1	13.3	9.9	61.0	8.8	13.7	11.6	8.1	11.8	12.1	6.7	11.4	10.3	6.0	8.9	8.6	10.7	8.7	8.4	8.8	10.8	7.5	14.8	13.6	12.4	17.2	8.7	9.7	8.7	9.1	8.7	7.4	13.0	5.2	8.6	10.7	8.9	12.2	9.2	8.4	10.1	8.3	17.6	12.6	4.6	8.8	10.1	9.7	2.0	4.6	2.9	2.8	6.3	3.5	2.0	7.3	5.2	4.0	8.5	14.3	11.8	7.9	7.9	8.8	5.2	6.2	2.4	5.5	6.0	7.8	5.9	8.6	9.3	5.7	8.2	7.4	4.7	3.9	2.4	3.2	10.1	5.4	9.3	14.5	10.4	2.9	10.1	6.8	4.7	6.5	6.8	4.9	2.8	2.0	3.7	8.3	4.0	6.4	2.0	8.8	11.0	8.5	4.2	8.9	6.4	5.2	8.2	8.4	9.5	10.6	4.0	7.9	3.9	3.9	3.1	3.5	6.6	4.0	5.2	0.0	2.8	2.9	3.5	1.9	2.4	1.8	2.4	1.8	2.2	2.0	3.2	2.3	1.4	6.3	1.7	4.6	2.9	2.0	7.3	10.6	13.3	9.9	8.9	8.6	10.8	7.5	9.7	8.3
TMEM35A	"FLJ14084, TMEM35"	ENSG00000126950	"Transmembrane protein 35A"	Q53FP2	X	101078720-101096364	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 33.8;seminal vesicle: 46.4"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 6.3;HUVEC TERT2: 31.7;SH-SY5Y: 8.1"	"Cancer enhanced"	"Detected in many"		"glioma: 6.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048583	Enhanced		Supported	"Vesicles,Focal adhesion sites,Cytosol"				Vesicles	"Focal adhesion sites, Cytosol"	"HPA048583: "	"unprognostic (7.98e-2)"	"unprognostic (7.22e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.35e-2)"	"unprognostic (3.02e-2)"	"unprognostic (3.89e-3)"	"unprognostic (2.77e-2)"	"unprognostic (6.66e-3)"	"unprognostic (1.05e-1)"	"unprognostic (3.34e-3)"	"unprognostic (9.20e-2)"	"unprognostic (4.72e-2)"	"unprognostic (3.49e-4)"	"unprognostic (5.91e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.48e-2)"	"unprognostic (9.37e-3)"	3.6	6.7	12.8	1.7	28.2	0.7	1.3	21.2	28.6	3.3	17.3	2.5	6.8	3.5	7.4	3.9	10.4	4.3	3.6	1.1	14.4	33.8	1.1	0.7	2.6	0.8	12.2	10.0	7.7	0.9	6.1	1.5	0.8	30.0	20.5	9.1	2.9	1.0	46.4	1.3	0.9	4.1	11.8	3.9	1.3	3.4	1.8	2.3	0.0	1.3	0.0	0.9	13.3	2.7	0.2	0.0	0.2	0.1	0.6	0.8	0.4	0.0	0.0	3.3	0.0	2.4	6.3	0.0	0.6	0.4	0.3	0.1	0.0	0.0	0.0	0.0	1.9	0.0	2.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	2.1	0.0	1.1	0.0	31.7	0.0	0.0	4.0	0.0	0.0	0.0	4.2	0.0	0.0	0.1	0.0	0.0	0.0	1.4	8.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.5	0.2	0.5	0.2	0.0	0.0	0.6	0.4	0.2	0.6	0.1	0.0	0.8	0.4	12.8	28.2	21.2	28.6	14.4	33.8	12.2	10.0	30.0	2.3
TMEM52B	"C12orf59, FLJ31166"	ENSG00000165685	"Transmembrane protein 52B"	Q4KMG9	12	10170542-10191801	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	23	"kidney: 85.1"	"Cell line enriched"	"Detected in some"	8	"CACO-2: 45.3"	"Cancer enriched"	"Detected in some"	5	"renal cancer: 6.9"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"myeloid DC: 3.7"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA058096	Enhanced		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA058096: AB_2683603"	"unprognostic (1.10e-2)"	"unprognostic (7.61e-2)"	"unprognostic (1.37e-3)"	"unprognostic (1.22e-1)"	"unprognostic (1.67e-1)"	"unprognostic (5.33e-3)"	"unprognostic (1.37e-1)"	"unprognostic (8.65e-2)"	"unprognostic (7.14e-4)"	"unprognostic (2.23e-1)"	"unprognostic (6.36e-2)"	"unprognostic (7.33e-2)"	"unprognostic (3.24e-2)"	"unprognostic (5.80e-2)"	"unprognostic (5.51e-2)"	"unprognostic (1.66e-1)"	"unprognostic (3.18e-1)"	0.1	0.0	0.1	0.1	0.6	0.9	0.1	0.1	0.6	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.1	85.1	0.1	0.2	0.1	0.3	0.1	0.1	0.1	0.0	0.1	2.0	0.1	0.1	0.0	0.1	0.5	0.1	0.1	0.0	0.1	0.1	0.5	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.9	3.7	1.4	1.3	0.6	0.5	0.4	1.1	0.0	0.0	0.0	0.0	0.0	0.5	1.0	0.0	0.0	0.0	45.3	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	5.8	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	3.3	4.3	0.0	2.4	0.6	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	2.2	0.0	1.4	1.3	1.0	0.4	0.2	0.4	0.4	0.4	0.5	3.7	0.9	0.5	0.5	1.0	0.6	0.2	0.6	0.4	0.4	0.1	0.6	0.1	0.2	0.2	0.1	0.3	0.1	0.1	0.1
TMEM53	"FLJ22353, NET4"	ENSG00000126106	"Transmembrane protein 53"	Q6P2H8	1	44635238-44674555	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 38.7;liver: 44.7"	"Cell line enhanced"	"Detected in all"		"CAPAN-2: 24.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	4	"plasmacytoid DC: 38.7"	"Lineage enriched"	"Detected in all"	4	"dendritic cells: 38.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA021134	Approved		Approved	"Golgi apparatus,Focal adhesion sites"				"Golgi apparatus"	"Focal adhesion sites"	"HPA021134: AB_2205162"	"unprognostic (5.28e-2)"	"unprognostic (2.60e-1)"	"unprognostic (5.37e-2)"	"unprognostic (4.62e-2)"	"unprognostic (3.93e-2)"	"unprognostic (1.14e-1)"	"unprognostic (2.82e-2)"	"unprognostic (2.88e-2)"	"unprognostic (2.19e-2)"	"prognostic favourable (6.96e-4)"	"unprognostic (3.00e-1)"	"unprognostic (1.34e-1)"	"prognostic favourable (1.02e-5)"	"unprognostic (1.15e-3)"	"unprognostic (1.84e-2)"	"unprognostic (4.07e-2)"	"unprognostic (2.29e-2)"	8.3	9.0	6.0	4.4	8.7	6.0	7.0	2.4	11.8	4.9	11.0	8.8	4.6	16.6	5.7	7.2	4.5	5.3	7.6	9.3	6.2	6.1	14.8	44.7	7.3	6.4	6.8	6.2	7.7	5.4	3.3	6.4	4.3	8.0	5.2	7.2	13.9	6.0	3.8	4.2	3.9	16.4	4.5	6.1	4.8	7.7	18.8	4.4	3.6	8.2	3.1	4.0	7.3	3.7	5.3	38.7	3.6	8.6	2.8	3.1	2.8	7.6	8.8	8.0	5.8	10.4	7.9	9.6	2.2	6.7	4.4	6.6	2.8	24.1	2.4	7.3	2.1	6.9	2.2	4.7	2.3	3.8	5.6	2.8	3.6	13.4	10.4	2.2	10.2	9.3	7.3	8.8	1.9	2.4	1.2	3.1	2.6	4.5	2.5	6.5	4.6	5.2	4.0	1.1	23.5	13.1	8.0	5.6	5.4	2.4	9.6	12.4	2.9	5.8	1.0	3.2	5.5	4.6	2.8	2.2	2.6	1.3	8.4	5.7	3.7	3.6	5.2	2.3	3.0	8.6	2.6	5.3	3.1	2.5	2.6	5.0	1.5	2.0	0.5	2.8	6.0	38.7	3.0	2.8	6.0	8.7	2.4	11.8	6.2	6.1	6.8	6.2	8.0	4.4
TNFRSF25	"APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR"	ENSG00000215788	"TNF receptor superfamily member 25"	Q93038	1	6461151-6466195	"Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 19.2;lymphoid tissue: 26.0;skin 1: 24.1"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 19.7;NB-4: 7.8;RPMI-8226: 19.3"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	11	"cerebellum: 19.2"	"Cell type enhanced"	"Detected in many"		"T-reg: 9.5"	"Lineage enriched"	"Detected in single"	10	"T-cells: 9.5"	"Group enriched"	"Detected in some"	6	"amygdala: 1.2;cerebral cortex: 1.3;hippocampal formation: 2.3"	"Not detected"	"Not detected"			HPA069834			Approved	"Nucleoplasm,Plasma membrane,Actin filaments,Focal adhesion sites"	"Secreted - unknown location"			"Plasma membrane, Actin filaments, Focal adhesion sites"	Nucleoplasm	"HPA069834: "	"unprognostic (8.09e-3)"	"unprognostic (6.91e-3)"	"prognostic unfavourable (4.46e-4)"	"unprognostic (1.97e-1)"	"unprognostic (9.63e-3)"	"prognostic favourable (3.09e-4)"	"unprognostic (2.16e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.04e-1)"	"unprognostic (2.07e-1)"	"unprognostic (6.01e-2)"	"unprognostic (3.98e-2)"	"prognostic unfavourable (1.65e-7)"	"unprognostic (1.21e-1)"	"unprognostic (1.61e-1)"	"unprognostic (3.44e-1)"	"unprognostic (8.68e-3)"	2.2	1.6	1.2	20.3	1.6	0.4	1.4	19.2	1.8	1.4	13.4	0.7	0.6	2.8	1.2	0.6	4.1	2.4	2.1	2.3	1.8	0.9	1.4	2.3	6.3	13.9	1.1	0.6	1.1	0.6	1.4	14.0	4.1	1.3	1.9	1.3	1.1	10.5	2.3	0.8	24.1	11.2	0.6	0.6	18.9	0.8	1.0	0.8	11.7	1.1	3.2	26.0	3.2	1.5	0.0	0.4	0.0	0.9	0.6	9.5	1.3	1.4	0.3	0.8	1.5	0.0	0.4	0.8	0.6	0.4	0.2	0.0	1.2	2.1	0.0	2.9	0.0	3.1	0.4	3.6	0.0	19.7	1.4	0.8	1.1	0.0	0.6	0.0	0.0	0.0	2.4	1.2	3.1	3.1	0.0	0.0	0.0	1.6	0.0	7.8	1.0	5.3	0.6	0.2	19.3	0.8	0.5	3.8	5.2	0.0	1.9	0.1	1.6	2.1	1.6	1.0	1.5	0.0	1.5	0.0	3.5	0.0	1.8	0.0	0.0	0.0	0.0	0.0	1.7	0.3	8.0	0.0	6.9	3.2	0.4	0.0	6.4	1.1	0.0	0.6	0.9	0.0	9.5	1.3	1.2	1.6	19.2	1.8	1.8	0.9	1.1	0.6	1.3	0.8
TNNT2	"CMD1D, CMH2, CMPD2"	ENSG00000118194	"Troponin T2, cardiac type"	P45379	1	201359008-201377762	"Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins"		"Muscle protein"	"Cardiomyopathy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	241	"heart muscle: 679.2"	"Cell line enriched"	"Detected in some"	26	"RH-30: 185.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"cerebral cortex: 5.7"	"CAB015371, HPA015774, HPA017888"	Enhanced		Uncertain	"Nucleoplasm,Nucleoli,Focal adhesion sites"			50000	"Nucleoplasm, Nucleoli"	"Focal adhesion sites"	"CAB015371: AB_630390, HPA015774: AB_1858354, HPA017888: AB_1858355"	"unprognostic (1.45e-1)"	"unprognostic (2.74e-1)"	"unprognostic (2.33e-4)"	"unprognostic (1.85e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.91e-2)"	"unprognostic (1.38e-1)"	"unprognostic (8.63e-2)"	"unprognostic (5.50e-3)"	"unprognostic (2.94e-1)"	"unprognostic (1.61e-1)"	"unprognostic (4.76e-2)"	"unprognostic (9.98e-2)"	0.1	0.3	0.1	0.1	0.7	0.0	0.8	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.0	1.2	679.2	0.9	0.0	1.9	0.0	0.7	0.3	0.1	1.1	0.1	0.3	0.0	0.2	0.7	0.1	0.7	0.0	0.0	0.2	0.1	2.0	1.3	0.0	2.8	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	2.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.1	0.0	0.0	0.4	0.0	0.0	185.3	0.0	0.0	0.0	0.2	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	2.1	0.9	0.0	0.1	1.1	0.1	0.0
TNS1	"DKFZp586K0617, MXRA6, PPP1R155, TNS"	ENSG00000079308	"Tensin 1"	Q9HBL0	2	217799588-218010421	"Plasma proteins, Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"smooth muscle: 153.0"	"Cell line enhanced"	"Detected in many"		"ASC diff: 46.3;ASC TERT1: 25.2;fHDF/TERT166: 21.9;REH: 24.1;TIME: 21.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 1.7"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB018774, HPA036089, HPA036090"	Approved		Enhanced	"Focal adhesion sites"				"Focal adhesion sites"		"CAB018774: AB_2207032, HPA036089: AB_10796111, HPA036090: AB_10794322"	"unprognostic (4.63e-2)"	"unprognostic (1.47e-1)"	"prognostic unfavourable (2.41e-4)"	"unprognostic (4.13e-2)"	"unprognostic (5.46e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.20e-3)"	"unprognostic (7.34e-2)"	"unprognostic (2.55e-2)"	"unprognostic (1.28e-3)"	"unprognostic (5.57e-2)"	"unprognostic (9.74e-2)"	"unprognostic (4.71e-3)"	"unprognostic (5.60e-3)"	"unprognostic (2.88e-2)"	"unprognostic (7.49e-2)"	"prognostic unfavourable (5.19e-4)"	77.6	15.6	5.2	21.1	13.7	9.2	33.5	2.9	8.9	50.0	68.9	17.2	45.6	6.0	61.1	29.8	52.0	31.1	46.7	41.0	6.8	4.8	24.0	9.2	28.9	6.1	15.8	4.1	32.3	14.1	6.0	3.8	14.0	14.3	55.1	11.4	27.6	12.8	63.4	40.8	10.1	17.2	153.0	13.7	17.0	30.0	22.6	12.2	1.5	18.3	9.8	4.0	124.6	53.6	0.2	1.0	0.9	1.7	0.0	0.0	2.9	0.0	0.1	3.0	0.0	46.3	25.2	0.3	7.8	2.6	0.4	0.3	3.4	0.0	0.0	4.5	21.9	0.5	0.3	0.4	0.2	3.1	0.2	6.6	1.9	0.9	3.4	0.0	0.8	12.0	0.0	8.3	0.0	10.9	0.2	0.7	6.5	0.9	0.0	0.4	0.3	0.1	24.1	5.8	0.3	1.6	0.0	0.7	3.5	1.3	3.3	0.8	1.1	2.4	21.4	5.7	10.3	5.7	1.7	0.4	0.0	0.0	3.3	0.9	0.4	0.0	0.4	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.9	0.0	0.7	1.0	0.0	2.9	5.2	13.7	2.9	8.9	6.8	4.8	15.8	4.1	14.3	12.2
TNS3	"FLJ13732, H_NH0549I23.2, TEM6, TENS1"	ENSG00000136205	"Tensin 3"	Q68CZ2	7	47275154-47582558	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A549: 66.6;LHCN-M2: 42.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 5.8;intermediate monocyte: 4.7;memory B-cell: 3.7;myeloid DC: 4.0;naive B-cell: 2.9;non-classical monocyte: 4.4;plasmacytoid DC: 5.6"	"Group enriched"	"Detected in many"	6	"B-cells: 3.7;dendritic cells: 5.6;monocytes: 5.8"	"Low region specificity"	"Detected in all"							"HPA055338, HPA056015"	Approved		Enhanced	"Focal adhesion sites"				"Focal adhesion sites"		"HPA055338: , HPA056015: "	"unprognostic (1.46e-1)"	"unprognostic (2.97e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.02e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.17e-1)"	"unprognostic (2.05e-1)"	"unprognostic (8.00e-2)"	"unprognostic (3.77e-2)"	"unprognostic (3.70e-1)"	"unprognostic (6.60e-2)"	"prognostic favourable (5.21e-4)"	"unprognostic (3.13e-2)"	"unprognostic (4.41e-2)"	"unprognostic (3.20e-2)"	"unprognostic (9.09e-3)"	46.9	18.5	16.4	19.3	12.7	2.8	29.8	8.1	11.7	18.2	15.7	11.4	9.1	9.9	27.4	13.9	7.7	12.3	29.6	13.5	12.1	13.2	27.3	24.9	25.1	37.7	16.0	3.6	22.4	35.5	16.4	5.5	44.9	9.6	15.0	9.3	40.3	36.4	11.7	14.9	6.7	20.7	14.7	11.6	42.7	13.9	9.6	7.8	3.8	23.8	9.6	19.9	12.5	19.3	3.7	5.6	0.8	5.8	0.1	0.2	1.8	6.4	66.6	4.0	7.0	9.3	7.6	12.9	5.9	33.8	5.8	8.9	14.9	8.7	3.3	10.5	21.4	12.4	6.5	9.6	5.3	0.0	0.4	9.1	9.6	7.9	9.6	0.0	0.1	7.5	4.2	3.3	5.3	4.5	0.0	20.5	42.9	4.0	0.0	0.2	3.9	7.9	2.9	9.9	10.8	20.0	13.2	0.4	8.2	11.7	2.4	6.5	8.9	6.8	18.1	9.0	7.2	0.1	9.0	13.2	17.1	7.7	2.2	6.4	32.6	0.2	5.8	0.0	0.1	4.7	0.2	3.7	0.0	0.0	4.0	2.9	0.0	0.0	0.8	0.1	4.4	5.6	0.0	1.8	16.4	12.7	8.1	11.7	12.1	13.2	16.0	3.6	9.6	7.8
TRIM62	"DEAR1, FLJ10759"	ENSG00000116525	"Tripartite motif containing 62"	Q9BVG3	1	33145402-33182059	"Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 20.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA050061			Approved	"Vesicles,Focal adhesion sites"				"Vesicles, Focal adhesion sites"		"HPA050061: "	"unprognostic (1.57e-1)"	"unprognostic (4.39e-2)"	"unprognostic (2.39e-2)"	"unprognostic (2.62e-2)"	"unprognostic (1.14e-2)"	"unprognostic (5.80e-2)"	"unprognostic (5.10e-5)"	"unprognostic (2.05e-2)"	"unprognostic (1.14e-1)"	"unprognostic (4.32e-2)"	"unprognostic (3.55e-3)"	"unprognostic (3.66e-1)"	"prognostic unfavourable (7.08e-5)"	"unprognostic (2.14e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.05e-3)"	4.8	11.8	10.1	6.4	19.2	9.3	6.2	19.0	13.9	5.6	4.9	31.8	1.6	5.6	4.9	6.9	6.9	5.1	4.9	5.3	12.3	10.5	5.3	2.7	5.6	9.6	28.1	9.1	6.7	4.8	7.5	9.2	19.6	15.4	8.7	5.4	5.0	10.8	7.5	6.7	20.5	5.8	6.9	12.8	8.3	6.5	4.0	23.7	8.7	6.3	5.1	10.4	9.8	7.3	3.0	1.8	6.0	3.5	1.7	8.5	2.1	2.9	2.3	20.7	3.4	5.2	2.3	6.3	2.9	8.7	5.4	4.8	2.4	3.0	4.7	3.2	2.6	6.0	4.1	3.8	5.2	4.5	3.2	5.4	2.5	1.9	5.0	1.7	13.5	4.5	3.5	7.2	1.8	5.4	0.8	3.1	5.5	7.8	5.3	1.7	4.9	2.9	6.7	10.9	2.2	3.5	7.7	5.0	3.1	3.2	12.3	13.8	3.4	1.2	5.2	2.3	3.2	6.6	2.2	5.8	2.5	2.3	4.3	3.2	2.8	2.2	2.0	6.0	2.7	3.5	4.6	2.2	4.1	3.7	1.8	3.0	2.8	2.7	4.4	1.7	2.2	0.8	8.5	2.1	10.1	19.2	19.0	13.9	12.3	10.5	28.1	9.1	15.4	23.7
TRIM71	"LIN-41, LIN41"	ENSG00000206557	"Tripartite motif containing 71"	Q2Q1W2	3	32818018-32897826	"Enzymes, Predicted intracellular proteins"	"RNA-mediated gene silencing, Ubl conjugation pathway"	"Developmental protein, RNA-binding, Transferase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lung: 6.5;testis: 11.1"	"Cell line enhanced"	"Detected in some"		"AF22: 12.4;BEWO: 37.5;CACO-2: 8.8;Hep G2: 24.2;NTERA-2: 33.2"	"Cancer enriched"	"Detected in some"	28	"testis cancer: 28.6"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA038141, HPA038142"	Uncertain		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"				"Plasma membrane, Actin filaments, Focal adhesion sites"		"HPA038141: , HPA038142: AB_10697240"	"unprognostic (2.93e-2)"	"unprognostic (4.29e-3)"	"unprognostic (1.70e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.58e-2)"	"unprognostic (3.27e-2)"	"unprognostic (2.09e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.16e-2)"	"unprognostic (3.04e-1)"	"unprognostic (1.11e-2)"	"unprognostic (3.11e-1)"	"unprognostic (4.36e-6)"	"unprognostic (3.92e-2)"	"unprognostic (9.27e-2)"	"unprognostic (8.17e-2)"	"unprognostic (4.65e-2)"	0.1	0.0	0.7	0.1	1.9	0.5	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	2.7	0.7	2.2	0.0	6.5	0.0	0.2	0.0	0.1	0.0	0.0	0.5	1.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.1	0.1	11.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.5	0.3	0.0	0.1	0.0	0.0	0.0	12.4	0.0	0.0	0.0	37.5	0.0	0.0	0.0	0.0	8.8	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.6	0.0	24.2	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.2	2.6	33.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.2	0.0	0.2	0.3	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.3	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.7	1.9	0.0	0.5	2.7	0.7	0.2	0.0	1.9	0.0
TRIP6	"MGC10556, MGC10558, MGC29959, MGC3837, MGC4423, OIP1, ZRP-1"	ENSG00000087077	"Thyroid hormone receptor interactor 6"	Q15654	7	100867138-100873454	"Predicted intracellular proteins"	"Cell adhesion, Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 7.7"	"Low lineage specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB046454, CAB046460, HPA052813"	Approved		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"			12000	"Plasma membrane, Focal adhesion sites, Cytosol"		"CAB046454: AB_10604048, CAB046460: AB_2303907, HPA052813: "	"unprognostic (7.94e-3)"	"unprognostic (1.06e-1)"	"unprognostic (3.22e-3)"	"unprognostic (2.84e-3)"	"unprognostic (3.52e-2)"	"unprognostic (2.92e-2)"	"unprognostic (3.18e-2)"	"unprognostic (4.61e-3)"	"unprognostic (8.48e-2)"	"unprognostic (4.18e-2)"	"unprognostic (5.08e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.25e-2)"	"unprognostic (5.07e-2)"	"unprognostic (9.71e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.25e-1)"	15.5	14.7	10.9	16.2	11.2	6.0	18.1	4.2	7.3	36.7	14.6	9.4	22.5	4.4	28.2	30.8	27.2	18.5	43.5	14.5	8.7	7.7	21.6	24.1	18.4	5.8	11.7	9.4	22.0	19.2	28.0	6.5	13.6	9.7	22.1	3.9	22.7	23.0	38.2	8.3	23.9	6.5	25.5	9.7	7.9	9.9	17.5	7.8	7.3	26.6	30.6	12.6	25.0	23.6	3.1	7.7	0.2	4.7	0.0	1.7	0.5	26.6	11.0	5.7	27.3	8.6	10.1	28.7	16.6	17.8	22.8	21.4	10.4	30.7	1.1	17.6	18.7	19.9	8.4	32.1	5.9	3.8	11.4	0.1	18.3	0.1	22.8	12.8	1.5	18.2	21.1	15.2	23.9	11.7	16.7	0.2	19.7	46.8	0.2	20.2	19.7	9.8	10.0	5.7	2.7	14.1	6.6	2.1	0.3	13.9	42.1	16.5	4.5	16.4	17.9	33.6	31.7	36.4	38.8	0.2	0.4	0.1	20.9	1.6	50.5	0.0	1.9	0.2	0.2	3.0	0.6	3.1	1.5	1.3	3.1	2.5	1.7	0.7	0.2	0.0	4.7	7.7	1.3	0.5	10.9	11.2	4.2	7.3	8.7	7.7	11.7	9.4	9.7	7.8
TRPC7		ENSG00000069018	"Transient receptor potential cation channel subfamily C member 7"	Q9HCX4	5	136213320-136365545	"Predicted membrane proteins, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"adrenal gland: 2.2;brain: 1.6;intestine: 1.3;kidney: 1.5;pituitary gland: 2.2;testis: 2.4"	"Cell line enhanced"	"Detected in some"		"EFO-21: 1.7;SCLC-21H: 1.0"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"CAB022592, HPA031126"	Uncertain		Uncertain	"Actin filaments,Focal adhesion sites"				"Focal adhesion sites"	"Actin filaments"	"CAB022592: , HPA031126: AB_10603221"			"unprognostic (1.49e-1)"		"unprognostic (2.08e-1)"					"unprognostic (3.03e-2)"	"unprognostic (2.89e-5)"	"unprognostic (3.26e-1)"	"unprognostic (2.75e-1)"	"unprognostic (9.99e-2)"	"unprognostic (1.77e-1)"	"unprognostic (6.78e-2)"		0.0	2.2	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0			1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.5	0.0	0.0	0.0	0.0		0.0	0.0	0.0	2.2	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	2.4			0.1		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0										
VASP		ENSG00000125753	"Vasodilator stimulated phosphoprotein"	P50552	19	45506579-45526983	"Plasma proteins, Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 63.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 23.6"	"Group enriched"	"Detected in all"	6	"granulocytes: 23.6;monocytes: 10.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004612, HPA005724"	Enhanced		Supported	"Plasma membrane,Cell Junctions,Focal adhesion sites"			110000000	"Plasma membrane, Cell Junctions, Focal adhesion sites"		"CAB004612: AB_2213431, HPA005724: AB_1858721"	"unprognostic (3.07e-2)"	"unprognostic (1.07e-2)"	"unprognostic (4.70e-2)"	"unprognostic (7.85e-3)"	"unprognostic (8.31e-2)"	"unprognostic (1.90e-2)"	"prognostic unfavourable (3.49e-5)"	"unprognostic (1.66e-3)"	"unprognostic (1.58e-1)"	"unprognostic (1.30e-2)"	"unprognostic (3.64e-3)"	"unprognostic (4.39e-1)"	"prognostic unfavourable (5.91e-7)"	"unprognostic (1.15e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.08e-2)"	29.1	10.3	4.9	33.3	5.9	40.3	19.0	3.9	4.7	22.6	38.2	5.3	15.4	28.8	37.5	13.3	34.3	23.8	32.2	21.1	5.2	4.3	17.9	21.1	30.5	44.5	7.7	2.2	22.5	10.5	2.9	7.5	31.5	6.2	26.8	9.8	8.9	12.9	20.3	10.4	13.0	43.7	36.7	4.8	69.2	33.4	14.4	6.6	28.3	11.7	12.8	33.2	39.2	17.5	1.8	2.6	23.6	10.4	2.0	2.1	2.2	15.3	16.1	4.7	8.1	2.4	4.1	12.1	15.8	12.2	10.9	9.5	7.3	32.2	7.1	13.4	12.6	14.3	1.4	15.6	3.7	20.8	3.7	40.7	8.0	12.3	13.4	14.9	63.9	6.3	8.8	10.2	6.6	16.3	24.3	15.5	6.7	12.8	6.8	12.8	8.3	11.1	5.1	2.9	2.6	9.3	49.1	5.6	3.9	18.8	9.6	11.1	10.4	25.5	24.1	17.5	17.7	5.6	24.9	8.3	9.9	12.1	12.2	18.1	21.0	5.6	4.0	23.6	2.1	6.5	1.5	1.8	1.7	2.0	2.6	1.7	1.1	1.3	17.1	2.0	10.4	1.0	1.2	2.2	4.9	5.9	3.9	4.7	5.2	4.3	7.7	2.2	6.2	6.6
VCL		ENSG00000035403	Vinculin	P18206	10	73995193-74121363	"Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"	Actin-binding	"Cardiomyopathy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 94.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002131, CAB002453, HPA063777"	Enhanced		Enhanced	"Focal adhesion sites"			1800000000	"Focal adhesion sites"		"CAB002453: AB_564057, HPA002131: AB_1080570, HPA063777: AB_2685121"	"unprognostic (8.49e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.14e-1)"	"unprognostic (6.31e-2)"	"unprognostic (3.34e-1)"	"unprognostic (9.62e-3)"	"unprognostic (2.72e-3)"	"unprognostic (2.67e-3)"	"unprognostic (3.42e-2)"	"unprognostic (1.46e-1)"	"prognostic unfavourable (2.75e-4)"	"unprognostic (1.29e-1)"	"unprognostic (3.68e-2)"	"unprognostic (4.03e-2)"	"unprognostic (4.02e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.37e-3)"	31.9	7.3	4.3	19.0	6.0	8.6	24.4	5.4	5.3	37.9	41.2	6.7	24.4	8.0	72.1	29.2	36.1	27.6	44.8	35.0	4.7	3.9	20.8	6.9	25.9	9.3	3.8	5.5	29.2	12.8	18.1	7.6	22.6	9.6	43.3	18.0	20.2	14.9	38.8	59.1	14.4	20.2	113.1	3.8	23.6	23.6	29.5	3.3	3.0	15.3	20.5	11.7	73.9	26.1	3.7	12.9	21.6	11.3	2.8	9.9	15.6	23.6	16.2	29.4	20.7	36.8	42.9	16.2	31.2	94.8	21.4	24.3	14.5	20.6	1.0	26.1	54.4	30.3	19.3	15.7	22.6	2.0	8.2	11.2	15.8	6.0	20.2	2.2	17.2	35.4	4.2	28.9	26.4	28.5	8.1	2.4	35.5	4.0	0.3	2.6	13.9	57.3	3.9	15.3	3.0	30.6	30.6	1.1	4.4	17.3	19.7	8.9	9.1	3.4	38.1	23.4	9.8	11.3	29.2	0.4	0.9	4.6	27.3	6.4	6.6	8.5	7.6	21.6	9.9	10.8	7.0	3.7	4.7	5.1	12.9	1.6	1.8	3.6	7.0	2.8	11.3	5.0	1.2	15.6	4.3	6.0	5.4	5.3	4.7	3.9	3.8	5.5	9.6	3.3
VIPR2	"VPAC2, VPAC2R"	ENSG00000106018	"Vasoactive intestinal peptide receptor 2"	P41587	7	159028175-159144957	"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HeLa: 4.1;HMC-1: 6.3;MOLT-4: 8.6;U-266/70: 29.1"	"Cancer enhanced"	"Detected in some"		"glioma: 2.8"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	16	"plasmacytoid DC: 13.1"	"Lineage enriched"	"Detected in single"	16	"dendritic cells: 13.1"	"Region enhanced"	"Detected in some"		"olfactory region: 33.2"	"Low region specificity"	"Detected in all"			HPA062707	Approved		Approved	"Focal adhesion sites"				"Focal adhesion sites"		"HPA062707: "	"unprognostic (3.65e-2)"	"unprognostic (2.13e-2)"	"unprognostic (4.26e-2)"	"unprognostic (2.04e-2)"	"unprognostic (6.31e-2)"	"unprognostic (4.10e-2)"	"unprognostic (1.03e-1)"	"unprognostic (8.58e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.02e-1)"	"unprognostic (9.60e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.88e-1)"	"unprognostic (2.49e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.21e-1)"	"unprognostic (8.89e-2)"	9.6	1.2	2.1	2.9	1.3	0.6	2.1	0.9	10.2	18.0	10.6	1.5	14.1	2.1	11.5	14.3	3.1	3.3	4.7	13.3	2.6	1.8	1.0	0.6	0.6	3.0	1.9	2.3	10.8	15.7	0.3	2.6	6.4	2.1	8.4	1.5	4.9	1.1	24.0	7.3	0.6	3.9	7.1	2.4	1.1	8.3	2.4	1.1	16.9	0.4	0.7	0.8	5.7	9.9	0.0	13.1	0.1	0.0	0.0	0.8	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	6.3	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.1	8.6	0.0	0.7	0.0	2.2	0.1	0.5	0.0	0.0	2.0	1.6	0.1	0.1	0.0	0.0	0.5	0.0	0.0	0.3	0.0	0.0	29.1	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.1	0.2	0.1	0.0	0.0	13.1	0.0	0.1	2.1	1.3	0.9	10.2	2.6	1.8	1.9	2.3	2.1	1.1
VTCN1	"B7-H4, B7H4, B7S1, B7X, FLJ22418"	ENSG00000134258	"V-set domain containing T cell activation inhibitor 1"	Q7Z7D3	1	117143587-117210960	"Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 46.4;epididymis: 29.9;kidney: 27.0;pancreas: 35.9"	"Cell line enriched"	"Detected in some"	5	"SK-BR-3: 72.8"	"Group enriched"	"Detected in many"	6	"breast cancer: 55.8;endometrial cancer: 45.2;ovarian cancer: 49.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA054200	Approved		Approved	"Plasma membrane,Cell Junctions,Focal adhesion sites"				"Plasma membrane"	"Cell Junctions, Focal adhesion sites"	"HPA054200: "	"unprognostic (4.13e-1)"	"unprognostic (1.71e-3)"	"unprognostic (2.95e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.71e-3)"	"unprognostic (2.56e-1)"	"unprognostic (7.94e-2)"	"unprognostic (4.86e-2)"	"unprognostic (3.53e-1)"	"unprognostic (1.17e-2)"	"unprognostic (4.54e-2)"	"unprognostic (5.47e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.06e-1)"	"unprognostic (2.42e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.45e-2)"	0.1	0.0	0.1	0.1	0.1	0.0	46.4	0.1	0.1	6.7	0.1	0.1	7.0	0.0	2.6	29.9	0.4	14.2	1.9	0.2	0.1	0.1	27.0	0.9	0.3	0.1	0.1	0.1	4.5	35.9	0.0	1.4	3.0	0.1	1.5	0.0	0.1	17.5	3.6	0.2	2.2	0.1	0.8	0.1	0.1	1.5	2.5	0.1	0.2	0.1	0.5	1.5	2.1	0.7	0.4	0.0	0.0	0.1	0.0	0.1	0.0	0.3	0.0	0.5	0.0	0.0	0.0	13.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	2.2	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.3	0.0	0.0	72.8	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
ZBTB8A	"BOZF1, FLJ90065, ZBTB8, ZNF916A"	ENSG00000160062	"Zinc finger and BTB domain containing 8A"	Q96BR9	1	32539427-32605939	"Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031768, HPA031769, HPA031770"	Approved		Approved	"Nuclear speckles,Focal adhesion sites"				"Nuclear speckles, Focal adhesion sites"		"HPA031768: AB_10610568, HPA031769: , HPA031770: "	"unprognostic (1.71e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.01e-1)"	"unprognostic (7.40e-2)"	"unprognostic (7.21e-2)"	"unprognostic (2.85e-2)"	"unprognostic (9.45e-5)"	"unprognostic (1.62e-2)"	"unprognostic (2.04e-1)"	"unprognostic (7.83e-3)"	"unprognostic (4.23e-3)"	"unprognostic (1.78e-1)"	"unprognostic (8.10e-2)"	"unprognostic (2.88e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.47e-1)"	"unprognostic (3.15e-2)"	8.8	4.9	4.4	3.2	5.0	2.3	19.1	11.1	5.9	13.6	6.2	4.8	12.2	3.8	12.7	8.6	7.2	7.8	5.7	6.9	4.4	3.4	5.7	4.4	14.0	1.9	3.3	4.5	8.6	10.9	10.7	8.9	5.5	7.9	7.8	6.2	6.9	9.9	11.4	10.3	4.8	4.2	15.4	5.2	2.7	6.4	6.2	3.5	1.8	11.2	6.6	3.0	9.1	7.6	1.6	2.1	4.1	1.0	2.6	1.0	0.5	6.5	1.8	7.7	8.3	5.5	7.4	5.8	6.5	5.2	6.2	6.3	0.8	5.3	5.3	4.5	7.0	5.2	7.6	5.2	5.5	1.4	5.1	0.3	6.5	2.8	7.1	1.2	0.4	5.0	7.5	4.5	11.9	6.9	1.1	3.8	6.2	6.7	3.6	0.6	7.0	2.7	6.5	11.2	4.2	3.8	6.8	6.5	5.9	9.2	4.6	8.7	6.0	3.0	7.1	8.3	6.8	11.3	4.7	7.0	3.3	4.1	5.7	1.3	3.4	4.1	1.0	0.8	0.8	0.6	1.0	0.8	0.7	0.7	0.7	1.6	0.8	0.9	3.8	2.6	0.8	2.1	0.6	0.5	4.4	5.0	11.1	5.9	4.4	3.4	3.3	4.5	7.9	3.5
ZNF185	SCELL	ENSG00000147394	"Zinc finger protein 185 with LIM domain"	O15231	X	152914442-152973480	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"epididymis: 93.5;esophagus: 67.6"	"Cell line enhanced"	"Detected in many"		"A-431: 31.0;EFO-21: 36.9;HBEC3-KT: 25.6;PC-3: 22.7;TIME: 60.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 21.6"	"Group enriched"	"Detected in many"	5	"granulocytes: 21.6;monocytes: 13.9"					"Low region specificity"	"Detected in all"			"HPA000400, HPA016438"	Enhanced		Supported	"Plasma membrane,Actin filaments,Focal adhesion sites,Cytosol"			5400	"Plasma membrane, Cytosol"	"Actin filaments, Focal adhesion sites"	"HPA000400: AB_1080685, HPA016438: AB_1859109"	"unprognostic (1.34e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.84e-1)"	"unprognostic (2.43e-2)"	"unprognostic (9.75e-3)"	"unprognostic (2.69e-1)"	"unprognostic (2.49e-2)"	"prognostic unfavourable (1.50e-4)"	"unprognostic (7.94e-2)"	"unprognostic (6.28e-2)"	"prognostic unfavourable (3.30e-5)"	"unprognostic (5.18e-2)"	"unprognostic (8.12e-2)"	"unprognostic (1.99e-1)"	"unprognostic (1.37e-1)"	"unprognostic (2.10e-1)"	"unprognostic (1.60e-1)"	3.9	1.7	1.8	2.0	3.2	0.8	1.8	2.7	2.0	14.3	1.8	1.4	10.7	0.0	3.8	93.5	67.6	3.1	2.0	1.9	1.7	0.8	2.0	1.1	3.3	3.1	2.1	1.1	1.2	0.9	0.1	2.3	4.0	1.7	4.2	0.3	1.3	10.1	28.1	1.5	9.9	1.2	1.4	1.2	3.7	0.8	1.9	2.0	1.2	3.9	1.4	6.6	2.1	22.8	0.4	3.8	21.6	13.9	0.2	0.6	10.2	31.0	6.6	0.6	0.4	0.8	1.0	1.4	1.5	0.1	3.9	0.5	0.2	9.4	0.4	36.9	2.3	4.4	0.9	25.6	15.9	0.3	0.6	2.0	2.7	1.0	1.8	0.1	0.1	0.7	18.4	0.4	15.1	19.7	0.1	0.3	0.1	7.3	0.1	0.1	0.4	22.7	0.1	0.1	0.2	2.0	2.9	0.2	2.1	0.0	5.9	0.9	6.0	0.6	60.4	0.2	13.4	0.7	1.1	0.3	0.2	0.2	0.4	2.2	0.4	21.6	13.9	5.7	0.5	12.9	0.3	0.4	0.4	0.6	3.8	0.3	0.6	0.3	9.5	0.2	10.2	2.5	0.5	10.2	1.8	3.2	2.7	2.0	1.7	0.8	2.1	1.1	1.7	2.0
ZYX		ENSG00000159840	Zyxin	Q15942	7	143381080-143391111	"Plasma proteins, Predicted intracellular proteins"	"Cell adhesion, Host-virus interaction"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 47.5"	"Group enriched"	"Detected in many"	4	"dendritic cells: 16.5;granulocytes: 47.5;monocytes: 22.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004835, CAB009321, HPA073497, CAB075747"	Approved		Enhanced	"Focal adhesion sites"			420000000	"Focal adhesion sites"		"CAB009321: AB_2221290, CAB075747: , HPA004835: AB_1080771, HPA073497: "	"unprognostic (1.96e-2)"	"unprognostic (5.35e-2)"	"unprognostic (2.36e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.21e-3)"	"unprognostic (1.66e-3)"	"unprognostic (2.60e-1)"	"unprognostic (4.22e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.43e-1)"	"prognostic unfavourable (7.92e-5)"	"unprognostic (1.39e-1)"	"unprognostic (8.12e-2)"	"unprognostic (1.95e-1)"	"unprognostic (6.72e-2)"	52.7	11.7	7.7	39.3	8.8	46.1	34.3	17.5	22.2	61.1	56.8	10.7	20.5	13.6	103.6	38.6	52.3	48.9	58.1	22.7	7.4	7.7	24.7	21.2	52.8	63.0	8.8	8.3	58.1	15.9	63.8	9.1	32.4	15.5	43.8	10.8	17.9	18.8	40.7	28.3	21.1	26.6	74.7	8.5	57.1	28.3	37.4	7.1	24.4	18.9	19.1	26.0	93.7	35.7	0.9	16.5	47.5	22.1	4.1	6.7	9.0	12.6	7.7	10.2	14.2	19.3	43.1	12.1	26.9	31.7	29.5	24.9	26.2	8.2	0.8	10.5	32.9	10.3	6.3	27.2	13.8	13.5	3.3	19.7	9.0	9.1	33.9	15.9	31.5	45.8	12.1	32.3	10.9	37.3	4.8	8.6	31.5	14.2	0.2	32.0	21.3	49.8	3.0	5.5	1.1	22.4	6.7	0.5	7.7	21.2	19.8	11.1	2.3	15.9	65.5	35.3	14.5	37.5	28.3	2.8	3.6	2.1	31.4	16.7	23.4	4.9	18.2	12.5	5.9	19.2	4.7	0.9	5.5	6.7	16.5	0.5	3.5	4.0	47.5	4.1	22.1	4.2	5.0	9.0	7.7	8.8	17.5	22.2	7.4	7.7	8.8	8.3	15.5	7.1